

CITATION REPORT

List of articles citing

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

DOI: 10.1002/hep.20701
Hepatology, 2005, 41, 1313-21.

Source: <https://exaly.com/paper-pdf/38329839/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2201	Discovery of a Novel Selective Dual Peroxisome Proliferator-Activated Receptor / Agonist for the Treatment of Primary Biliary Cirrhosis.		
2200	New Generation Oxyntomodulin Peptides with Improved Pharmacokinetic Profiles Exhibit Weight Reducing and Anti-Steatotic Properties in Mice.		
2199	.		
2198	Nonalcoholic fatty liver disease in the pediatric population: a review. 2005 , 17, 636-41		91
2197	Histopathology of pediatric nonalcoholic fatty liver disease. <i>Hepatology</i> , 2005 , 42, 641-9	11.2	549
2196	The histopathology of pediatric nonalcoholic fatty liver disease. <i>Hepatology</i> , 2005 , 42, 536-8	11.2	8
2195	The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. 2005 , 4, 10		227
2194	Nonalcoholic steatohepatitis: pathologic features and differential diagnosis. 2005 , 22, 330-8		77
2193	A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. 2006 , 355, 2297-307		1311
2192	Acute and chronic hepatitis. 2006 , 23, 132-48		18
2191	Alcoholic liver disease. 2006 , 23, 149-60		122
2190	84 P75 neurotrophin receptor promotes liver regeneration via regulation of hepatic stellate cell differentiation. 2006 , 44, S37-S38		
2189	Nonalcoholic fatty liver disease in children. 2006 , 10, 109-31, vi-vii		33
2188	Histologic spectrum of nonalcoholic fatty liver disease in morbidly obese adolescents. 2006 , 4, 226-32		90
2187	Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement. 2006 , 4, 1048-52		79
2186	Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease. 2006 , 130, 1564-72		223
2185	Enfermedades hepáticas. 2006 , 29, 99-111		1

2184	Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis. 2006 , 4, 1537-43	265
2183	Non-alcoholic fatty liver disease: current concepts and management strategies. 2006 , 6, 19-25	116
2182	The ratio of phosphatidylcholine to phosphatidylethanolamine influences membrane integrity and steatohepatitis. 2006 , 3, 321-31	402
2181	Adaptive failure to high-fat diet characterizes steatohepatitis in Alms1 mutant mice. 2006 , 342, 1152-9	99
2180	Non-alcoholic steatohepatitis: from cell biology to clinical practice. 2006 , 44, 197-208	152
2179	Is HCV infection associated with liver steatosis also in children?. 2006 , 45, 350-4	16
2178	Interleukin-15 increases hepatic regenerative activity. 2006 , 45, 410-8	34
2177	Diagnostic and predictive factors of significant liver fibrosis and minimal lesions in patients with persistent unexplained elevated transaminases. A prospective multicenter study. 2006 , 45, 592-9	47
2176	Hepatic histology in obese patients undergoing bariatric surgery. 2006 , 45, 600-6	401
2175	[Insulin resistance/hyperinsulinemia associated diseases not included in the metabolic syndrome]. 2006 , 50, 360-7	16
2174	In Reply. 2006 , 24, 5467-5468	
2173	Steatosis and hepatitis C in an Alaska Native/American Indian population. 2006 , 65, 253-60	4
2172	Design and Validation of a Histological Scoring System for Nonalcoholic Fatty Liver Disease. 2006 , 2006, 41-43	
2171	Current World Literature. 2006 , 11, 311-350	
2170	Non-alcoholic steatohepatitis. 2006 , 13, 119-126	3
2169	Bibliography. Current world literature. Hyperlipidaemia and cardiovascular disease. 2006 , 17, 445-75	
2168	Hepatobiliary pathology. 2006 , 22, 198-208	11
2167	Pediatric nonalcoholic fatty liver disease: a critical appraisal of current data and implications for future research. 2006 , 43, 413-27	174

2166	Non-alcoholic steatohepatitis and metabolic syndrome. 2006 , 9, 637-42	78
2165	Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease: echocardiographic and tissue Doppler imaging assessment. 2006 , 40, 949-55	128
2164	NAFLD, NASH and now NAS. 2006 , 13, 101	
2163	[Diagnosis of and therapy for nonalcoholic steatohepatitis]. 2006 , 95, 1876-80	
2162	Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholic steato hepatitis in patients with non-alcoholic fatty liver disease. 2006 , 6, 34	199
2161	Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. 2006 , 6, 6	304
2160	Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. 2006 , 87, 1-16	527
2159	Intracellular retention of hepatic serpins caused by severe hyperlipidemia. 2006 , 26, 708-15	8
2158	Prevalence of primary non-alcoholic fatty liver disease in a population-based study and its association with biochemical and anthropometric measures. 2006 , 26, 856-63	198
2157	Nutritional aspects of non-alcoholic steatohepatitis treatment. 2006 , 63, 79-90	5
2156	Effect of vitamin E on aminotransferase levels and insulin resistance in children with non-alcoholic fatty liver disease. 2006 , 24, 1553-61	132
2155	Screening for liver disease using non-invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia. 2007 , 25, 207-18	43
2154	Histological assessment of non-alcoholic fatty liver disease. 2006 , 49, 450-65	210
2153	The prevalence of nonalcoholic steatohepatitis is greater in morbidly obese men compared to women. 2006 , 16, 1351-8	45
2152	Hepatic histopathology of morbid obesity: concurrence of other forms of chronic liver disease. 2006 , 16, 1584-93	45
2151	Cholesterol-fed rabbit as a unique model of nonalcoholic, nonobese, non-insulin-resistant fatty liver disease with characteristic fibrosis. 2006 , 41, 971-80	75
2150	H�patopathie non alcoolique: de la st�tose � la cirrhose. 2006 , 36, 299-314	1
2149	Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. 2006 , 22, 437-43	239

2148	Nonalcoholic fatty liver disease: from steatosis to cirrhosis. <i>Hepatology</i> , 2006 , 43, S99-S112	11.2	1802
2147	In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. <i>Hepatology</i> , 2006 , 44, 27-33	11.2	545
2146	NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice. <i>Hepatology</i> , 2006 , 44, 458-65	11.2	273
2145	Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. <i>Hepatology</i> , 2006 , 44, 874-80	11.2	241
2144	Controversies in the management of pediatric liver disease: Hepatitis B, C and NAFLD: Summary of a single topic conference. <i>Hepatology</i> , 2006 , 44, 1344-54	11.2	44
2143	Leptin, free leptin index, insulin resistance and liver fibrosis in children with non-alcoholic fatty liver disease. 2006 , 155, 735-43		75
2142	Chemotherapy-induced steatohepatitis in colorectal cancer patients. 2006 , 24, 5467; author reply 5467-8		14
2141	Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. 2006 , 24, 2065-72		1026
2140	Increased infiltration of macrophages in omental adipose tissue is associated with marked hepatic lesions in morbid human obesity. 2006 , 55, 1554-61		452
2139	Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease. 2006 , 55, 1650-60		96
2138	Case records of the Massachusetts General Hospital. Case 31-2006. A 15-year-old girl with severe obesity. 2006 , 355, 1593-602		16
2137	Metabolic syndrome is associated with greater histologic severity, higher carbohydrate, and lower fat diet in patients with NAFLD. 2006 , 101, 2247-53		155
2136	Third Annual World Congress on the Insulin Resistance Syndrome: associated conditions. 2006 , 29, 2165-74		7
2135	Pathology of nonalcoholic fatty liver disease. 2007 , 128, 837-47		229
2134	Intrauterine growth retardation, insulin resistance, and nonalcoholic fatty liver disease in children. 2007 , 30, 2638-40		98
2133	Usefulness of a combined evaluation of the serum adiponectin level, HOMA-IR, and serum type IV collagen 7S level to predict the early stage of nonalcoholic steatohepatitis. 2007 , 102, 1931-8		120
2132	The proinflammatory phenotype of PECAM-1-deficient mice results in atherogenic diet-induced steatohepatitis. 2007 , 293, G1205-14		30
2131	Short-term outcome in the first 10 morbidly obese adolescent patients in the FDA-approved trial for laparoscopic adjustable gastric banding. 2007 , 45, 465-73		52

2130	Definitive diagnosis and assessment of risk for nonalcoholic fatty liver disease in children and adolescents. 2007 , 27, 312-8	59
2129	Comparison of CT methods for determining the fat content of the liver. 2007 , 188, 1307-12	338
2128	Present and future therapeutic strategies in non-alcoholic fatty liver disease. 2007 , 11, 1231-49	39
2127	Importance of cytokines, oxidative stress and expression of BCL-2 in the pathogenesis of non-alcoholic steatohepatitis. 2007 , 42, 1095-101	26
2126	Correlation of serum TNF-alpha levels and histologic liver injury scores in pediatric nonalcoholic fatty liver disease. 2007 , 127, 954-60	136
2125	A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. 2007 , 56, 553-9	222
2124	Nonalcoholic fatty liver disease: from pathogenesis to patient care. 2007 , 3, 458-69	69
2123	Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease. 2007 , 86, 285-300	292
2122	Nonalcoholic Fatty Liver Disease. 830-839	2
2121	Current World Literature. 2007 , 23, 199-215	
2120	Potential of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) for differential diagnosis of nonalcoholic steatohepatitis and fatty liver in rats using magnetic resonance imaging. 2007 , 42, 242-7	83
2119	Fatty liver and the metabolic syndrome. 2007 , 23, 193-8	78
2118	Impact of laparoscopic resection for colorectal cancer on operative outcomes and survival. 2007 , 246, 338-9; author reply 339-40	5
2117	Steatosis as a risk factor in liver surgery. 2007 , 246, 340-1; author reply 341	7
2116	Hormone Receptor Status as a Prognostic Factor in Breast Cancer Patients With Hepatic Metastases Treated by Liver Resection. 2007 , 246, 338	1
2115	Steatosis as a Risk Factor in Liver Surgery. 2007 , 246, 341	78
2114	Impact of Laparoscopic Resection for Colorectal Cancer on Operative Outcomes and Survival. 2007 , 246, 339-340	78
2113	Relationship among histologic, radiologic, and biochemical assessments of hepatic steatosis: a study of human liver samples. 2007 , 41, 206-10	44

2112	Lower expression of Nrf2 mRNA in older donor livers: a possible contributor to increased ischemia-reperfusion injury?. 2007 , 84, 1272-8	14
2111	Hormone receptor status as a prognostic factor in breast cancer patients with hepatic metastases treated by liver resection. 2007 , 246, 338; author reply 338	1
2110	Diabetes and hepatic oxidative damage are associated with hepatitis C progression after liver transplantation. 2007 , 84, 587-91	18
2109	Evaluation and management of obesity-related nonalcoholic fatty liver disease. 2007 , 4, 432-41	74
2108	Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. 2007 , 46, 1111-8	158
2107	Influence of TNF gene polymorphisms in Japanese patients with NASH and simple steatosis. 2007 , 46, 1104-10	122
2106	Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: a review of 589 consecutive liver biopsies in a single center. 2007 , 47, 239-44	199
2105	Pediatric nonalcoholic fatty liver disease (NAFLD): a "growing" problem?. 2007 , 46, 1133-42	139
2104	Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. 2007 , 47, 412-7	159
2103	Grading and staging systems for inflammation and fibrosis in chronic liver diseases. 2007 , 47, 598-607	496
2102	A prospective study of acute drug-induced liver injury in patients suffering from non-alcoholic fatty liver disease. 2007 , 37, 410-5	122
2101	Combined pantethine and probucol therapy for Japanese patients with non-alcoholic steatohepatitis. 2007 , 37, 872-7	12
2100	Combination of N-acetylcysteine and metformin improves histological steatosis and fibrosis in patients with non-alcoholic steatohepatitis. 2008 , 38, 159-65	75
2099	Serotonin mediates oxidative stress and mitochondrial toxicity in a murine model of nonalcoholic steatohepatitis. 2007 , 133, 608-18	119
2098	Nonalcoholic fatty liver disease as a complication of insulin resistance. 2007 , 91, 1125-49, ix	117
2097	Liver fat: effect of hepatic iron deposition on evaluation with opposed-phase MR imaging. 2007 , 242, 450-5	134
2096	Antioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitis. 2007 , CD004996	36
2095	Steatosi epatica non alcolica: un aspetto emergente della sindrome metabolica. 2007 , 8, 136-143	

2094	Ultrasonographic evaluation of liver volume and the metabolic syndrome in obese women. 2007 , 30, 104-10	12
2093	Plasminogen activator inhibitor-1 and thrombin activatable fibrinolysis inhibitor levels in non-alcoholic steatohepatitis. 2007 , 30, 810-9	12
2092	Medical treatment of non-alcoholic steatohepatitis. 2007 , 11, 119-40, ix	26
2091	Pathogenesis of NASH: animal models. 2007 , 11, 55-74, viii	79
2090	Pathologic assessment of non-alcoholic fatty liver disease. 2007 , 11, 17-23, vii	53
2089	Histopathologic variability between the right and left lobes of the liver in morbidly obese patients undergoing Roux-en-Y bypass. 2007 , 5, 1329-32	76
2088	Optimizing diagnosis from the medical liver biopsy. 2007 , 5, 898-907	40
2087	Non-alcoholic steatohepatitis in children. 2007 , 11, 155-72, x	44
2086	Noninvasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). 2007 , 149, 114-25	26
2085	[A 73-year-old male with multiple hepatic lesions]. 2007 , 129, 551-6	0
2084	Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction. 2007 , 133, 80-90	363
2083	Role of liver biopsy and serum markers of liver fibrosis in non-alcoholic fatty liver disease. 2007 , 11, 25-35, viii	58
2082	Association between nonalcoholic hepatic steatosis and hepatic cytochrome P-450 3A activity. 2007 , 5, 388-93	60
2081	Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. 2007 , 13, 837-44	150
2080	Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease. 2007 , 13, 3540-53	177
2079	Changes in histological criteria lead to different prevalences of nonalcoholic steatohepatitis in severe obesity. 2007 , 6, 255-261	12
2078	Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. 2007 , 94, 274-86	383
2077	Portal vein embolization before major hepatectomy and its effects on regeneration, resectability and outcome. 2007 , 94, 1386-94	367

2076	Uridine supplementation antagonizes zalcitabine-induced microvesicular steatohepatitis in mice. <i>Hepatology</i> , 2007 , 45, 72-9	11.2	32
2075	The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. <i>Hepatology</i> , 2007 , 45, 846-54	11.2	1757
2074	Effects of rosiglitazone on the liver histology and mitochondrial function in ob/ob mice. <i>Hepatology</i> , 2007 , 46, 414-23	11.2	94
2073	Evidence for a role of nonalcoholic steatohepatitis in hepatitis C: a prospective study. <i>Hepatology</i> , 2007 , 46, 380-7	11.2	109
2072	A lipidomic analysis of nonalcoholic fatty liver disease. <i>Hepatology</i> , 2007 , 46, 1081-90	11.2	866
2071	The impact of fat distribution on the severity of nonalcoholic fatty liver disease and metabolic syndrome. <i>Hepatology</i> , 2007 , 46, 1091-100	11.2	84
2070	Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet. <i>Hepatology</i> , 2007 , 46, 1392-403	11.2	368
2069	Nonalcoholic steatohepatitis in chronic hepatitis C: A new classification?. <i>Hepatology</i> , 2008 , 47, 759; author reply 759-60	11.2	0
2068	Keratins let liver live: Mutations predispose to liver disease and crosslinking generates Mallory-Denk bodies. <i>Hepatology</i> , 2007 , 46, 1639-49	11.2	130
2067	Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. <i>Hepatology</i> , 2008 , 47, 455-60	11.2	494
2066	Noninvasive diagnosis of nonalcoholic fatty liver disease using serum biomarkers. <i>Hepatology</i> , 2007 , 46, 2047-8; author reply 2048	11.2	11
2065	Behavior therapy for nonalcoholic fatty liver disease: The need for a multidisciplinary approach. <i>Hepatology</i> , 2008 , 47, 746-54	11.2	167
2064	Measurement of liver fat content using selective saturation at 3.0 T. 2007 , 25, 743-8		25
2063	Non-alcoholic fatty liver disease: what is it, when does it occur, and why does it matter?. 2007 , 24, 310-316		0
2062	Microarray analyses and molecular profiling of steatosis induction in immortalized human hepatocytes. 2007 , 87, 792-806		56
2061	Pathology of fatty liver disease. 2007 , 20 Suppl 1, S40-8		153
2060	Non-alcoholic fatty liver disease: further expression of the metabolic syndrome. 2007 , 22, 293-303		123
2059	Effects of bariatric surgery on nonalcoholic fatty liver disease: preliminary findings after 2 years. 2007 , 22, 510-4		144

2058	Novel mutations of the ferroportin gene (SLC40A1): analysis of 56 consecutive patients with unexplained iron overload. 2008 , 73, 171-8	25
2057	Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines. 2007 , 22, 778-87	227
2056	Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary. 2007 , 22, 775-7	328
2055	How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences?. 2007 , 22, 788-93	274
2054	LAPAROSCOPIC FEATURES AND INTEROBSERVER VARIATION OF HISTOLOGICAL DIAGNOSIS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE. 2007 , 20, 22-28	1
2053	Patterns of histological change in liver disease: my approach to 'medical' liver biopsy reporting. 2007 , 51, 585-96	15
2052	Serum concentrations of the tissue polypeptide specific antigen in patients suffering from non-alcoholic steatohepatitis. 2007 , 37, 48-53	37
2051	Histological progression of non-alcoholic fatty liver disease: a critical reassessment based on liver sampling variability. 2007 , 26, 821-30	43
2050	Review article: Non-alcoholic fatty liver disease in morbidly obese patients and the effect of bariatric surgery. 2007 , 26 Suppl 2, 195-201	82
2049	Yo jyo hen shi ko, a novel Chinese herbal, prevents nonalcoholic steatohepatitis in ob/ob mice fed a high fat or methionine-choline-deficient diet. 2007 , 27, 227-34	10
2048	Hepatocyte senescence in end-stage chronic liver disease: a study of cyclin-dependent kinase inhibitor p21 in liver biopsies as a marker for progression to hepatocellular carcinoma. 2007 , 27, 662-71	16
2047	Expression and activity of the cytochrome P450 2E1 in patients with nonalcoholic steatosis and steatohepatitis. 2007 , 27, 764-71	41
2046	Modulation of hepatic microsomal triglyceride transfer protein (MTP) induced by S-nitroso-N-acetylcysteine in ob/ob mice. 2007 , 74, 290-7	13
2045	From Mallory to Mallory-Denk bodies: what, how and why?. 2007 , 313, 2033-49	252
2044	Assessment of intrahepatic triglyceride content using magnetic resonance spectroscopy. 2007 , 2, 136-8	38
2043	Effect of insulin-metformin combination on hepatic steatosis in patients with type 2 diabetes. 2007 , 21, 137-42	36
2042	[Metabolic fatty liver diseases: hepatic consequences of the metabolic syndrome]. 2007 , 31, 1127-34	2
2041	[Steatosis during chronic hepatitis C: the role of insulin resistance and viral factors]. 2007 , 31, 643-54	3

2040	Nonalcoholic fatty liver disease and insulin resistance in youth. 2007 , 30, 1663-9	16
2039	Methylenetetrahydrofolate reductase C677T mutation and nonalcoholic fatty liver disease. 2007 , 52, 1183-6	15
2038	Nonalcoholic steatohepatitis (NASH) in ob/ob mice treated with yo jyo hen shi ko (YHK): effects on peroxisome proliferator-activated receptors (PPARs) and microsomal triglyceride transfer protein (MTP). 2007 , 52, 3448-54	16
2037	Pathological study of 130 cases of nonalcoholic fatty liver disease based on NASH-CRN system. 2007 , 1, 413-7	1
2036	Influence of liver biopsy heterogeneity and diagnosis of nonalcoholic steatohepatitis in subjects undergoing gastric bypass. 2007 , 17, 155-61	44
2035	Resolution of nonalcoholic steatohepatitis after gastric bypass surgery. 2007 , 17, 486-92	120
2034	IL-6 and IGF-1 are independent prognostic factors of liver steatosis and non-alcoholic steatohepatitis in morbidly obese patients. 2007 , 17, 493-503	86
2033	Metabolic syndrome is related to nonalcoholic steatohepatitis in severely obese subjects. 2007 , 17, 1457-63	42
2032	Klinische Bedeutung [Sinn und Unsinn] der Leberbiopsie bei NAFLD. 2007 , 3, 192-201	
2031	Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome. 2007 , 11, 860-8	209
2030	Association of apolipoprotein E polymorphisms in patients with non-alcoholic steatohepatitis. 2008 , 53, 3218-24	55
2029	Effects of a long-term high-fat diet and switching from a high-fat to low-fat, standard diet on hepatic fat accumulation in Sprague-Dawley rats. 2008 , 53, 3206-12	22
2028	[Quality and quantity in hepatopathology. Diagnostic and clinically relevant grading for non-tumourous liver diseases]. 2008 , 29, 15-26	5
2027	Risks of neoadjuvant chemotherapy for resectable colorectal carcinoma hepatic metastases. 2008 , 4, 87-92	1
2026	Neoadjuvant or adjuvant therapy for patients with resectable liver metastases. 2008 , 4, 160-166	1
2025	Nonalcoholic fatty liver disease: diagnosis and relation to metabolic syndrome and approach to treatment. 2008 , 8, 25-30	23
2024	The obesity epidemic and nonalcoholic fatty liver disease in children. 2008 , 10, 67-72	81
2023	Angiotensin receptor blockers in the treatment of NASH/NAFLD: could they be a first-class option?. 2008 , 25, 1141-74	44

2022	Development from simple steatosis to liver cirrhosis and hepatocellular carcinoma: a 27-year follow-up case. 2008 , 1, 116-121		22
2021	The utility of the "NAFLD fibrosis score" in morbidly obese subjects with NAFLD. 2008 , 18, 264-70		48
2020	Fatty liver disease: predictors of nonalcoholic steatohepatitis and gallbladder disease in morbid obesity. 2008 , 18, 847-53		31
2019	A "biomarker biopsy" for the diagnosis of NASH: promises from CK-18 fragments. 2008 , 18, 1507-8; author reply 1509-10		16
2018	Management of hepatic metastasis from colorectal cancers: an update. 2008 , 15, 570-80		55
2017	Liver diseases and metabolic syndrome. 2008 , 43, 509-18		128
2016	Adipocytokines and liver disease. 2008 , 43, 811-22		136
2015	Pioglitazone retrieves hepatic antioxidant DNA repair in a mice model of high fat diet. 2008 , 9, 82		32
2014	Evaluating the severity of nonalcoholic steatohepatitis with superparamagnetic iron oxide-enhanced magnetic resonance imaging. 2008 , 28, 1444-50		22
2013	Posttransplant plasma cell hepatitis (de novo autoimmune hepatitis) is a variant of rejection and may lead to a negative outcome in patients with hepatitis C virus. 2008 , 14, 861-71		103
2012	Methylenetetrahydrofolate reductase gene polymorphisms in patients with nonalcoholic steatohepatitis (NASH). 2008 , 26, 291-6		27
2011	Insulin resistance, adipocytokines, and hepatitis C virus infection: a missing link?. <i>Hepatology</i> , 2008 , 47, 760-1; author reply 761	11.2	
2010	Steatohepatitis: Risk factors and impact on disease severity in human immunodeficiency virus/hepatitis C virus coinfection. <i>Hepatology</i> , 2008 , 47, 1118-27	11.2	46
2009	Health-related fitness and physical activity in patients with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2008 , 47, 1158-66	11.2	105
2008	The future is around the corner: Noninvasive diagnosis of progressive nonalcoholic steatohepatitis. <i>Hepatology</i> , 2008 , 47, 373-5	11.2	28
2007	Reply:. <i>Hepatology</i> , 2008 , 47, 759-760	11.2	
2006	A clinical scoring system for predicting nonalcoholic steatohepatitis in morbidly obese patients. <i>Hepatology</i> , 2008 , 47, 1916-23	11.2	115
2005	Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. <i>Hepatology</i> , 2008 , 48, 119-28	11.2	307

2004	Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. <i>Hepatology</i> , 2008 , 48, 792-8	11.2	481
2003	Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. <i>Hepatology</i> , 2008 , 48, 1810-20	11.2	498
2002	Regulatable fatty acid transport mechanisms are central to the pathophysiology of obesity, fatty liver, and metabolic syndrome. <i>Hepatology</i> , 2008 , 48, 1362-76	11.2	33
2001	Hepatic microcirculation in fatty liver disease. 2008 , 291, 684-92		183
2000	Pathology of fatty liver: differential diagnosis of non-alcoholic fatty liver disease. 2008 , 14, 586-597		3
1999	Metabolic syndrome and liver histology in paediatric non-alcoholic steatohepatitis. 2008 , 32, 381-7		126
1998	<i>Macaca radiata</i> (bonnet monkey): a spontaneous model of nonalcoholic fatty liver disease. 2008 , 28, 856-64		10
1997	Protein glutathionylation increases in the liver of patients with non-alcoholic fatty liver disease. 2008 , 23, e457-64		22
1996	Activation of peroxisome proliferator-activated receptor alpha by dietary fish oil attenuates steatosis, but does not prevent experimental steatohepatitis because of hepatic lipoperoxide accumulation. 2008 , 23, 267-75		57
1995	Prevalence and risk factors of hepatic steatosis and its impact on liver injury in Chinese patients with chronic hepatitis B infection. 2008 , 23, 1419-25		67
1994	Animal models of NASH: getting both pathology and metabolic context right. 2008 , 23, 1635-48		256
1993	Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. 2008 , 28, 2-12		114
1992	Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis. 2008 , 28, 200-8		93
1991	Review article: diagnosis and treatment of non-alcoholic fatty liver disease. 2008 , 28, 503-22		84
1990	High-fat diet: a trigger of non-alcoholic steatohepatitis? Preliminary findings in obese subjects. 2008 , 24, 1097-102		41
1989	Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations. 2008 , 115, 141-50		212
1988	Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. 2008 , 57, 1711-8		156
1987	[Non-alcoholic hepatic steatosis. An update]. 2008 , 40, 419-24		1

1986	Enhanced serum concentrations of transforming growth factor-beta1 in simple fatty liver: is it really benign?. 2008 , 6, 72	60
1985	PTEN down-regulation by unsaturated fatty acids triggers hepatic steatosis via an NF-kappaBp65/mTOR-dependent mechanism. 2008 , 134, 268-80	113
1984	Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. 2008 , 134, 568-76	427
1983	Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. 2008 , 134, 1369-75	403
1982	Obesity-induced lymphocyte hyperresponsiveness to chemokines: a new mechanism of Fatty liver inflammation in obese mice. 2008 , 134, 1459-69	63
1981	Diagnosis and therapy of nonalcoholic steatohepatitis. 2008 , 134, 1682-98	277
1980	Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. 2008 , 135, 100-10	490
1979	Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. 2008 , 135, 1176-84	516
1978	Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis. 2008 , 135, 1961-1971.e2	189
1977	The natural history of nonalcoholic fatty liver disease: insights from children and mice. 2008 , 135, 1860-2	3
1976	A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. 2008 , 40, 200-5	169
1975	Nonalcoholic fatty liver disease in children. 2008 , 27, 667-76	54
1974	Adipose tissue transcriptomic signature highlights the pathological relevance of extracellular matrix in human obesity. 2008 , 9, R14	300
1973	Hepatitis C infection and nonalcoholic fatty liver disease. 2008 , 12, 573-85, viii-ix	25
1972	Apoptosis markers in liver biopsy of nonalcoholic steatohepatitis in pediatric patients. 2008 , 39, 1816-22	13
1971	Hepatic free fatty acids accumulate in experimental steatohepatitis: role of adaptive pathways. 2008 , 48, 638-47	62
1970	Hepatic steatosis in HIV/HCV co-infected patients: correlates, efficacy and outcomes of anti-HCV therapy: a paired liver biopsy study. 2008 , 48, 756-64	36
1969	Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease. 2008 , 48, 829-34	141

1968	Ballooned hepatocytes in steatohepatitis: the value of keratin immunohistochemistry for diagnosis. 2008 , 48, 821-8	182
1967	Hepcidin and iron-related gene expression in subjects with Dysmetabolic Hepatic Iron Overload. 2008 , 49, 123-33	81
1966	MCD-induced steatohepatitis is associated with hepatic adiponectin resistance and adipogenic transformation of hepatocytes. 2008 , 49, 407-16	96
1965	Citrin deficiency as a cause of chronic liver disorder mimicking non-alcoholic fatty liver disease. 2008 , 49, 810-20	70
1964	A rodent model of NASH with cirrhosis, oval cell proliferation and hepatocellular carcinoma. 2008 , 49, 1055-61	74
1963	Monosodium glutamate (MSG): a villain and promoter of liver inflammation and dysplasia. 2008 , 30, 42-50	95
1962	Evolving trends in nonalcoholic fatty liver disease. 2008 , 19, 75-82	25
1961	Hepatic complications following preoperative chemotherapy with oxaliplatin or irinotecan for hepatic colorectal metastases. 2008 , 34, 609-14	87
1960	Patterns of hepatotoxicity after chemotherapy for colorectal cancer liver metastases. 2008 , 34, 1231-6	68
1959	Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study. 2008 , 30, 1168-76	97
1958	Dephosphorylation of translation initiation factor 2alpha enhances glucose tolerance and attenuates hepatosteatosis in mice. 2008 , 7, 520-32	329
1957	Should patients with type 2 diabetes and raised liver enzymes be referred for further evaluation of liver disease?. 2008 , 80, e10-2	9
1956	Nonalcoholic Fatty Liver Disease: Pathogenesis, Identification, Progression, and Management. 2008 , 65, 376-384	33
1955	Effectiveness of antiplatelet drugs against experimental non-alcoholic fatty liver disease. 2008 , 57, 1583-91	77
1954	Prevalence of esophagogastric varices in patients with non-alcoholic steatohepatitis. 2008 , 38, 572-9	12
1953	A possible rat model for non-alcoholic steatohepatitis: Histological findings in SHR/NDmcr-cp rats. 2008 , 38, 743-4	3
1952	Serum neopterin levels in patients with non-alcoholic steatohepatitis. 2008 , 38, 904-8	1
1951	Nonalcoholic steatohepatitis and hepatocellular carcinoma in galectin-3 knockout mice. 2008 , 38, 1241-51	24

1950	Definition and natural history of metabolic steatosis: histology and cellular aspects. 2008 , 34, 638-42	36
1949	Non-invasive diagnosis of steatosis and fibrosis. 2008 , 34, 674-9	50
1948	Placebo in nonalcoholic steatohepatitis: insight into natural history and implications for future clinical trials. 2008 , 6, 1243-8	33
1947	Regression of hepatic fibrosis after intestinal transplantation in total parenteral nutrition liver disease. 2008 , 6, 926-33	41
1946	Fatty liver: a novel component of the metabolic syndrome. 2008 , 28, 27-38	626
1945	Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients. 2008 , 6, 1249-54	124
1944	Chitosan ameliorates the severity of steatohepatitis induced by high fat diet in rats. 2008 , 43, 1371-7	8
1943	Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. 2008 , 103, 1372-9	422
1942	Chemotherapy prior to hepatic resection for colorectal liver metastases: helpful until harmful?. 2008 , 25, 421-9	40
1941	Histopathology of liver biopsies from a thiopurine-naïve inflammatory bowel disease cohort: prevalence of nodular regenerative hyperplasia. 2008 , 43, 604-8	53
1940	NASH may be trash. 2008 , 57, 141-4	25
1939	Fatigue in non-alcoholic fatty liver disease (NAFLD) is significant and associates with inactivity and excessive daytime sleepiness but not with liver disease severity or insulin resistance. 2008 , 57, 807-13	130
1938	Increased expression and activity of the transcription factor FOXO1 in nonalcoholic steatohepatitis. 2008 , 57, 1355-62	128
1937	Bloodletting ameliorates insulin sensitivity and secretion in parallel to reducing liver iron in carriers of HFE gene mutations. 2008 , 31, 3-8	42
1936	Pathogenesis and Clinical Practice in Gastroenterology. 2008 ,	
1935	Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. 2008 , 57, 1441-7	511
1934	Nonalcoholic fatty liver disease and mitochondrial dysfunction. 2008 , 14, 193-9	245
1933	Waist circumference correlates with liver fibrosis in children with non-alcoholic steatohepatitis. 2008 , 57, 1283-7	100

1932 ANSWER. **2008**, 57, 1447-1447

1931 Evaluation of the severity of chronic hepatitis C with 3-T1H-MR spectroscopy. **2008**, 190, 1331-9 23

1930 Hepatic, cardiovascular, and endocrine outcomes of the histological subphenotypes of nonalcoholic fatty liver disease. **2008**, 28, 380-5 52

1929 [Diagnosis and treatment of colorectal liver metastases - workflow]. **2008**, 133, 267-84 35

1928 Liver steatosis: investigation of opposed-phase T1-weighted liver MR signal intensity loss and visceral fat measurement as biomarkers. **2008**, 249, 160-6 43

1927 [Chemotherapy associated hepatotoxicity in the treatment of advanced colorectal cancer (CRC)]. **2008**, 46, 435-40 10

1926 The epidemiology of nonalcoholic fatty liver disease: a global perspective. **2008**, 28, 339-50 547

1925 Diagnosis of nonalcoholic fatty liver disease: invasive versus noninvasive. **2008**, 28, 386-95 205

1924 Role of fatty acids in the pathogenesis of obesity and fatty liver: impact of bariatric surgery. **2008**, 28, 407-26 63

1923 Recent advances in nonalcoholic fatty liver disease. **2008**, 24, 320-7 72

1922 Complications digestives du diab e. **2008**, 3, 1-8

1921 Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. **2008**, 138, 1452-5 303

1920 Nonalcoholic Fatty Liver Disease. 77-97 1

1919 Nutrition in pathophysiology and treatment of nonalcoholic fatty liver disease. **2008**, 11, 620-5 14

1918 Reply. **2008**, 190, W168-W168

1917 MRI in identifying hepatic steatosis in obese children and relation to ultrasonography and metabolic findings. **2008**, 47, 493-9 29

1916 Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis. **2008**, 42, 413-8 192

1915 Nonalcoholic fatty liver disease induced by leuprorelin acetate. **2008**, 42, 107-10 12

1914	CAN WE USE CLINICAL PARAMETERS TO PREDICT NONALCOHOLIC STEATOHEPATITIS IN MORBIDLY OBESE PATIENTS?. 2008 , 9, 69-70	
1913	Serum leptin and soluble leptin receptor in non-alcoholic fatty liver disease. 2008 , 14, 2888-93	57
1912	Pathways underlying iron accumulation in human nonalcoholic fatty liver disease. 2008 , 87, 1374-83	131
1911	Clinical update on non-alcoholic fatty liver disease and steatohepatitis. 2008 , 7, 157-160	9
1910	[Vascularization in hepatic cirrhosis: an immunohistochemical study on necropsies]. 2008 , 45, 38-45	
1909	Liver histology in ICU patients dying from sepsis: a clinico-pathological study. 2008 , 14, 1389-93	65
1908	Liver Disease in Obesity. 273-283	
1907	Does hepatocellular carcinoma in non-alcoholic steatohepatitis exist in cirrhotic and non-cirrhotic patients?. 2009 , 42, 958-62	49
1906	Fatty Liver Disease. 2009 , 1087-1114	7
1905	Expression of perilipin and adipophilin in nonalcoholic fatty liver disease; relevance to oxidative injury and hepatocyte ballooning. 2009 , 16, 893-901	69
1904	IL-6 deficiency attenuates murine diet-induced non-alcoholic steatohepatitis. 2009 , 4, e7929	65
1903	Altered clot kinetics in patients with non-alcoholic fatty liver disease. 2009 , 8, 331-338	20
1902	Non-invasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD). 2009 , 8, 89-94	33
1901	Noninvasive diagnosis of nonalcoholic fatty liver disease. 2009 , 8, S25-S33	29
1900	NASH and cryptogenic cirrhosis: A histological analysis. 2009 , 8, 346-352	90
1899	Kupffer cell activation by ambient air particulate matter exposure may exacerbate non-alcoholic fatty liver disease. 2009 , 6, 266-75	81
1898	A protective effect of breastfeeding on the progression of non-alcoholic fatty liver disease. 2009 , 94, 801-5	60
1897	Compartmental analysis of plasma and liver n-3 essential fatty acids in alcohol-dependent men during withdrawal. 2009 , 50, 154-61	10

1896	The correlation between sonographic diagnosis and laparoscopic observations on fatty liver. 2009 , 19, 163-9	2
1895	Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease. 2009 , 37, 2087-94	220
1894	The histologic spectrum of liver disease in African-American, non-Hispanic white, and Hispanic obesity surgery patients. 2009 , 104, 64-9	58
1893	The Effect of Metformin and Standard Therapy versus Standard Therapy alone in Nondiabetic Patients with Insulin Resistance and Nonalcoholic Steatohepatitis (NASH): A Pilot Trial. 2009 , 2, 157-63	107
1892	Hyperlipidemic chicken as a model of non-alcoholic steatohepatitis. 2009 , 234, 10-6	29
1891	Thyroid hormone-related regulation of gene expression in human fatty liver. 2009 , 94, 3521-9	108
1890	Pharmacological interventions for nonalcoholic fatty liver disease in adults and in children: a systematic review. 2009 , 48, 587-96	74
1889	Obstructive sleep apnea, insulin resistance, and steatohepatitis in severe obesity. 2009 , 179, 228-34	148
1888	MR imaging of liver fibrosis: current state of the art. 2009 , 29, 1615-35	186
1887	Gynaecological cause for bowel obstruction. 2009 , 58, 1466, 1544	1
1886	Farnesoid X receptor deficiency induces nonalcoholic steatohepatitis in low-density lipoprotein receptor-knockout mice fed a high-fat diet. 2009 , 328, 116-22	146
1885	Can nonalcoholic steatohepatitis be diagnosed without liver biopsy?. 2009 , 3, 353-61	4
1884	Hepatic fatty acid composition differs between chronic hepatitis C patients with and without steatosis. 2009 , 139, 691-5	18
1883	JNK1-dependent PUMA expression contributes to hepatocyte lipoapoptosis. 2009 , 284, 26591-602	156
1882	Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. 2009 , 249, 420-5	192
1881	Risk factors for chemotherapy-associated liver injuries: A multivariate analysis of a group of 146 patients with colorectal metastases. 2009 , 145, 362-71	94
1880	The pediatric NAFLD fibrosis index: a predictor of liver fibrosis in children with non-alcoholic fatty liver disease. 2009 , 7, 21	98
1879	Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C. 2009 , 9, 1406-13	103

1878	Serum levels of adipokines in patients with chronic HCV infection: relationship with steatosis and fibrosis. 2009 , 40, 294-8		25
1877	Curcumin ameliorates rabbits's steatohepatitis via respiratory chain, oxidative stress, and TNF-alpha. 2009 , 47, 924-31		58
1876	[Diagnosis and management of non alcoholic fatty liver disease]. 2009 , 33, 413-24		3
1875	[Non-alcoholic fatty liver disease: overview of the natural history]. 2009 , 33, 398-404		3
1874	[Noninvasive tools for the diagnosis of steatosis and fibrosis in patients with NAFLD]. 2009 , 33, 405-12		2
1873	[Nonalcoholic fatty liver disease: 30 years research changed NASH]. 2009 , 33, 850-8		2
1872	Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats. 2009 , 613, 119-27		82
1871	P.111 Caractéristiques cliniques et histologiques, traitement et survie de 40 patients atteints de carcinome hépatocellulaire en l'absence de cirrhose. 2009 , 33, A74		
1870	Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial. <i>Hepatology</i> , 2009 , 49, 80-6	11.2	325
1869	Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. <i>Hepatology</i> , 2009 , 49, 306-17	11.2	406
1868	Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy. <i>Hepatology</i> , 2009 , 49, 436-42	11.2	102
1867	The interleukin-17 pathway is involved in human alcoholic liver disease. <i>Hepatology</i> , 2009 , 49, 646-57	11.2	270
1866	Serum M30 levels: a potential biomarker of severe liver disease in nonalcoholic fatty liver disease and normal aminotransferase levels. <i>Hepatology</i> , 2009 , 49, 697; author reply 697	11.2	16
1865	Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. <i>Hepatology</i> , 2009 , 49, 809-20	11.2	265
1864	Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. <i>Hepatology</i> , 2009 , 49, 851-9	11.2	399
1863	Liver biopsy. <i>Hepatology</i> , 2009 , 49, 1017-44	11.2	1386
1862	Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. <i>Hepatology</i> , 2009 , 49, 1877-87	11.2	914
1861	Intramitochondrial crystalline inclusions in nonalcoholic steatohepatitis. <i>Hepatology</i> , 2009 , 49, 1888-95	11.2	52

1860	Quality of life in adults with nonalcoholic fatty liver disease: baseline data from the nonalcoholic steatohepatitis clinical research network. <i>Hepatology</i> , 2009 , 49, 1904-12	11.2	100
1859	Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease. <i>Hepatology</i> , 2009 , 49, 1926-34	11.2	119
1858	Nutritional model of steatohepatitis and metabolic syndrome in the Ossabaw miniature swine. <i>Hepatology</i> , 2009 , 50, 56-67	11.2	156
1857	Ethanol-induced cytochrome P4502E1 causes carcinogenic etheno-DNA lesions in alcoholic liver disease. <i>Hepatology</i> , 2009 , 50, 453-61	11.2	111
1856	Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. <i>Hepatology</i> , 2009 , 50, 1072-8	11.2	476
1855	Advances in pediatric nonalcoholic fatty liver disease. <i>Hepatology</i> , 2009 , 50, 1282-93	11.2	185
1854	Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study. <i>Hepatology</i> , 2009 , 50, 1113-20	11.2	139
1853	Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis. <i>Hepatology</i> , 2009 , 50, 1421-30	11.2	179
1852	Chronically inflamed livers up-regulate expression of inhibitory B7 family members. <i>Hepatology</i> , 2009 , 50, 1625-37	11.2	108
1851	Maternal high-fat feeding primes steatohepatitis in adult mice offspring, involving mitochondrial dysfunction and altered lipogenesis gene expression. <i>Hepatology</i> , 2009 , 50, 1796-808	11.2	322
1850	The plasma lipidomic signature of nonalcoholic steatohepatitis. <i>Hepatology</i> , 2009 , 50, 1827-38	11.2	431
1849	Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. 2009 , 115, 5651-61		304
1848	Fatigue and autonomic dysfunction in non-alcoholic fatty liver disease. 2009 , 19, 319-26		60
1847	Insulin resistance and exercise capacity in male children and adolescents with non-alcoholic fatty liver disease. 2009 , 46, 97-104		14
1846	Albuminuria and insulin resistance in children with biopsy proven non-alcoholic fatty liver disease. 2009 , 24, 1211-7		24
1845	Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases. 2009 , 16, 137-44		107
1844	Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. 2009 , 44 Suppl 19, 89-95		233
1843	Influence of adiponectin gene polymorphisms in Japanese patients with non-alcoholic fatty liver disease. 2009 , 44, 976-82		53

1842	'Designer oils' low in n-6:n-3 fatty acid ratio beneficially modifies cardiovascular risks in mice. 2009 , 48, 307-14	20
1841	Clinical and histological features of nonalcoholic fatty liver disease in children. 2009 , 54, 2225-30	49
1840	Chemotherapy-associated liver injury: Does it really matter?. 2009 , 5, 108-113	
1839	Rapid reversal of parenteral-nutrition-associated cirrhosis following isolated intestinal transplantation. 2009 , 13, 1717-23	26
1838	Adipokine serum levels are related to liver histology in severely obese patients undergoing bariatric surgery. 2009 , 19, 1313-23	37
1837	Alcohol-related cirrhosis--early abstinence is a key factor in prognosis, even in the most severe cases. 2009 , 104, 768-74	94
1836	Metabolic and histological features of non-alcoholic fatty liver disease patients with different serum alanine aminotransferase levels. 2009 , 29, 387-96	87
1835	Clinical trial: a nutritional supplement Viusid, in combination with diet and exercise, in patients with nonalcoholic fatty liver disease. 2009 , 30, 999-1009	73
1834	An inhibitor of interleukin-6 trans-signalling, sgp130, contributes to impaired acute phase response in human chronic liver disease. 2009 , 156, 518-27	26
1833	The impact of hepatic steatosis on the natural history of chronic hepatitis C infection. 2009 , 16, 492-9	37
1832	Retrospective, observational, multicentre study on an Italian population affected by chronic hepatitis C who failed to clear HCV-RNA after the combined therapy (PEG-IFN and ribavirin): NADIR study. 2010 , 17, 427-34	4
1831	Chronic intermittent hypoxia and acetaminophen induce synergistic liver injury in mice. 2009 , 94, 228-39	31
1830	Liver NF-kappaB and AP-1 DNA binding in obese patients. 2009 , 17, 973-9	74
1829	Ultrasonography to quantify hepatic fat content: validation by 1H magnetic resonance spectroscopy. 2009 , 17, 2239-44	35
1828	Triglyceride levels and not adipokine concentrations are closely related to severity of nonalcoholic fatty liver disease in an obesity surgery cohort. 2009 , 17, 1696-701	70
1827	Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. 2009 , 24, 248-54	238
1826	Effects of probucol on hepatic tumor necrosis factor-alpha, interleukin-6 and adiponectin receptor-2 expression in diabetic rats. 2009 , 24, 1058-63	11
1825	The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease. 2009 , 24, 564-8	68

1824	An association between non-alcoholic fatty liver disease and polycystic ovarian syndrome. 2009 , 24, 243-7	74
1823	Apoptosis in experimental NASH is associated with p53 activation and TRAIL receptor expression. 2009 , 24, 443-52	97
1822	Will non-invasive markers replace liver biopsy for diagnosing and staging fibrosis in non-alcoholic steatohepatitis?. 2009 , 24, 501-3	15
1821	When liver stiffness is not so straight forward and Fibroscan not so simple. 2009 , 24, 934-6	
1820	Roles of adipose restriction and metabolic factors in progression of steatosis to steatohepatitis in obese, diabetic mice. 2009 , 24, 1658-68	61
1819	Angiotensin-converting enzyme inhibitors improve hepatic steatosis by modulating expression of tumour necrosis factor-alpha, interleukin-6 and adiponectin receptor-2 in rats with type 2 diabetes. 2009 , 36, 631-6	14
1818	Nitric oxide-mediated intestinal injury is required for alcohol-induced gut leakiness and liver damage. 2009 , 33, 1220-30	89
1817	Effect of steatosis and inflammation on liver fibrosis in chronic hepatitis C. 2009 , 29, 153-8	8
1816	Elevated concentrations of 15-deoxy-Delta12,14-prostaglandin J2 in chronic liver disease propose therapeutic trials with peroxisome proliferator activated receptor gamma-inducing drugs. 2009 , 29, 730-5	5
1815	The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C. 2009 , 29, 748-53	65
1814	Cross-species immunohistochemical investigation of the activation of the liver progenitor cell niche in different types of liver disease. 2009 , 29, 1241-52	25
1813	Teucrium polium in prevention of steatohepatitis in rats. 2009 , 29, 1216-21	17
1812	Genetic differences in oxidative stress and inflammatory responses to diet-induced obesity do not alter liver fibrosis in mice. 2009 , 29, 1262-72	25
1811	Apoptosis is associated with CD36/fatty acid translocase upregulation in non-alcoholic steatohepatitis. 2010 , 30, 850-9	65
1810	The challenge of developing novel pharmacological therapies for non-alcoholic steatohepatitis. 2010 , 30, 795-808	48
1809	Respiratory motion-corrected proton magnetic resonance spectroscopy of the liver. 2009 , 27, 570-6	21
1808	In vivo quantification of liver stiffness in a rat model of hepatic fibrosis with acoustic radiation force. 2009 , 35, 1709-21	45
1807	Decreased plasma levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with nonalcoholic fatty liver disease. 2009 , 42, 802-7	53

1806	Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases. 2009 , 16, 35-41	87
1805	Chemotherapy-associated hepatotoxicity: do we need to be concerned?. 2009 , 16, 2391-4	51
1804	Serum protein N-glycans profiling for the discovery of potential biomarkers for nonalcoholic steatohepatitis. 2009 , 8, 463-70	44
1803	Serum proteomic profiling of obese patients: correlation with liver pathology and evolution after bariatric surgery. 2009 , 58, 825-32	46
1802	A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity. 2009 , 50, 2111-6	276
1801	Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases. 2009 , 35, 515-20	126
1800	Accuracy of liver-specific magnetic resonance imaging as a predictor of chemotherapy-associated hepatic cellular injury prior to liver resection. 2009 , 35, 1085-91	28
1799	Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. 2009 , 30, 88-96	118
1798	Hepatic steatosis in organ donors: disparity between surgery and histology?. 2009 , 41, 2557-60	29
1797	Hepatic lipid metabolism and non-alcoholic fatty liver disease. 2009 , 19, 291-302	213
1796	[Advances in nonalcoholic fatty liver disease]. 2009 , 133, 258-60	0
1795	Hepatic steatosis is uncommon in children with chronic hepatitis B. 2009 , 46, 360-2	5
1794	Comparison of blood tests for liver fibrosis specific or not to NAFLD. 2009 , 50, 165-73	195
1793	Can imaging modalities diagnose and stage hepatic fibrosis and cirrhosis accurately?. 2009 , 50, 17-35	145
1792	Serum retinol-binding protein 4 is inversely correlated with disease severity of chronic hepatitis C. 2009 , 50, 471-8	18
1791	Eicosapentaenoic acid ameliorates steatohepatitis and hepatocellular carcinoma in hepatocyte-specific Pten-deficient mice. 2009 , 50, 562-71	67
1790	Influence of ethnicity on histological differences in non-alcoholic fatty liver disease. 2009 , 50, 797-804	101
1789	Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH. 2009 , 50, 789-96	239

1788	Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients. 2009 , 50, 712-8	124
1787	Association between omental adipose tissue macrophages and liver histopathology in morbid obesity: influence of glycemic status. 2009 , 51, 354-62	83
1786	Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. 2009 , 51, 371-9	393
1785	Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. 2009 , 51, 433-45	556
1784	Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. 2009 , 51, 778-86	170
1783	Effects of weight loss induced by bariatric surgery on hepatic adipocytokine expression. 2009 , 51, 765-77	113
1782	Elevated serum ALT in children presenting to the emergency unit: Relationship with NAFLD. 2009 , 41, 749-52	37
1781	Serum levels of hyaluronic acid and tissue metalloproteinase inhibitor-1 combined with age predict the presence of nonalcoholic steatohepatitis in a pilot cohort of subjects with nonalcoholic fatty liver disease. 2009 , 154, 194-201	33
1780	New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD). 2009 , 41, 265-78	95
1779	Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease. 2009 , 136, 160-7	195
1778	Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. 2009 , 137, 532-40	364
1777	Nonalcoholic fatty liver disease and low-carbohydrate diets. 2009 , 29, 365-79	47
1776	Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. 2009 , 7, 1104-12	734
1775	Nonalcoholic fatty liver disease: a practical approach to evaluation and management. 2009 , 13, 249-66	48
1774	Utility of quantitative 99mTc-phytate scintigraphy to diagnose early-stage non-alcoholic steatohepatitis. 2009 , 44, 229-36	13
1773	Histopathology of non-alcoholic fatty liver disease. 2009 , 13, 533-44	90
1772	Retinol-binding protein 4: a promising circulating marker of liver damage in pediatric nonalcoholic fatty liver disease. 2009 , 7, 575-9	57
1771	Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. 2009 , 44, 853-60	224

1770	The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. 2009 , 58, 1538-44	452
1769	Metformin plus pentoxifylline versus prescriptive diet in non-alcoholic steatohepatitis (NASH): a randomized controlled pilot trial. 2009 , 33, 984-6	8
1768	Proteomic analysis of serum in patients with non-alcoholic steatohepatitis using matrix-assisted laser desorption ionization time-of-flight mass spectrometry. 2009 , 44, 1471-6	11
1767	Nonalcoholic fatty liver disease: diagnostic and fat-grading accuracy of low-flip-angle multiecho gradient-recalled-echo MR imaging at 1.5 T. 2009 , 251, 67-76	258
1766	Pro-atherogenic effects of probucol in apo E-KO mice may be mediated through alterations in immune system: Parallel alterations in gene expression in the aorta and liver. 2009 , 206, 427-33	3
1765	Evidence that chronic alcohol exposure promotes intestinal oxidative stress, intestinal hyperpermeability and endotoxemia prior to development of alcoholic steatohepatitis in rats. 2009 , 50, 538-47	256
1764	Magnetic resonance imaging and spectroscopy accurately estimate the severity of steatosis provided the stage of fibrosis is considered. 2009 , 51, 389-97	133
1763	Phenotyping murine models of non-alcoholic fatty liver disease through metabolic profiling of intact liver tissue. 2009 , 116, 403-13	29
1762	Surgical management of colorectal liver metastases. 2009 , 6, 349-357	1
1761	Diagnosis and treatment of pediatric nonalcoholic steatohepatitis and the implications for bariatric surgery. 2009 , 18, 144-51	37
1760	Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases. 2009 , 10, 278-86	125
1759	Non-alcoholic steatohepatitis: an overview. 2009 , 108, 4-12	24
1758	Fatty acid composition and development of hepatic lipodosis during food deprivation--mustelids as a potential animal model for liver steatosis. 2009 , 234, 278-86	23
1757	Sex difference in the liver of hepatocyte-specific Pten-deficient mice: A model of nonalcoholic steatohepatitis. 2009 , 39, 609-18	22
1756	Treatment of nonalcoholic steatohepatitis with colestimide. 2009 , 39, 685-93	20
1755	Clinical significance of serum ornithine carbamoyltransferase in patients with non-alcoholic steatohepatitis. 2009 , 39, 939-43	5
1754	Circulating and liver tissue levels of retinol-binding protein-4 in non-alcoholic fatty liver disease. 2009 , 39, 972-8	29
1753	Does liver appearance predict histopathologic findings: prospective analysis of routine liver biopsies during bariatric surgery. 2009 , 5, 323-8	33

1752	Effects of liver biopsy sample length and number of readings on sampling variability in nonalcoholic Fatty liver disease. 2009 , 7, 481-6	127
1751	Noninvasive assessment of fibrosis and steatosis in NASH and ASH. 2009 , 33, 940-8	12
1750	Noninvasive assessment of hepatic steatosis. 2009 , 7, 135-40	108
1749	Liver biopsy in alcoholic and non-alcoholic steatohepatitis patients. 2009 , 33, 930-9	25
1748	[Adenocarcinoma of gallbladder revealed by acanthosis nigricans]. 2009 , 33, 986-8	2
1747	Obesity, metabolic syndrome, and the surgical patient. 2009 , 27, 705-19	5
1746	Alcohol pretreatment increases hepatic and pulmonary injury in experimental pancreatitis. 2009 , 9, 258-66	7
1745	Obesity, metabolic syndrome, and the surgical patient. 2009 , 93, 1049-63	17
1744	Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B. 2009 , 58, 111-7	168
1743	Low serum adiponectin levels are predictive of advanced hepatic fibrosis in patients with NAFLD. 2009 , 43, 765-72	52
1742	Could inflammatory markers help diagnose nonalcoholic steatohepatitis?. 2009 , 21, 504-11	133
1741	Effects of light-to-moderate alcohol consumption on steatosis and steatohepatitis in severely obese patients. 2009 , 21, 969-72	57
1740	Role of liver-infiltrating CD3+CD56+ natural killer T cells in the pathogenesis of nonalcoholic fatty liver disease. 2009 , 21, 673-80	92
1739	Author's Response. 2009 , 49, 371-372	
1738	Methods for assessing intrahepatic fat content and steatosis. 2009 , 12, 474-81	33
1737	Thiazolidinediones for the treatment in NASH: sustained benefit after drug discontinuation?. 2009 , 43, 565-8	23
1736	Serum concentrations of human angiopoietin-like protein 3 in patients with nonalcoholic fatty liver disease: association with insulin resistance. 2009 , 21, 1247-51	32
1735	Liver steatosis quantification using magnetic resonance imaging: a prospective comparative study with liver biopsy. 2009 , 33, 672-7	36

- 1734 Imaging of nonalcoholic steatohepatitis: advantages and pitfalls of ultrasonography and computed tomography. **2009**, 48, 739-46 59
- 1733 Hepatic Diseases Such as Fatty Liver and Diabetes Mellitus. **2009**, 98, 1756-1762
- 1732 Commentary on "Cytokeratin 18, a Marker of Cell Death, is Increased in Children With Suspected Nonalcoholic Fatty Liver Disease". **2009**, 49, 371; author reply 371-2
- 1731 Epigallocatechin-3-gallate improves nonalcoholic steatohepatitis model mice expressing nuclear sterol regulatory element binding protein-1c in adipose tissue. **2009**, 24, 17-22 22
- 1730 Nutrient composition vs food ingredients in the treatment of hospitalized and severely malnourished children. **2009**, 49, 372-3
- 1729 Non-Alcoholic Fatty Liver Disease. 119-134 4
- 1728 Non-Alcoholic Fatty Liver Disease. **2009**, 1-14
- 1727 Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis: histological diagnostic criteria and scoring systems. **2010**, 22, 643-50 57
- 1726 Assessment of hepatic steatosis by expert pathologists: the end of a gold standard. **2009**, 250, 691-7 198
- 1725 Nonalcoholic fatty liver disease in children. **2010**, 13, 397-402 29
- 1724 Macrophage migration inhibitory factor expression and MIF gene -173 G/C polymorphism in nonalcoholic fatty liver disease. **2010**, 22, 192-8 20
- 1723 Liver Disease in Diabetes Mellitus: Potential Therapeutic Value of Vitamin E-Silybin Phytosomal Complex. **2010**, 10, 84-90
- 1722 Non-Alcoholic Fatty Liver Disease. **2010**, 19, 36-50 4
- 1721 The importance of fatty liver disease in clinical practice. **2010**, 69, 518-27 13
- 1720 1Chapter 5 Intestinal Failure and Liver Disease Related to Parenteral Nutrition and Intestinal Transplantation. **2010**, 251-270
- 1719 Implications of diet on nonalcoholic fatty liver disease. **2010**, 26, 160-4 46
- 1718 Effects of gadolinium chloride and glycine on hepatic and pancreatic tissue damage in alcoholic pancreatitis. **2010**, 39, 502-9 14
- 1717 Endotoxin and plasminogen activator inhibitor-1 serum levels associated with nonalcoholic steatohepatitis in children. **2010**, 50, 645-9 105

1716	Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease. 2010 , 22, 18-23	89
1715	Noninvasive liver steatosis quantification using MRI techniques combined with blood markers. 2010 , 22, 973-82	22
1714	Nonalcoholic Steatohepatitis (NASH). 2010 , 15, 65-71	
1713	Serum B12 concentration is elevated in patients receiving chronic parenteral nutrition, but is not a marker of intestinal failure-associated liver disease. 2010 , 44, 571-4	6
1712	Biomarkers in nonalcoholic fatty liver disease: a new era in diagnosis and staging of disease in children. 2010 , 51, 378-9	9
1711	Serum apoptotic caspase activity in chronic hepatitis C and nonalcoholic Fatty liver disease. 2010 , 44, e87-95	35
1710	Prevalence and factors associated with the presence of nonalcoholic fatty liver disease in an adult population in Spain. 2010 , 22, 24-32	135
1709	Nonalcoholic fatty liver disease is related to nonalcoholic fatty pancreas disease. 2010 , 39, 1185-90	111
1708	Serum retinol-binding protein 4 in patients with nonalcoholic fatty liver disease: does it have a significant impact on pathogenesis?. 2010 , 22, 813-9	25
1707	Chemotherapy-induced liver injury in metastatic colorectal cancer: semiquantitative histologic analysis of 334 resected liver specimens shows that vascular injury but not steatohepatitis is associated with preoperative chemotherapy. 2010 , 34, 784-91	69
1706	Statins for non-alcoholic steatohepatitis. 2010 ,	3
1705	Hepatic Steatosis and Non-Alcoholic Fatty Liver Disease. 2010 , 224-234	
1704	Oxidative stress parameters in paediatric non-alcoholic fatty liver disease. 2010 , 26, 471-6	67
1703	Liver fat change in obese children after a 1-year nutrition-behavior intervention. 2010 , 51, 331-5	33
1702	Hypoxia aggravates non-alcoholic steatohepatitis in mice lacking hepatocellular PTEN. 2009 , 118, 401-10	68
1701	Perioperative chemotherapy with bevacizumab and liver resection for colorectal cancer liver metastasis. 2010 , 12, 37-42	17
1700	Recovery of liver function after the cessation of preoperative chemotherapy for colorectal liver metastasis. 2010 , 17, 2747-55	46
1699	Transient elastography with a new probe for obese patients for non-invasive staging of non-alcoholic steatohepatitis. 2010 , 20, 2390-6	91

1698	Liver immunolocalization and plasma levels of MMP-9 in non-alcoholic steatohepatitis (NASH) and hepatitis C infection. 2010 , 112, 474-81	18
1697	Non-alcoholic fatty liver disease in liver transplant recipients: another story of "seed and soil". 2010 , 105, 613-20	148
1696	Histological and immediate postoperative outcome after preoperative cetuximab: case-matched control study. 2010 , 34, 2765-72	13
1695	[Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease. Grade 2 consensus-based guidelines]. 2010 , 31, 225-37	19
1694	Steatosis hepatis. 2010 , 158, 1070-1076	1
1693	Histological liver injury and surgical outcome after FOLFOX followed by a hepatectomy for colorectal liver metastases in Japanese patients. 2010 , 15, 263-70	21
1692	Oral supplementation with L-aspartate and L-glutamate inhibits atherogenesis and fatty liver disease in cholesterol-fed rabbit. 2010 , 38, 1323-31	20
1691	Hepatic senescence marker protein-30 is involved in the progression of nonalcoholic fatty liver disease. 2010 , 45, 426-34	29
1690	Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH. 2010 , 45, 750-7	119
1689	Prospective study of hepatocellular carcinoma in nonalcoholic steatohepatitis in comparison with hepatocellular carcinoma caused by chronic hepatitis C. 2010 , 45, 960-7	58
1688	Accurate and simple method for quantification of hepatic fat content using magnetic resonance imaging: a prospective study in biopsy-proven nonalcoholic fatty liver disease. 2010 , 45, 1263-71	29
1687	Fatty liver disease in children: eat now pay later. 2010 , 4, 375-85	23
1686	Hypoadiponectinemia and its association with liver fibrosis in morbidly obese patients. 2010 , 20, 1400-7	15
1685	Overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in hepatic and visceral adipose tissue is associated with metabolic disorders in morbidly obese patients. 2010 , 20, 77-83	47
1684	A noninvasive clinical scoring model predicts risk of nonalcoholic steatohepatitis in morbidly obese patients. 2010 , 20, 685-91	42
1683	The decrease of serum levels of human neutrophil alpha-defensins parallels with the surgery-induced amelioration of NASH in obesity. 2010 , 20, 1682-9	13
1682	Hepatic gene networks in morbidly obese patients with nonalcoholic fatty liver disease. 2010 , 20, 1698-709	25
1681	Pro- and anti-inflammatory cytokines in steatosis and steatohepatitis. 2010 , 20, 906-12	23

1680	Characterization of high-fat, diet-induced, non-alcoholic steatohepatitis with fibrosis in rats. 2010 , 55, 931-40	135
1679	The effects of a fat- and sugar-enriched diet and chronic stress on nonalcoholic fatty liver disease in male Wistar rats. 2010 , 55, 2227-36	27
1678	The inflamed liver and atherosclerosis: a link between histologic severity of nonalcoholic fatty liver disease and increased cardiovascular risk. 2010 , 55, 2644-50	85
1677	Nonalcoholic fatty liver disease: a review and update. 2010 , 55, 560-78	245
1676	Digital quantification is more precise than traditional semiquantitation of hepatic steatosis: correlation with fibrosis in 220 treatment-naïve patients with chronic hepatitis C. 2010 , 55, 2049-57	18
1675	Plasma apelin levels in subjects with nonalcoholic fatty liver disease. 2010 , 59, 977-81	32
1674	Microalbuminuria in nondiabetic patients with nonalcoholic fatty liver disease: association with liver fibrosis. 2010 , 59, 1327-30	82
1673	Prevalence and clinical relevance of pathological hepatic changes occurring after neoadjuvant chemotherapy for colorectal liver metastases. 2010 , 147, 185-94	30
1672	Clinicopathological correlations in a series of adult patients with non-alcoholic fatty liver disease. 2010 , 60, 87-92	13
1671	Nuclear size measurement is a simple method for the assessment of hepatocellular aging in non-alcoholic fatty liver disease: Comparison with telomere-specific quantitative FISH and p21 immunohistochemistry. 2010 , 60, 175-83	35
1670	Inhibition of JNK along with activation of ERK1/2 MAPK pathways improve steatohepatitis among the rats. 2010 , 29, 381-5	24
1669	Enhanced steatosis by nuclear receptor ligands: a study in cultured human hepatocytes and hepatoma cells with a characterized nuclear receptor expression profile. 2010 , 184, 376-87	65
1668	Resveratrol attenuates hyperglycemia-mediated oxidative stress, proinflammatory cytokines and protects hepatocytes ultrastructure in streptozotocin-nicotinamide-induced experimental diabetic rats. 2010 , 186, 200-10	87
1667	[Influence of pre-surgical chemotherapy on liver parenchyma and post-surgical outcome of patients subjected to hepatectomy due to colorectal carcinoma metastases]. 2010 , 88, 404-12	6
1666	Clinical review of nonalcoholic steatohepatitis in liver surgery and transplantation. 2010 , 210, 515-26	30
1665	Major histocompatibility complex class I-related chains A and B (MIC A/B): a novel role in nonalcoholic steatohepatitis. <i>Hepatology</i> , 2010 , 51, 92-102	11.2 78
1664	Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. <i>Hepatology</i> , 2010 , 51, 445-53	11.2 260
1663	Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. <i>Hepatology</i> , 2010 , 51, 121-9	11.2 823

1662	Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. <i>Hepatology</i> , 2010 , 51, 679-89	11.2	1196
1661	Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. <i>Hepatology</i> , 2010 , 51, 454-62	11.2	790
1660	Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. <i>Hepatology</i> , 2010 , 51, 595-602	11.2	537
1659	Toxicant-associated steatohepatitis in vinyl chloride workers. <i>Hepatology</i> , 2010 , 51, 474-81	11.2	102
1658	Serum cytokeratin-18 fragment level: a noninvasive biomarker for not only nonalcoholic steatohepatitis, but also alcoholic steatohepatitis. <i>Hepatology</i> , 2010 , 51, 1865-6	11.2	8
1657	Molecular signatures of nonalcoholic fatty liver disease: the present and future. <i>Hepatology</i> , 2010 , 51, 1866	11.2	
1656	Thiazolidinediones as potent inducers of hepatocyte growth factor. <i>Hepatology</i> , 2010 , 51, 1866-7	11.2	1
1655	Cigarette smoking exacerbates nonalcoholic fatty liver disease in obese rats. <i>Hepatology</i> , 2010 , 51, 1567-76	11.2	90
1654	Long-term mortality in nonalcoholic fatty liver disease: is liver histology of any prognostic significance?. <i>Hepatology</i> , 2010 , 51, 373-5	11.2	153
1653	Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2010 , 51, 1961-71	11.2	479
1652	Is oil red-O staining and digital image analysis the gold standard for quantifying steatosis in the liver?. <i>Hepatology</i> , 2010 , 51, 1859; author reply 1859-60	11.2	12
1651	Routine hepatitis B virus DNA testing in patients with human immunodeficiency virus. <i>Hepatology</i> , 2010 , 52, 397	11.2	
1650	Think twice if you consider entecavir treatment in cases with lamivudine refractoriness. <i>Hepatology</i> , 2010 , 52, 397-8	11.2	2
1649	Hemochromatosis protein HFE C282Y conformational considerations. <i>Hepatology</i> , 2010 , 52, 398-9	11.2	1
1648	Natural approach against lipotoxic traffic in nonalcoholic fatty liver disease. <i>Hepatology</i> , 2010 , 52, 399	11.2	
1647	Genetic variations in heme oxygenase-1 and chronic hepatitis. <i>Hepatology</i> , 2010 , 52, 400-1	11.2	10
1646	Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. <i>Hepatology</i> , 2010 , 51, 1593-602	11.2	286
1645	Quantification of genotype 4 serum samples: Impact of hepatitis C virus genetic variability. <i>Hepatology</i> , 2010 , 52, 401	11.2	7

1644	Comments on AASLD practice guidelines for alcoholic liver disease. <i>Hepatology</i> , 2010 , 51, 1860-1; author reply 1861	11.2	3
1643	Hepatitis C virus genotype 2/3 patients who can receive an abbreviated course of peginterferon/ribavirin: the important role of initial ribavirin doses. <i>Hepatology</i> , 2010 , 51, 1861-2; author reply 1862-4	11.2	0
1642	Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2010 , 51, 1209-17	11.2	445
1641	Fibrosis in liver as a predictive marker for hepatitis C virus therapy. <i>Hepatology</i> , 2010 , 51, 1858; author reply 1858	11.2	
1640	Reply: Fibrosis in liver as a predictive marker for hepatitis C virus therapy. <i>Hepatology</i> , 2010 , 51, 1858-1858	11.2	
1639	Reply: Is oil red-O staining and digital image analysis the gold standard for quantifying steatosis in the liver?. <i>Hepatology</i> , 2010 , 51, 1859-1860	11.2	2
1638	Reply: Comments on AASLD practice guidelines for alcoholic liver disease. <i>Hepatology</i> , 2010 , 51, 1861-1861	11.2	1
1637	Reply: Hepatitis C virus genotype 2/3 patients who can receive an abbreviated course of peginterferon/ribavirin: The important role of initial ribavirin doses. <i>Hepatology</i> , 2010 , 51, 1862-1864	11.2	
1636	Adjunctive vitamin E treatment in Wilson disease and suggestions for future trials. <i>Hepatology</i> , 2010 , 51, 1864; author reply 1864-5	11.2	6
1635	Reply: Adjunctive vitamin E treatment in Wilson disease and suggestions for future trials. <i>Hepatology</i> , 2010 , 51, 1864-1865	11.2	
1634	Diagnostic utility of chromosome 17 and p16 abnormalities in fluorescence in situ hybridization tests in primary sclerosing cholangitis. <i>Hepatology</i> , 2010 , 52, 393-4; author reply 394-5	11.2	
1633	Cigarette smoking is not associated with specific histological features or severity of nonalcoholic fatty liver disease. <i>Hepatology</i> , 2010 , 52, 391; author reply 391-2	11.2	10
1632	High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. <i>Hepatology</i> , 2010 , 52, 472-9	11.2	217
1631	Ferritin and liver allocation? Impact on mortality not only on the waiting list but also after orthotopic liver transplantation should be considered. <i>Hepatology</i> , 2010 , 52, 392-3; author reply 393	11.2	5
1630	Reply: Cigarette Smoking Is Not Associated with Specific Histological Features or Severity of Nonalcoholic Fatty Liver Disease. <i>Hepatology</i> , 2010 , 52, 391-392	11.2	
1629	Reply: Ferritin and Liver Allocation? Impact on Mortality Not Only on the Waiting List But Also After Orthotopic Liver Transplantation Should Be Considered. <i>Hepatology</i> , 2010 , 52, 393-393	11.2	
1628	Reply: Diagnostic Utility of Chromosome 17 and p16 Abnormalities in Fluorescence In Situ Hybridization Tests in Primary Sclerosing Cholangitis. <i>Hepatology</i> , 2010 , 52, 394-395	11.2	
1627	The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. <i>Hepatology</i> , 2010 , 52, 894-903	11.2	333

1626	Methodological issues in a meta-analysis. <i>Hepatology</i> , 2010 , 52, 395-6; author reply 396-7	11.2	1
1625	Reply: Methodological issues in a meta-analysis. <i>Hepatology</i> , 2010 , 52, 396-397	11.2	
1624	PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease. <i>Hepatology</i> , 2010 , 52, 904-12	11.2	267
1623	Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2010 , 52, 913-24	11.2	309
1622	Vitamin E for nonalcoholic steatohepatitis: ready for prime time?. <i>Hepatology</i> , 2010 , 52, 789-92	11.2	6
1621	I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease. <i>Hepatology</i> , 2010 , 52, 1274-80	11.2	200
1620	Epigenetic regulation of insulin resistance in nonalcoholic fatty liver disease: impact of liver methylation of the peroxisome proliferator-activated receptor α activator 1 promoter. <i>Hepatology</i> , 2010 , 52, 1992-2000	11.2	233
1619	Rosiglitazone attenuates age- and diet-associated nonalcoholic steatohepatitis in male low-density lipoprotein receptor knockout mice. <i>Hepatology</i> , 2010 , 52, 2001-11	11.2	76
1618	Relationship between insulin resistance, inflammation and liver cell apoptosis in patients with severe obesity. 2010 , 26, 187-92		24
1617	Noninvasive quantification of hepatic steatosis in rats using 3.0 T 1H-magnetic resonance spectroscopy. 2010 , 32, 148-54		24
1616	Do steatosis and steatohepatitis impact on sustained virological response (SVR) rates in patients receiving pegylated interferon and ribavirin for chronic hepatitis C infection?. 2010 , 82, 958-64		7
1615	Frequency and predictors of nonalcoholic fatty liver disease in myotonic dystrophy. 2010 , 41, 197-201		22
1614	Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease. 2010 , 16, 431-9		167
1613	Lack of association between peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms and progressive liver damage in patients with non-alcoholic fatty liver disease: a case control study. 2010 , 10, 102		46
1612	Non-alcoholic fatty liver disease proteomics. 2010 , 4, 362-71		38
1611	Pathological response grade of colorectal liver metastases treated with neoadjuvant chemotherapy. 2010 , 12, 277-84		23
1610	Non-alcoholic steatohepatitis induces non-fibrosis-related portal hypertension associated with splanchnic vasodilation and signs of a hyperdynamic circulation in vitro and in vivo in a rat model. 2010 , 30, 365-75		33
1609	Diagnosis of different liver fibrosis characteristics by blood tests in non-alcoholic fatty liver disease. 2010 , 30, 1346-54		35

1608	Prevalence, risk factors and causes of discordance in fibrosis staging by transient elastography and liver biopsy. 2010 , 30, 1471-80	67
1607	Symptoms and quality of life in obese children and adolescents with non-alcoholic fatty liver disease. 2010 , 31, 396-406	64
1606	Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis. 2010 , 32, 1211-21	111
1605	A new composite model including metabolic syndrome, alanine aminotransferase and cytokeratin-18 for the diagnosis of non-alcoholic steatohepatitis in morbidly obese patients. 2010 , 32, 1315-22	101
1604	Physiological hepatic nuclear vacuolation--how long does it persist?. 2010 , 56, 426-9	19
1603	Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease. 2010 , 40, 887-92	129
1602	Hepatic expression of cell death-inducing DFFA-like effector C in obese subjects is reduced by marked weight loss. 2010 , 18, 417-9	28
1601	Nonalcoholic fatty liver disease: a challenge for pediatricians. 2010 , 34, 1451-67	49
1600	Attenuated progression of diet-induced steatohepatitis in glutathione-deficient mice. 2010 , 90, 1704-17	57
1599	The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease. 2010 , 12, 365-83	170
1598	Association of polymorphisms of glutamate-cystein ligase and microsomal triglyceride transfer protein genes in non-alcoholic fatty liver disease. 2010 , 25, 357-61	60
1597	Electron microscopic findings in non-alcoholic fatty liver disease: is there a difference between hepatosteatosis and steatohepatitis?. 2010 , 25, 619-26	24
1596	A fresh look at NASH pathogenesis. Part 1: the metabolic movers. 2010 , 25, 672-90	132
1595	Liver Histopathology. 2010 , 239-248	
1594	Digestive and metabolic physiology of obesity. 28-43	
1593	Nonalcoholic fatty liver disease in asymptomatic obese women. 2010 , 9, 144-149	8
1592	Serum fragmented cytokeratin 18 levels reflect the histologic activity score of nonalcoholic fatty liver disease more accurately than serum alanine aminotransferase levels. 2010 , 44, 440-7	58
1591	Nonalcoholic fatty liver disease in children. 2011 , 14, 151-7	61

1590	Transient elastography for the noninvasive assessment of liver fibrosis: a multicentre Canadian study. 2010 , 24, 661-70	46
1589	Comparative evaluation of whole body and hepatic insulin resistance using indices from oral glucose tolerance test in morbidly obese subjects with nonalcoholic Fatty liver disease. 2010 , 2010,	18
1588	Serum Markers of Liver Fibrosis: Combining the BIPED Classification and the Neo-Epitope Approach in the Development of New Biomarkers. 2010 , 28, 15-28	28
1587	Evaluation of the nonalcoholic fat liver disease fibrosis score for patients undergoing bariatric surgery. 2010 , 47, 170-3	18
1586	Experimental induction of steatosis in different tissues after the ingestion of a carbohydrate-rich diet: effect on the liver, on the heart and on indicators of oxidation. 2010 , 47, 388-92	3
1585	Mice with null mutation of Ceam I develop nonalcoholic steatohepatitis. 2010 , 2010, 69-78	19
1584	The Effect of Citrullus colocynthis Pulp Extract on the Liver of Diabetic Rats a Light and Scanning Electron Microscopic Study. 2010 , 6, 155-163	13
1583	[Nonalcoholic fatty liver disease]. 2010 , 56, 6-14	7
1582	Non-alcoholic fatty liver disease (NAFLD) in the Western Cape: a descriptive analysis. 2010 , 100, 168-71	17
1581	Histopathology of nonalcoholic fatty liver disease. 2010 , 16, 5286-96	262
1580	El Propileno Reduce la Esteatosis Hepática Inducida por Dieta en Ratones. 2010 , 28,	2
1579	Cardiovascular physiology. 1-18	
1578	Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. 2010 , 59, 969-74	431
1577	Expression, cellular distribution, and prognostic relevance of TRAIL receptors in hepatocellular carcinoma. 2010 , 16, 5529-38	42
1576	Digital analysis of hepatic sections in mice accurately quantitates triglycerides and selected properties of lipid droplets. 2010 , 235, 1282-6	16
1575	Intake of trans fatty acids causes nonalcoholic steatohepatitis and reduces adipose tissue fat content. 2010 , 140, 1127-32	60
1574	A silybin-phospholipid complex prevents mitochondrial dysfunction in a rodent model of nonalcoholic steatohepatitis. 2010 , 332, 922-32	47
1573	Liver biopsy for histological assessment: The case against. 2010 , 16, 124-32	49

1572	Serum fetuin A/ α 2HS-glycoprotein levels in patients with non-alcoholic fatty liver disease: relation with liver fibrosis. 2010 , 47, 549-53	49
1571	Increased arterial stiffness and impaired endothelial function in nonalcoholic Fatty liver disease: a pilot study. 2010 , 23, 1183-9	89
1570	Paediatric non-alcoholic fatty liver disease. 2010 , 59, 561-4	14
1569	Severity of liver injury and atherogenic lipid profile in children with nonalcoholic fatty liver disease. 2010 , 67, 665-70	52
1568	A novel non-alcoholic steatohepatitis animal model featured with insulin resistance, hepatic inflammation and fibrosis. 2010 , 45, 1360-71	10
1567	Association between metabolic syndrome and liver histology among children with nonalcoholic Fatty liver disease. 2010 , 105, 2093-102	126
1566	Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. 2010 , 59, 1265-9	499
1565	Genome-wide association studies and genetic risk assessment of liver diseases. 2010 , 7, 669-81	61
1564	Serum levels of osteoprotegerin in the spectrum of nonalcoholic fatty liver disease. 2010 , 70, 541-6	31
1563	Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease. 2010 , 59, 267-73	117
1562	Practical management of the increasing burden of non-alcoholic fatty liver disease. 2010 , 1, 149-155	7
1561	Diversity in antioxidant response enzymes in progressive stages of human nonalcoholic fatty liver disease. 2010 , 38, 2293-301	142
1560	Authors' response. 2010 , 59, 279-279	
1559	Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. 2010 , 51, 3046-54	194
1558	Insulin- and leptin-regulated fatty acid uptake plays a key causal role in hepatic steatosis in mice with intact leptin signaling but not in ob/ob or db/db mice. 2010 , 299, G855-66	47
1557	Super paramagnetic iron oxide MRI shows defective Kupffer cell uptake function in non-alcoholic fatty liver disease. 2010 , 59, 258-66	49
1556	Serum levels of CK18 M30 and leptin are useful predictors of steatohepatitis and fibrosis in paediatric NAFLD. 2010 , 51, 500-6	73
1555	Pathology and biopsy assessment of non-alcoholic fatty liver disease. 2010 , 28, 197-202	42

1554	Assessment of hepatic steatosis in patients undergoing liver resection: comparison of US, CT, T1-weighted dual-echo MR imaging, and point-resolved 1H MR spectroscopy. 2010 , 256, 159-68	227
1553	Rapid progression from hepatopulmonary syndrome to portopulmonary hypertension in an adolescent female with hypopituitarism. 2010 , 50, 334-6	8
1552	Nonalcoholic steatohepatitis: risk factors and diagnosis. 2010 , 4, 623-35	38
1551	Olive leaf extract prevents spontaneous occurrence of non-alcoholic steatohepatitis in SHR/NDmcr-cp rats. 2010 , 42, 66-72	22
1550	[Histopathological diagnose of non-alcoholic and alcoholic fatty liver disease]. 2010 , 48, 486-98	7
1549	A promoter polymorphism in the liver-specific fatty acid transport protein 5 is associated with features of the metabolic syndrome and steatosis. 2010 , 42, 854-9	33
1548	Obesity and microvascular invasion in hepatocellular carcinoma. 2010 , 28, 1063-9	20
1547	Liquid chromatography-mass spectrometry-based parallel metabolic profiling of human and mouse model serum reveals putative biomarkers associated with the progression of nonalcoholic fatty liver disease. 2010 , 9, 4501-12	119
1546	[Liver biopsy: Which role in patient management?]. 2010 , 30, 464-9	5
1545	[Non-alcoholic fatty liver disease]. 2010 , 30, 413-20	1
1544	Regional anthropometric measures and hepatic fibrosis in patients with nonalcoholic Fatty liver disease. 2010 , 8, 1062-9	16
1543	Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee. 2010 , 42, 272-82	159
1542	Consequences of chemotherapy on resection of colorectal liver metastases. 2010 , 147, e193-201	39
1541	Hyaluronic acid predicts hepatic fibrosis in children with nonalcoholic fatty liver disease. 2010 , 156, 229-34	50
1540	Nonalcoholic Fatty Liver Disease. 2010 , 1153-1179	
1539	Nonalcoholic fatty liver disease: pathology and pathogenesis. 2010 , 5, 145-71	598
1538	Nonalcoholic fatty liver disease. 2010 , 14, 591-604	57
1537	Effects of Teucrium polium on Insulin Resistance in Nonalcoholic Steatohepatitis. 2010 , 3, 104-10	9

1536	Influence of pre-surgical chemotherapy on liver parenchyma and post-surgical outcome of patients subjected to hepatectomy due to colorectal carcinoma metastases. 2010 , 88, 404-412	
1535	Nuevos métodos diagnósticos de NASH. 2010 , 9, 217-222	
1534	HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. 2010 , 138, 905-12	203
1533	Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. 2010 , 139, 323-34.e7	528
1532	Stress signaling in the methionine-choline-deficient model of murine fatty liver disease. 2010 , 139, 1730-9, 1739.e1	44
1531	Genome-wide association study identifies variants associated with histologic features of nonalcoholic Fatty liver disease. 2010 , 139, 1567-76, 1576.e1-6	242
1530	Induction pegylated interferon alfa-2a and high dose ribavirin do not increase SVR in heavy patients with HCV genotype 1 and high viral loads. 2010 , 139, 1972-83	28
1529	Chemerin correlates with markers for fatty liver in morbidly obese patients and strongly decreases after weight loss induced by bariatric surgery. 2010 , 95, 2892-6	198
1528	Anti-inflammatory effects of excessive weight loss: potent suppression of adipose interleukin 6 and tumour necrosis factor alpha expression. 2010 , 59, 1259-64	173
1527	Portal inflammation is associated with advanced histological changes in alcoholic and non-alcoholic fatty liver disease. 2010 , 63, 790-5	35
1526	Serum chemerin and vaspin in non-alcoholic fatty liver disease. 2010 , 45, 235-42	88
1525	L-carnitine supplementation to diet: a new tool in treatment of nonalcoholic steatohepatitis--a randomized and controlled clinical trial. 2010 , 105, 1338-45	153
1524	Serum resistin levels in nonalcoholic fatty liver disease and their relationship to severity of liver disease. 2010 , 15, 53-56	6
1523	A comparison of the fibrotic potential of nonalcoholic fatty liver disease and chronic hepatitis C. 2010 , 41, 1178-85	9
1522	Hepatic lipid profiling in chronic hepatitis C: an in vitro and in vivo proton magnetic resonance spectroscopy study. 2010 , 52, 16-24	36
1521	Mitochondrial dysfunction precedes insulin resistance and hepatic steatosis and contributes to the natural history of non-alcoholic fatty liver disease in an obese rodent model. 2010 , 52, 727-36	317
1520	Involvement of microsomal triglyceride transfer protein in nonalcoholic steatohepatitis in novel spontaneous mouse model. 2010 , 52, 903-12	47
1519	Maternal obesity during pregnancy and lactation programs the development of offspring non-alcoholic fatty liver disease in mice. 2010 , 52, 913-20	225

1518	Non-invasive assessment of hepatic steatosis: prospective comparison of the accuracy of imaging examinations. 2010 , 52, 579-85	255
1517	Possible involvement and the mechanisms of excess trans-fatty acid consumption in severe NAFLD in mice. 2010 , 53, 326-34	65
1516	Impact of pan-caspase inhibition in animal models of established steatosis and non-alcoholic steatohepatitis. 2010 , 53, 542-50	122
1515	A position statement on NAFLD/NASH based on the EASL 2009 special conference. 2010 , 53, 372-84	726
1514	Hepatocellular ballooning in NASH. 2010 , 53, 719-23	138
1513	Down-regulation of SREBP-1c is associated with the development of burned-out NASH. 2010 , 53, 724-31	75
1512	Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. 2010 , 53, 934-40	271
1511	Beta-globin mutations are associated with parenchymal siderosis and fibrosis in patients with non-alcoholic fatty liver disease. 2010 , 53, 927-33	51
1510	Oral N-acetylcysteine rescues lethality of hepatocyte-specific Gclc-knockout mice, providing a model for hepatic cirrhosis. 2010 , 53, 1085-94	21
1509	Fibroblast growth factor 21 as a biomarker for NAFLD: integrating pathobiology into clinical practice. 2010 , 53, 795-6	21
1508	Conséquences de la chimiothérapie sur la résection des métastases hépatiques d'origine colorectale. 2010 , 147, 255-264	
1507	Suppression of ABCA1 by unsaturated fatty acids leads to lipid accumulation in HepG2 cells. 2010 , 92, 958-63	43
1506	Effect of atorvastatin and diet on non-alcoholic fatty liver disease activity score in hyperlipidemic chickens. 2010 , 64, 275-81	23
1505	Distribution of abdominal adipose tissue as a predictor of hepatic steatosis assessed by MRI. 2010 , 65, 695-700	15
1504	Fish oil-based emulsion for the treatment of parenteral nutrition associated liver disease in an adult patient. 2010 , 5, e243-e246	16
1503	Targeted molecular therapies (cetuximab and bevacizumab) do not induce additional hepatotoxicity: preliminary results of a case-control study. 2010 , 36, 575-82	21
1502	The fatty acid composition of plasma cholesteryl esters and estimated desaturase activities in patients with nonalcoholic fatty liver disease and the effect of long-term ezetimibe therapy on these levels. 2010 , 411, 1735-40	29
1501	Treatment of nonalcoholic fatty liver disease in children: TONIC trial design. 2010 , 31, 62-70	60

1500	Fatty liver: role of inflammation and fatty acid nutrition. 2010 , 82, 265-71	77
1499	Novel treatment modalities for nonalcoholic steatohepatitis. 2010 , 21, 668-75	55
1498	Pediatric nonalcoholic fatty liver disease: a comprehensive review. 2010 , 57, 85-140	35
1497	Pathology of NASH and fibrosis. 2010 , 10, S17-S20	1
1496	Enfermedad del hígado graso no alcohólico y riesgo cardiovascular. 2010 , 22, 259-271	
1495	Impact of amino acid substitutions in the core region of HCV on multistep hepatocarcinogenesis. 2010 , 40, 171-8	11
1494	Measurement of spleen volume is useful for distinguishing between simple steatosis and early-stage non-alcoholic steatohepatitis. 2010 , 40, 693-700	27
1493	Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis: An open-label, pilot study. 2010 , 40, 566-73	100
1492	Lower circulating levels of dehydroepiandrosterone, independent of insulin resistance, is an important determinant of severity of non-alcoholic steatohepatitis in Japanese patients. 2010 , 40, 901-10	18
1491	Tissue factor-deficiency and protease activated receptor-1-deficiency reduce inflammation elicited by diet-induced steatohepatitis in mice. 2010 , 176, 177-86	38
1490	[Chemotherapy's hepatotoxicity: what is the impact on surgery?]. 2010 , 147 Suppl 1, S7-S11	2
1489	[Does bevacizumab have a protective effect on hepatotoxicity induced by chemotherapy?]. 2010 , 147 Suppl 1, S18-24	4
1488	Circulating levels and hepatic expression of molecular mediators of atherosclerosis in nonalcoholic fatty liver disease. 2010 , 209, 585-91	90
1487	Intima-media thickness and liver histology in obese children and adolescents with non-alcoholic fatty liver disease. 2010 , 209, 463-8	52
1486	Coronary flow reserve is impaired in patients with nonalcoholic fatty liver disease: association with liver fibrosis. 2010 , 211, 182-6	70
1485	Acidic sphingomyelinase controls hepatic stellate cell activation and in vivo liver fibrogenesis. 2010 , 177, 1214-24	70
1484	Ethnicity and body mass index are associated with hepatitis C presentation and progression. 2010 , 8, 72-8	30
1483	Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. 2010 , 362, 1675-85	2119

1482	Hepatobiliary System. 2010 , 411-444	
1481	Differential effect of Pistacia vera extracts on experimental atherosclerosis in the rabbit animal model: an experimental study. 2010 , 9, 73	14
1480	Comparative antilipidemic effect of N-acetylcysteine and sesame oil administration in diet-induced hypercholesterolemic mice. 2010 , 9, 23	22
1479	Pathology of nonalcoholic fatty liver disease. 2010 , 7, 195-203	350
1478	Quantification of liver fat with magnetic resonance imaging. 2010 , 18, 337-57, ix	197
1477	Circulating levels of interleukin-18 in patients with non-alcoholic fatty liver disease. 2010 , 70, 399-403	7
1476	Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. 2011 , 108, 16381-5	404
1475	Adenovirus-mediated peroxisome proliferator activated receptor gamma overexpression prevents nutritional fibrotic steatohepatitis in mice. 2011 , 46, 358-69	41
1474	Suboptimal maternal nutrition, during early fetal liver development, promotes lipid accumulation in the liver of obese offspring. 2011 , 141, 119-26	45
1473	Dietary cholesterol exacerbates hepatic steatosis and inflammation in obese LDL receptor-deficient mice. 2011 , 52, 1626-35	160
1472	Serum osteocalcin levels in patients with nonalcoholic fatty liver disease: association with ballooning degeneration. 2011 , 71, 631-6	29
1471	Nonalcoholic Fatty Liver Disease. 2011 , 868-907	1
1470	A combination of the pediatric NAFLD fibrosis index and enhanced liver fibrosis test identifies children with fibrosis. 2011 , 9, 150-5	71
1469	Serum levels of omentin, chemerin and adiponin in patients with biopsy-proven nonalcoholic fatty liver disease. 2011 , 46, 91-7	89
1468	Changing trends in malignant transformation of hepatocellular adenoma. 2011 , 60, 85-9	212
1467	Design and validation of the biliary atresia research consortium histologic assessment system for cholestasis in infancy. 2011 , 9, 357-362.e2	107
1466	Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis. 2011 , 141, 1393-403, 1403.e1-5	226
1465	Comment diagnostiquer de façon non invasive la fibrose au cours de la stéatopathie métabolique?. 2011 , 5, 60-65	

- 1464 The Possibility of differentiation between nonalcoholic steatohepatitis and fatty liver in rabbits on Gd-EOB-DTPA-enhanced open-type MRI scans. **2011**, 18, 525-9 11
- 1463 Inflammation h patique li  l b sit (NASH). **2011**, 46, 240-246
- 1462 Fatty liver and its clinical management in obese adolescents. **2011**, 58, 32-37
- 1461 Polymorphism in the farnesyl diphosphate farnesyl transferase 1 gene and nonalcoholic fatty liver disease severity. **2011**, 140, 1694-5 13
- 1460 Diagnostic challenges of nonalcoholic fatty liver disease (NAFLD) in children of normal weight. **2011**, 35, 500-5 8
- 1459 Relationship between portal chronic inflammation and disease severity in paediatric non-alcoholic fatty liver disease. **2011**, 43, 143-6 9
- 1458 Adiponectin isoforms, insulin resistance and liver histology in nonalcoholic fatty liver disease. **2011**, 43, 73-7 14
- 1457 Normal liver stiffness and its determinants in healthy blood donors. **2011**, 43, 231-6 53
- 1456 Clinical feasibility of liver elastography by acoustic radiation force impulse imaging (ARFI). **2011**, 43, 491-7 104
- 1455 Omega-3 fatty acids reduce hepatic steatosis and consequently attenuate ischemia-reperfusion injury following partial hepatectomy in rats. **2011**, 43, 984-90 37
- 1454 Progression from isolated steatosis to steatohepatitis and fibrosis in nonalcoholic fatty liver disease. **2011**, 35, 23-8 46
- 1453 Animal models of nonalcoholic fatty liver disease. **2011**, 8, 35-44 327
- 1452 Cell death and nonalcoholic steatohepatitis: where is ballooning relevant?. **2011**, 5, 213-22 33
- 1451 Weight reduction for non-alcoholic fatty liver disease. **2011**, CD003619 35
- 1450 Inflammation in nonalcoholic steatohepatitis. **2011**, 5, 189-200 60
- 1449 Alcohol-Induced Liver Disease. **2011**, 417-433 1
- 1448 Metabolic disorders associated with obstructive sleep apnea in adults. **2011**, 46, 67-138 24
- 1447 Markedly lower follow-up rate after liver biopsy in patients with non-alcoholic fatty liver diseases than those with viral hepatitis in Japan. **2011**, 4, 341 2

1446	High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis. 2011 , 60, 829-36	183
1445	Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial. 2011 , 96, 350-3	195
1444	Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic fatty liver disease. 2011 , 39, 1954-60	111
1443	Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. 2011 , 9, 428-33; quiz e50	292
1442	Fibrosis as a Major Mechanism of Chronic Liver Disease. 2011 , 91-107	1
1441	Chronic Liver Failure. 2011 ,	2
1440	Circulating vaspin and its relationship with insulin sensitivity, adiponectin, and liver histology in subjects with non-alcoholic steatohepatitis. 2011 , 46, 1355-61	12
1439	Venous Embolization of the Liver. 2011 ,	1
1438	Smoking is related to pancreatic fibrosis in humans. 2011 , 106, 1161-6; quiz 1167	50
1437	Protease-activated receptor 1 and hematopoietic cell tissue factor are required for hepatic steatosis in mice fed a Western diet. 2011 , 179, 2278-89	30
1436	Effects of interventions on intra- and interobserver agreement on interpretation of nonalcoholic fatty liver disease histology. 2011 , 15, 19-24	53
1435	Serum pigment epithelium-derived factor levels are increased in patients with biopsy-proven nonalcoholic fatty liver disease and independently associated with liver steatosis. 2011 , 412, 2296-9	11
1434	[Non-alcoholic fatty liver disease. How and who to screen]. 2011 , 34, 278-88	
1433	Differential effects of shiitake- and white button mushroom-supplemented diets on hepatic steatosis in C57BL/6 mice. 2011 , 49, 3074-80	18
1432	Alterations in lipid, carbohydrate and iron metabolism in patients with non-alcoholic steatohepatitis (NASH) and metabolic syndrome. 2011 , 22, 305-10	25
1431	Prognostic effect of steatosis on hepatocellular carcinoma patients after liver resection. 2011 , 37, 618-22	7
1430	Lipotoxicity and steatohepatitis in an overfed mouse model for non-alcoholic fatty liver disease. 2011 , 1812, 447-58	67
1429	Comparing morphometric, biochemical, and visual measurements of macrovesicular steatosis of liver. 2011 , 42, 356-60	25

1428	Whey protein isolate protects against diet-induced obesity and fatty liver formation. 2011 , 21, 513-522	28
1427	Hepatic insulin resistance is associated with increased apoptosis and fibrogenesis in nonalcoholic steatohepatitis and chronic hepatitis C. 2011 , 54, 142-52	72
1426	Comparison of NAFLD fibrosis score and BARD score in predicting fibrosis in nonalcoholic fatty liver disease. 2011 , 54, 160-3	57
1425	Smoking and severity of hepatic fibrosis in nonalcoholic fatty liver disease. 2011 , 54, 753-9	137
1424	An apoptosis panel for nonalcoholic steatohepatitis diagnosis. 2011 , 54, 1224-9	137
1423	A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. 2011 , 54, 1011-9	214
1422	Risk of nonalcoholic steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease and low visceral adiposity. 2011 , 54, 1244-9	82
1421	UDCA for NASH: end of the story?. 2011 , 54, 856-8	21
1420	Validation of a liver adenoma classification system in a tertiary referral centre: implications for clinical practice. 2011 , 55, 120-5	78
1419	Presence and significance of microvesicular steatosis in nonalcoholic fatty liver disease. 2011 , 55, 654-659	181
1418	Early interplay of intra-hepatic iron and insulin resistance in children with non-alcoholic fatty liver disease. 2011 , 55, 647-653	27
1417	C-reactive protein levels in relation to various features of non-alcoholic fatty liver disease among obese patients. 2011 , 55, 660-665	68
1416	Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease. 2011 , 55, 666-672	264
1415	The role of liver biopsy in the diagnosis and prognosis of patients with acute deterioration of alcoholic cirrhosis. 2011 , 55, 1103-11	109
1414	The role of thiazolidinediones in non-alcoholic steatohepatitis - a systematic review and meta analysis. 2011 , 55, 1383-90	120
1413	The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver. 2011 , 55, 1409-14	65
1412	Effect of anti-oxidants, Ricetrienol and Tocopherol, on adipocytokine abnormalities and fatty liver in Otsuka Long-Evans Tokushima Fatty diabetic rats. 2011 , 2, 186-92	1
1411	Impact of glucose tolerance on the severity of non-alcoholic steatohepatitis. 2011 , 2, 483-9	8

1410	Characterization of elevated alanine aminotransferase levels during pegylated-interferon α 2b plus ribavirin treatment for chronic hepatitis C. 2011 , 41, 118-25	11
1409	Hepatic Akt expression correlates with advanced fibrosis in patients with chronic hepatitis C infection. 2011 , 41, 430-6	9
1408	Weight loss amelioration of non-alcoholic steatohepatitis linked to shifts in hepatic ceramide expression and serum ceramide levels. 2011 , 41, 754-62	34
1407	NASH: A global health problem. 2011 , 41, 670-4	110
1406	Efficacy of pitavastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label, pilot study. 2011 , 41, 1057-65	55
1405	Histopathological characteristics of non-alcoholic fatty liver disease in children: Comparison with adult cases. 2011 , 41, 1066-74	22
1404	Angiotensinogen gene haplotype is associated with the prevalence of Japanese non-alcoholic steatohepatitis. 2011 , 41, 1223-9	12
1403	Transcriptional profile of genes involved in oxidative stress and antioxidant defense in a dietary murine model of steatohepatitis. 2011 , 15, 437-45	47
1402	DSS induced colitis increases portal LPS levels and enhances hepatic inflammation and fibrogenesis in experimental NASH. 2011 , 55, 1391-9	186
1401	Ultrastructural findings in human nonalcoholic steatohepatitis. 2011 , 5, 141-5	7
1400	Olmesartan severely weakened the development of NASH in an animal model of hypercholesterolemia. 2011 , 216, 97-102	14
1399	Circulating vaspin levels and epicardial adipose tissue thickness are associated with impaired coronary flow reserve in patients with nonalcoholic fatty liver disease. 2011 , 217, 125-9	45
1398	Liver transcriptional profile of atherosclerosis-related genes in human nonalcoholic fatty liver disease. 2011 , 218, 378-85	73
1397	Cannabinoid receptor type I modulates alcohol-induced liver fibrosis. 2011 , 17, 1285-94	56
1396	Nonalcoholic Fatty Liver Disease in Children. 2011 , 14, 209	4
1395	Biological study of the effect of licorice roots extract on serum lipid profile, liver enzymes and kidney function tests in albino mice. 2011 , 10,	0
1394	Association among Histopathology, Clinical Manifestation, and Ultrasonographic Grades in Pediatric Non-alcoholic Fatty Liver Disease. 2011 , 57, 158	5
1393	Dopplerfluxometria da veia hepática em pacientes com esteatose não alcoólica. 2011 , 44, 1-6	7

- 1392 Gluco-lipidic indices in treated hypothyroidism associated with nonalcoholic fatty liver disease. **2011**, 48, 186-9 27
- 1391 Plasminogen activator inhibitor type 1 serum levels and 4G/5G gene polymorphism in morbidly obese Hispanic patients with non-alcoholic fatty liver disease. **2011**, 10, 493-501 10
- 1390 Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. **2011**, 10, 277-286 123
- 1389 [Pediatric obesity and non-alcoholic fatty liver disease: is it really problematic?]. **2011**, 57, 141-3 1
- 1388 Comment rechercher la NASH chez les patients porteurs d'un foie gras non alcoolique. **2011**, N° 1, 2
- 1387 Histopathological Diagnosis of Non-Alcoholic and Alcoholic Fatty Liver Disease. **2011**, 2
- 1386 Non-Invasive Assessment of the Liver [Serum Markers and Imaging Techniques]. **2011**, 1
- 1385 Liver Biopsy in Transplantation: Nonalcoholic Fatty Liver Disease and the Eosinophils. **2011**,
- 1384 Proposed Protocol for Histopathological Examination of Liver Specimen in Diagnosing Chronic Hepatitis. **2011**,
- 1383 Validation of P2/MS and other noninvasive fibrosis scoring systems in the Korean population with nonalcoholic fatty liver disease. **2011**, 57, 19-27 10
- 1382 Role of Fatty Liver Disease in Childhood Obesity. **2011**, 221-230
- 1381 Mallory-Denk Bodies in chronic hepatitis. **2011**, 17, 2172-7 28
- 1380 Effect of silybin on high-fat-induced fatty liver in rats. **2011**, 44, 652-9 29
- 1379 Comparison of 1H MR spectroscopy, 3-point DIXON, and multi-echo gradient echo for measuring hepatic fat fraction. **2011**, 10, 41-8 14
- 1378 Methionine- and choline-deficient diet induces hepatic changes characteristic of non-alcoholic steatohepatitis. **2011**, 48, 72-9 33
- 1377 Distinct effects of calorie restriction and resveratrol on diet-induced obesity and Fatty liver formation. **2011**, 2011, 525094 55
- 1376 Evaluation of Biomarkers of NAFLD in a Cohort of Morbidly Obese Patients. **2011**, 2011, 369168 20
- 1375 Inflammation hépatique liée à l'obésité (NASH). **2011**, 18, 21-26 1

- 1374 Advantages and disadvantages of hyperbaric oxygen treatment in mice with obesity hyperlipidemia and steatohepatitis. **2011**, 11, 2124-35 15
- 1373 Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. **2011**, 7, e1001324 629
- 1372 Activation of peroxisome proliferator-activated receptor gamma by rosiglitazone increases sirt6 expression and ameliorates hepatic steatosis in rats. **2011**, 6, e17057 61
- 1371 Upregulation of hemoglobin expression by oxidative stress in hepatocytes and its implication in nonalcoholic steatohepatitis. **2011**, 6, e24363 79
- 1370 Hepatic lipid peroxidation and cytochrome P-450 2E1 in pediatric nonalcoholic fatty liver disease and its subtypes. **2011**, 45, 800-7 22
- 1369 Update on fatty liver disease and steatohepatitis. **2011**, 18, 294-300 43
- 1368 NAFLD recurrence in liver transplant recipients. **2011**, 91, 684-9 118
- 1367 Steatosis degree, measured by morphometry, is linked to other liver lesions and metabolic syndrome components in patients with NAFLD. **2011**, 23, 974-81 12
- 1366 Novel evidence for chronic exposure to endotoxin in human nonalcoholic steatohepatitis. **2011**, 45, 149-52 117
- 1365 Elevated hepatic fatty acid oxidation, high plasma fibroblast growth factor 21, and fasting bile acids in nonalcoholic steatohepatitis. **2011**, 23, 382-8 91
- 1364 Generalizability of the nonalcoholic steatohepatitis Clinical Research Network histologic scoring system for nonalcoholic fatty liver disease. **2011**, 45, 55-8 85
- 1363 Fatty liver and ischemia/reperfusion: are there drugs able to mitigate injury?. **2011**, 18, 4987-5002 15
- 1362 Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity. **2011**, 23, 499-506 68
- 1361 Estrogen deficiency worsens steatohepatitis in mice fed high-fat and high-cholesterol diet. **2011**, 301, G1031-43 92
- 1360 Keratin 18, Apoptosis, and Liver Disease in Children. **2011**, 7, 310-315 3
- 1359 Foie mtabolique. **2011**, 6, 1-12
- 1358 Stãtohpãtite non alcoolique. **2011**, 8, 1-12
- 1357 De Gruyter. **2011**, 16,

1356	Enhanced expression of pro-inflammatory mediators and liver X-receptor-regulated lipogenic genes in non-alcoholic fatty liver disease and hepatitis C. 2011 , 120, 239-50	98
1355	Methionine and protein metabolism in non-alcoholic steatohepatitis: evidence for lower rate of transmethylation of methionine. 2011 , 121, 179-89	47
1354	Non-Alcoholic Fatty Liver Disease and Nutrition. 2011 , 546-567	6
1353	Tumor necrosis factor- α -converting enzyme inactivation ameliorates high-fat diet-induced insulin resistance and altered energy homeostasis. 2011 , 75, 2482-90	17
1352	Centrizonal arteries and microvessels in nonalcoholic steatohepatitis. 2011 , 35, 1400-4	52
1351	T1-weighted dual-echo MRI for fat quantification in pediatric nonalcoholic fatty liver disease. 2011 , 17, 3012-9	58
1350	The non-invasive (13 C)-methionine breath test detects hepatic mitochondrial dysfunction as a marker of disease activity in non-alcoholic steatohepatitis. 2011 , 16, 258-64	33
1349	Current therapeutic strategies in non-alcoholic fatty liver disease. 2011 , 13, 692-702	84
1348	Reversal of hepatic steatosis by omega-3 fatty acids measured non-invasively by (1 H)-magnetic resonance spectroscopy in a rat model. 2011 , 26, 356-63	40
1347	The usefulness of liver stiffness measurement using FibroScan in chronic hepatitis C in South Korea: a multicenter, prospective study. 2011 , 26, 171-8	33
1346	Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in Japan. 2011 , 26 Suppl 1, 153-62	87
1345	Postprandial insulin secretion pattern is associated with histological severity in non-alcoholic fatty liver disease patients without prior known diabetes mellitus. 2011 , 26, 517-22	32
1344	Impact of amino acid substitutions in hepatitis C virus genotype 1b core region on liver steatosis and glucose tolerance in non-cirrhotic patients without overt diabetes. 2011 , 26, 836-42	13
1343	Biomarkers of liver fibrosis. 2011 , 26, 802-9	71
1342	Non-invasive estimation of liver fibrosis in non-alcoholic fatty liver disease using the 13 C-caffeine breath test. 2011 , 26, 1411-6	16
1341	Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease. 2011 , 26, 1536-43	115
1340	Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. 2011 , 33, 525-40	215
1339	Enteric-coated cysteamine for the treatment of paediatric non-alcoholic fatty liver disease. 2011 , 33, 1036-44	51

1338	Validation of the non-alcoholic fatty liver disease activity score. 2011 , 34, 214-8	40
1337	Dual cut-off transient elastography to assess liver fibrosis in chronic hepatitis B: a cohort study with internal validation. 2011 , 34, 353-62	63
1336	Do we need a histological score to diagnose non-alcoholic steatohepatitis? authors' reply. 2011 , 34, 495-496	2
1335	The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases. 2011 , 34, 1202-16	94
1334	Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease. 2011 , 166, 281-90	182
1333	Pathology of the liver in obese and diabetic ob/ob and db/db mice fed a standard or high-calorie diet. 2011 , 92, 413-21	88
1332	Discriminant value of serum HBV DNA levels as predictors of liver fibrosis in chronic hepatitis B. 2011 , 18, e217-25	24
1331	Metabolic syndrome and hepatic resection: improving outcome. 2011 , 13, 846-59	9
1330	Decreased immunoexpression of survivin could be a potential marker in human non-alcoholic fatty liver disease progression?. 2011 , 31, 377-85	14
1329	Role of insulin resistance and hepatic steatosis in the progression of fibrosis and response to treatment in hepatitis C. 2011 , 31 Suppl 1, 23-8	24
1328	Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. 2011 , 31, 1285-97	281
1327	Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors. 2011 , 31, 700-6	109
1326	Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients. 2011 , 31, 730-9	92
1325	Hepcidin response to acute iron intake and chronic iron loading in dysmetabolic iron overload syndrome. 2011 , 31, 994-1000	20
1324	Updated thresholds for alanine aminotransferase do not exclude significant histological disease in chronic hepatitis C. 2011 , 31, 1039-46	9
1323	Chronic ethanol consumption in mice alters hepatocyte lipid droplet properties. 2011 , 35, 1020-33	41
1322	Psoriasis and non-alcoholic fatty liver disease. 2011 , 25, 383-91	42
1321	Diet prescription for non-alcoholic fatty liver disease: Is it worth the effort? A systematic review. 2011 , 68, 33-40	1

1320	Microvesicular fat, inter cellular adhesion molecule-1 and regulatory T-lymphocytes are of importance for the inflammatory process in livers with non-alcoholic steatohepatitis. 2011 , 119, 412-20	23
1319	Liver iron overloading in captive muriquis (<i>Brachyteles</i> spp.). 2011 , 40, 129-34	5
1318	Visceral adiposity and insulin resistance are independent predictors of the presence of non-cirrhotic NAFLD-related portal hypertension. 2011 , 35, 270-8	32
1317	Reproducibility of glucose, fatty acid and VLDL kinetics and multi-organ insulin sensitivity in obese subjects with non-alcoholic fatty liver disease. 2011 , 35, 1233-40	27
1316	Epidemiology of the metabolic syndrome in the USA. 2011 , 12, 333-40	98
1315	Histopathological evaluation of fatty and alcoholic liver diseases. 2011 , 12, 17-24	19
1314	Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: update 2010: (published in Chinese on Chinese Journal of Hepatology 2010; 18:163-166). 2011 , 12, 38-44	178
1313	Systemic chemotherapy and its implications for resection of colorectal liver metastasis. 2011 , 20, 57-72	25
1312	Plasma metabolomic profile in nonalcoholic fatty liver disease. 2011 , 60, 404-13	318
1311	Serum levels of vaspin, obestatin, and apelin-36 in patients with nonalcoholic fatty liver disease. 2011 , 60, 544-9	53
1310	Nonalcoholic steatohepatitis and increased risk of chronic kidney disease. 2011 , 60, 735-9	108
1309	Plasma levels of asymmetric dimethylarginine in patients with biopsy-proven nonalcoholic fatty liver disease. 2011 , 60, 776-81	36
1308	Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. 2011 , 60, 313-26	213
1307	Lipid in the livers of adolescents with nonalcoholic steatohepatitis: combined effects of pathways on steatosis. 2011 , 60, 1001-11	46
1306	Histological assessment of the liver. 2011 , 39, 523-528	1
1305	Pathophysiology and clinical management of non-alcoholic fatty liver disease. 2011 , 39, 592-596	3
1304	Effect of <i>Lawsonia inermis</i> on tumor expression induced by Dalton's lymphoma ascites in Swiss albino mice. 2011 , 18, 353-9	17
1303	Protective and ameliorative effects of <i>mat</i> *(<i>Ilex paraguariensis</i>) on metabolic syndrome in TSOD mice. 2011 , 19, 88-97	35

1302	The CEACAM1 expression is decreased in the liver of severely obese patients with or without diabetes. 2011 , 6, 40	35
1301	Greater age and hepatocellular aging are independent risk factors for hepatocellular carcinoma arising from non-B non-C non-alcoholic chronic liver disease. 2011 , 61, 572-6	6
1300	Effects of bezafibrate in nonalcoholic steatohepatitis model mice with monosodium glutamate-induced metabolic syndrome. 2011 , 662, 1-8	28
1299	Anti-apoptotic and anti-inflammatory effects of Silybum marianum in treatment of experimental steatohepatitis. 2011 , 63, 569-74	42
1298	Circulating levels of vascular endothelial growth factor A and its soluble receptor in patients with biopsy-proven nonalcoholic fatty liver disease. 2011 , 42, 38-43	12
1297	Recent advances in biomarkers for noninvasive diagnosis of nonalcoholic steatohepatitis: the role of lipid analysis/profiling. 2011 , 6, 427-436	1
1296	Nonalcoholic Fatty Liver Disease. 2011 , 804-810.e2	
1295	The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis. 2011 , 21, 87-97	338
1294	Sinusoidal obstruction syndrome compromises liver regeneration in patients undergoing two-stage hepatectomy with portal vein embolization. 2011 , 41, 7-17	39
1293	Chemotherapy-associated liver injury: impact on surgical management of colorectal cancer liver metastases. 2011 , 18, 181-90	42
1292	Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy. 2011 , 18, 421-30	100
1291	Nonalcoholic fatty liver disease and the coronary artery disease. 2011 , 56, 35-45	56
1290	Prevalence and impact of hepatic steatosis on the response to antiviral therapy in Saudi patients with genotypes 1 and 4 chronic hepatitis C. 2011 , 56, 1222-8	6
1289	Small intestinal bacterial overgrowth in nonalcoholic steatohepatitis: association with toll-like receptor 4 expression and plasma levels of interleukin 8. 2011 , 56, 1524-34	139
1288	Non-contrasted computed tomography for the accurate measurement of liver steatosis in obese patients. 2011 , 56, 2145-51	30
1287	Altered phenotype and functionality of circulating immune cells characterize adult patients with nonalcoholic steatohepatitis. 2011 , 31, 1120-30	63
1286	An experimental research on chronic intermittent hypoxia leading to liver injury. 2011 , 15, 493-502	31
1285	Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. 2011 , 46, 101-7	143

1284	A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. 2011 , 46, 257-68	158
1283	The pathological role of visceral fat accumulation in steatosis, inflammation, and progression of nonalcoholic fatty liver disease. 2011 , 46 Suppl 1, 70-8	49
1282	Clinical characteristics of de novo nonalcoholic fatty liver disease following pancreaticoduodenectomy. 2011 , 46, 758-68	76
1281	Platelet count for predicting fibrosis in nonalcoholic fatty liver disease. 2011 , 46, 1300-6	77
1280	Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease. 2011 , 458, 511-23	91
1279	A critical analysis of three quantitative methods of assessment of hepatic steatosis in liver biopsies. 2011 , 459, 477-85	90
1278	Telmisartan improves nonalcoholic steatohepatitis in medaka (<i>Oryzias latipes</i>) by reducing macrophage infiltration and fat accumulation. 2011 , 344, 125-34	31
1277	MR spectroscopy as a tool for in vivo determination of steatosis in liver transplant recipients. 2011 , 24, 297-304	22
1276	Apoptosis and insulin resistance in liver and peripheral tissues of morbidly obese patients is associated with different stages of non-alcoholic fatty liver disease. 2011 , 54, 1788-98	73
1275	[Steatohepatitis after chemotherapy for colorectal liver metastases (CASH)]. 2011 , 32, 330-5	5
1274	Transient elastography for assessment of fibrosis in paediatric liver disease. 2011 , 41, 1232-8	30
1273	Invasive and non-invasive methods for the assessment of fibrosis and disease progression in chronic liver disease. 2011 , 25, 291-303	94
1272	Non-alcoholic fatty liver disease and cardiovascular risk: metabolic aspects and novel treatments. 2011 , 40, 332-43	53
1271	Nucleometric study of anisonucleosis, diabetes and oxidative damage in liver biopsies of orthotopic liver transplant recipients with chronic hepatitis C virus infection. 2011 , 17, 191-9	8
1270	Chemotherapy, liver injury, and postoperative complications in colorectal liver metastases. 2011 , 15, 153-64	27
1269	Surgical outcomes for hepatocellular carcinoma in nonalcoholic fatty liver disease. 2011 , 15, 1450-8	62
1268	NAFLD and insulin resistance do not increase the risk of postoperative complications among patients undergoing bariatric surgery--a prospective analysis. 2011 , 21, 310-5	26
1267	Hepatic expression of adiponectin receptors increases with non-alcoholic fatty liver disease progression in morbid obesity in correlation with glutathione peroxidase 1. 2011 , 21, 492-500	24

1266	The Role of Hepatic Steatosis in Chronic Hepatitis B Infection. 2011 , 10, 134-141		1
1265	Liver fatty acid composition in mice with or without nonalcoholic fatty liver disease. 2011 , 10, 234		49
1264	The effect of cocoa supplementation on hepatic steatosis, reactive oxygen species and LFABP in a rat model of NASH. 2011 , 10, 10		22
1263	Increased production of sonic hedgehog by ballooned hepatocytes. 2011 , 224, 401-10		113
1262	Multi-excitation fluorescence spectroscopy for analysis of non-alcoholic fatty liver disease. 2011 , 43, 392-400		10
1261	Hepatic steatosis at 1 year is an additional predictor of subsequent fibrosis severity in liver transplant recipients with recurrent hepatitis C virus. 2011 , 17, 1380-6		31
1260	Hepatic steatosis assessment with CT or MRI in patients with colorectal liver metastases after neoadjuvant chemotherapy. 2011 , 104, 10-6		10
1259	Hepatic fat quantification using chemical shift MR imaging and MR spectroscopy in the presence of hepatic iron deposition: validation in phantoms and in patients with chronic liver disease. 2011 , 33, 1390-8		50
1258	Reproducibility of MRI-determined proton density fat fraction across two different MR scanner platforms. 2011 , 34, 928-34		111
1257	Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease. <i>Hepatology</i> , 2011 , 53, 448-57	11.2	191
1256	Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. <i>Hepatology</i> , 2011 , 53, 810-20	11.2	712
1255	Inflammation does not always kill hepatocytes during liver damage. <i>Hepatology</i> , 2011 , 54, 366; author reply 367	11.2	1
1254	Neutralization of lipopolysaccharide effects in liver diseases, the quest for the Holy Grail. <i>Hepatology</i> , 2011 , 54, 376	11.2	2
1253	Alpha-fetoprotein in hepatocellular carcinoma surveillance: wake not the dead. <i>Hepatology</i> , 2011 , 54, 376-7	11.2	9
1252	Are there more factors other than hepatitis B virus DNA level and A1762T/G1764A mutation in liver tissue that also independently predict postoperative survival in hepatocellular carcinoma?. <i>Hepatology</i> , 2011 , 54, 378	11.2	
1251	Treatment implication from the potential association between nonalcoholic fatty liver disease and cardiovascular disease. <i>Hepatology</i> , 2011 , 54, 377-8	11.2	8
1250	Risk factors for infection in chronic hepatitis C: a high prevalence of sexual exposure among human immunodeficiency virus-coinfected women. <i>Hepatology</i> , 2011 , 54, 379	11.2	2
1249	Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. <i>Hepatology</i> , 2011 , 53, 1874-82	11.2	422

1248	Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. <i>Hepatology</i> , 2011 , 53, 1883-94	11.2	608
1247	Nonalcoholic fatty liver disease activity score and Brunt's pathologic criteria for the diagnosis of nonalcoholic steatohepatitis: what do they mean and do they agree?. <i>Hepatology</i> , 2011 , 53, 2142-3; author reply 2143	11.2	7
1246	Efforts at making the diagnosis of acute-onset autoimmune hepatitis. <i>Hepatology</i> , 2011 , 54, 371-2; author reply 373	11.2	22
1245	Autoimmune acute liver failure. <i>Hepatology</i> , 2011 , 54, 372-3; author reply 373	11.2	7
1244	Reply:. <i>Hepatology</i> , 2011 , 53, 2143-2143	11.2	
1243	Screening for biliary atresia: Swiss stool color card. <i>Hepatology</i> , 2011 , 54, 367-8; author reply 369	11.2	25
1242	Misuse of scoring systems. <i>Hepatology</i> , 2011 , 54, 369-70; author reply 370-1	11.2	25
1241	Endpoints and clinical trial design for nonalcoholic steatohepatitis. <i>Hepatology</i> , 2011 , 54, 344-53	11.2	463
1240	Occult hepatitis B virus infection and hepatocellular carcinoma development in patients with chronic hepatitis C. <i>Hepatology</i> , 2011 , 54, 373-4; author reply 374	11.2	1
1239	Reply:. <i>Hepatology</i> , 2011 , 54, 370-371	11.2	1
1238	Reply:. <i>Hepatology</i> , 2011 , 54, 372-373	11.2	1
1237	Reply:. <i>Hepatology</i> , 2011 , 54, 369-369	11.2	
1236	Reply:. <i>Hepatology</i> , 2011 , 54, 367-368	11.2	0
1235	Diagnosing steatohepatitis and predicting liver-related mortality in patients with NAFLD: two distinct concepts. <i>Hepatology</i> , 2011 , 53, 1792-4	11.2	41
1234	Reply:. <i>Hepatology</i> , 2011 , 54, 373-374	11.2	
1233	Association between human leukocyte antigen DP gene polymorphisms and chronic hepatitis B in a Chinese population. <i>Hepatology</i> , 2011 , 54, 375; author reply 375-6	11.2	
1232	Reply:. <i>Hepatology</i> , 2011 , 54, 375-376	11.2	
1231	Role of ethnicity in overweight and obese patients with nonalcoholic steatohepatitis. <i>Hepatology</i> , 2011 , 54, 837-45	11.2	63

1230	The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. <i>Hepatology</i> , 2011 , 54, 1208-16	11.2	323
1229	Biomarkers of liver fibrosis: what lies beneath the receiver operating characteristic curve?. <i>Hepatology</i> , 2011 , 54, 1454-62	11.2	42
1228	Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. <i>Hepatology</i> , 2011 , 54, 1610-9	11.2	257
1227	Dysregulation of the unfolded protein response in db/db mice with diet-induced steatohepatitis. <i>Hepatology</i> , 2011 , 54, 1600-9	11.2	51
1226	Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open-label trial. <i>Hepatology</i> , 2011 , 54, 1631-9	11.2	125
1225	Apolipoprotein CIII overexpressing mice are predisposed to diet-induced hepatic steatosis and hepatic insulin resistance. <i>Hepatology</i> , 2011 , 54, 1650-60	11.2	102
1224	Pentoxifylline for steatohepatitis: magic bullet or smoking gun?. <i>Hepatology</i> , 2011 , 54, 1496-9	11.2	3
1223	Where are we in the search for noninvasive nonalcoholic steatohepatitis biomarkers?. <i>Hepatology</i> , 2011 , 54, 1115-7	11.2	8
1222	Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified?. 2011 , 117, 4484-92		27
1221	Serum galectin-3 levels in patients with nonalcoholic fatty liver disease. 2011 , 44, 955-8		9
1220	Liver fibrosis in paediatric liver diseases. 2011 , 25, 259-68		19
1219	Fibrosis in alcoholic and nonalcoholic steatohepatitis. 2011 , 25, 231-44		50
1218	Experimental study of non-alcoholic fatty liver disease (NAFLD) on a model of starving chickens: is generalization of steatosis accompanied by fibrosis of the liver tissue?. 2011 , 207, 151-5		13
1217	Strategies for the early detection of drug-induced hepatic steatosis in preclinical drug safety evaluation studies. 2011 , 279, 10-8		40
1216	Altered lipid metabolism in Hfe-knockout mice promotes severe NAFLD and early fibrosis. 2011 , 301, G865-76		26
1215	CD40L deficiency ameliorates adipose tissue inflammation and metabolic manifestations of obesity in mice. 2011 , 31, 2251-60		67
1214	Biopsy-proven nonsteatotic liver in adults: estimation of reference range for difference in attenuation between the liver and the spleen at nonenhanced CT. 2011 , 258, 760-6		65
1213	Perspectives on cellular dysfunction in nonalcoholic steatohepatitis: a case of 'multiorganelle failure'? Proceedings of a virtual workshop on nonalcoholic steatohepatitis. 2011 , 5, 135-9		10

1212	Hepatic steatosis in morbidly obese patients undergoing gastric bypass surgery: assessment with open-system 1H-MR spectroscopy. 2011 , 196, W736-42	14
1211	Measurement of ER stress response and inflammation in the mouse model of nonalcoholic fatty liver disease. 2011 , 489, 329-48	21
1210	ASH and NASH. 2011 , 29, 202-10	59
1209	Carotid intima-media thickness and liver histology in hemodialysis patients with nonalcoholic Fatty liver disease. 2011 , 20, 149-56	9
1208	Insulin resistance in nonalcoholic steatohepatitis: necessary but not sufficient - death of a dogma from analysis of therapeutic studies?. 2011 , 5, 279-89	48
1207	Estimation of hepatic proton-density fat fraction by using MR imaging at 3.0 T. 2011 , 258, 749-59	215
1206	Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C. 2011 , 60, 1394-402	259
1205	Daily exercise vs. caloric restriction for prevention of nonalcoholic fatty liver disease in the OLETF rat model. 2011 , 300, G874-83	103
1204	Type of steatosis influences microcirculation and fibrogenesis in different rat strains. 2011 , 24, 273-82	27
1203	Genetic determinants of hepatic steatosis in man. 2011 , 52, 593-617	90
1202	Nonalcoholic steatohepatitis: the therapeutic challenge of a global epidemic. 2011 , 22, 479-88	86
1201	Current world literature. 2011 , 22, 497-500	
1200	Recommendations for the evaluation of pathology data in nonclinical safety biomarker qualification studies. 2011 , 39, 1129-37	26
1199	Non-alcoholic fatty liver disease: what's new under the microscope?. 2011 , 60, 1152-8	23
1198	Nonalcoholic fatty liver disease: a review of the spectrum of disease, diagnosis, and therapy. 2011 , 26, 565-76	78
1197	PPARalpha expression protects male mice from high fat-induced nonalcoholic fatty liver. 2011 , 141, 603-10	189
1196	Bariatric surgery and cardiovascular risk factors: a scientific statement from the American Heart Association. 2011 , 123, 1683-701	240
1195	The role of hepatic liver X receptor β and sterol regulatory element binding protein-1c-mediated lipid disorder in the pathogenesis of non-alcoholic steatohepatitis in rats. 2011 , 39, 1219-29	19

1194	Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography. 2011 , 259, 749-56	320
1193	Aging is associated with a shift of fatty metabolism toward lipogenesis. 2011 , 66, 1192-200	35
1192	Metabolic syndrome in childhood from impaired carbohydrate metabolism to nonalcoholic fatty liver disease. 2011 , 30, 295-303	27
1191	Hepatocellular ballooning in nonalcoholic steatohepatitis: the pathologist's perspective. 2011 , 5, 223-31	42
1190	Performance of the international classifications criteria for autoimmune hepatitis diagnosis in Mexican patients. 2011 , 44, 543-8	13
1189	Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. 2011 , 6, e23937	418
1188	Insulin sensitizers in the treatment of non-alcoholic fatty liver disease: a systematic review. 2011 , 15, 1-110	49
1187	Fibrogenesis in nonalcoholic steatohepatitis. 2011 , 5, 179-87	25
1186	Teucrium polium reversed the MCD diet-induced liver injury in rats. 2011 , 30, 1303-12	6
1185	Assessing adiposity: a scientific statement from the American Heart Association. 2011 , 124, 1996-2019	553
1184	Serum zinc- α -glycoprotein concentrations in patients with non-alcoholic fatty liver disease. 2011 , 49, 93-7	11
1183	Predictors of non-alcoholic fatty liver disease in obese and overweight Egyptian children: single center study. 2011 , 17, 40-6	9
1182	Genetic polymorphisms in non-alcoholic fatty liver disease in obese Egyptian children. 2011 , 17, 265-70	26
1181	The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis. 2011 , 4, 249-63	56
1180	Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. 2011 , 305, 1659-68	721
1179	Non-invasive assessment of liver fibrosis: it is time for laboratory medicine. 2011 , 49, 13-32	16
1178	Nonalcoholic Fatty Liver Disease. 2011 , 435-440	1
1177	The role of apolipoprotein A5 in non-alcoholic fatty liver disease. 2011 , 60, 985-91	32

1176	Histological Remission during Corticosteroid Therapy of Overlapping Nonalcoholic Steatohepatitis and Autoimmune Hepatitis: Case Report and Literature Review. 2011 , 5, 553-7	9
1175	Ultrasonographic quantitative estimation of hepatic steatosis in children With NAFLD. 2011 , 53, 190-5	174
1174	Nonalcoholic fatty liver disease and type 2 diabetes mellitus: the hidden epidemic. 2011 , 341, 485-92	18
1173	Relations of steatosis type, grade, and zonality to histological features in pediatric nonalcoholic fatty liver disease. 2011 , 52, 190-7	38
1172	Human C-reactive protein exacerbates metabolic disorders in association with adipose tissue remodelling. 2011 , 91, 546-55	16
1171	Venesection for non-alcoholic fatty liver disease unresponsive to lifestyle counselling--a propensity score-adjusted observational study. 2011 , 104, 141-9	49
1170	Variations in ATP-binding cassette transporter regulation during the progression of human nonalcoholic fatty liver disease. 2011 , 39, 2395-402	99
1169	Serum levels of hepcidin in patients with biopsy-proven nonalcoholic fatty liver disease. 2011 , 9, 287-90	35
1168	Editorial: Exercise for NAFLD: does intensity matter?. 2011 , 106, 470-5	8
1167	Effect of spironolactone and vitamin E on serum metabolic parameters and insulin resistance in patients with nonalcoholic fatty liver disease. 2011 , 12, 498-503	38
1166	The cytoskeleton in nonalcoholic steatohepatitis: 100 years old but still youthful. 2011 , 5, 167-77	8
1165	Animal models for the study of liver fibrosis: new insights from knockout mouse models. 2011 , 300, G729-38	51
1164	Antioxidant and hepatoprotective effects of silibinin in a rat model of nonalcoholic steatohepatitis. 2011 , 2011, nep164	63
1163	Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease. 2011 , 106, 460-8; quiz 469	271
1162	Experimental evidence for therapeutic potential of taurine in the treatment of nonalcoholic fatty liver disease. 2011 , 301, R1710-22	75
1161	Comparison of portal vein doppler indices and hepatic vein doppler waveform in patients with nonalcoholic fatty liver disease with healthy control. 2011 , 11, 740-4	11
1160	NCX 1000 Alone or in Combination with Vitamin E Reverses Experimental Nonalcoholic Steatohepatitis in the Rat Similarly to UDCA. 2011 , 2011, 136816	3
1159	Insulin resistance and necroinflammation drives ductular reaction and epithelial-mesenchymal transition in chronic hepatitis C. 2011 , 60, 108-15	22

1158	Participation of bile ductular cells in the pathological progression of non-alcoholic fatty liver disease. 2011 , 64, 564-70	29
1157	Nonalcoholic fatty liver disease in adult hypopituitary patients with GH deficiency and the impact of GH replacement therapy. 2012 , 167, 67-74	85
1156	The association of metabolic syndrome, insulin resistance and non-alcoholic fatty liver disease in overweight/obese children. 2012 , 18, 44-9	45
1155	Steatohepatitis in laboratory opossums exhibiting a high lipemic response to dietary cholesterol and fat. 2012 , 303, G12-9	16
1154	Ectopic fat and insulin resistance: pathophysiology and effect of diet and lifestyle interventions. 2012 , 2012, 983814	160
1153	Study of the effects of monacolin k and other constituents of red yeast rice on obesity, insulin-resistance, hyperlipidemia, and nonalcoholic steatohepatitis using a mouse model of metabolic syndrome. 2012 , 2012, 892697	25
1152	Low clinical relevance of the nonalcoholic fatty liver disease activity score (NAS) in predicting fibrosis progression. 2012 , 47, 108-15	39
1151	Transient elastography in patients with celiac disease: a noninvasive method to detect liver involvement associated with celiac disease. 2012 , 47, 640-8	4
1150	Liver fibrogenesis in non-alcoholic steatohepatitis. 2012 , 3, 248	24
1149	A prospective evaluation of the role of transient elastography for the detection of hepatic fibrosis in type 2 diabetes without overt liver disease. 2012 , 47, 836-41	22
1148	Recurrent diseases following liver transplantation: current concepts. 2012 , 17, 293-302	2
1147	Graft fibrosis and recipient survival in postorthotopic liver transplant nonalcoholic fatty liver disease. 2012 , 2, 1-6	
1146	From nonalcoholic fatty liver to nonalcoholic steatohepatitis and cirrhosis in HIV-infected patients: diagnosis and management. 2012 , 25, 10-6	49
1145	Liver biopsy in modern clinical practice: a pediatric point-of-view. 2012 , 19, 250-62	77
1144	Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2. 2012 , 302, G1310-21	328
1143	Choline intake in a large cohort of patients with nonalcoholic fatty liver disease. 2012 , 95, 892-900	79
1142	MRI steatosis grading: development and initial validation of a color mapping system. 2012 , 198, 582-8	37
1141	Serum biomarkers in nonalcoholic steatohepatitis: value for assessing drug effects?. 2012 , 6, 743-57	7

1140	Effect of food restriction and leptin supplementation on fetal programming in mice. 2012 , 153, 4556-67	23
1139	A novel murine model for non-alcoholic steatohepatitis developed by combination of a high-fat diet and oxidized low-density lipoprotein. 2012 , 92, 265-81	45
1138	Liver steatosis: concordance of MR imaging and MR spectroscopic data with histologic grade. 2012 , 264, 88-96	31
1137	Nonalcoholic fatty liver disease and bariatric surgery. 2012 , 6, 163-71	25
1136	Caspase-1-mediated regulation of fibrogenesis in diet-induced steatohepatitis. 2012 , 92, 713-23	114
1135	Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research. 2012 , 32, 3-13	250
1134	Prevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease (NAFLD). 2012 , 35, 873-8	172
1133	Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. 2012 , 107, 1862-71	244
1132	Menin liver-specific hemizygous mice challenged with high fat diet show increased weight gain and markers of metabolic impairment. 2012 , 2, e34	6
1131	Increased intrahepatic resistance in severe steatosis: endothelial dysfunction, vasoconstrictor overproduction and altered microvascular architecture. 2012 , 92, 1428-39	72
1130	Group IVA phospholipase A2 participates in the progression of hepatic fibrosis. 2012 , 26, 4111-21	28
1129	Fatty liver, insulin resistance, and features of metabolic syndrome: relationships with coronary artery calcium in 10,153 people. 2012 , 35, 2359-64	103
1128	The interaction of rs738409, obesity, and alcohol: a population-based autopsy study. 2012 , 107, 1668-74	21
1127	Liver fibrogenesis. 2012 , 102-112.e4	
1126	Pediatric Metabolic Syndrome. 2012 ,	5
1125	Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress. 2012 , 107, 202-10	124
1124	Effect of neoadjuvant chemotherapy in hepatic steatosis. 2012 , 58, 89-94	4
1123	Consequences of stopping and restarting leptin in an adolescent with lipodystrophy. 2012 , 78, 320-5	16

1122	Liver Biopsy Interpretation. 2012 , 184-200	
1121	Myeloid deletion of nuclear factor erythroid 2-related factor 2 increases atherosclerosis and liver injury. 2012 , 32, 2839-46	65
1120	Obstructive sleep apnea and non-alcoholic Fatty liver disease: is the liver another target?. 2012 , 3, 149	46
1119	Serum TGF- β Serum MMP-1, and HOMA-IR as non-invasive predictors of fibrosis in Egyptian patients with NAFLD. 2012 , 18, 327-33	23
1118	Ezetimibe: its novel effects on the prevention and the treatment of cholesterol gallstones and nonalcoholic Fatty liver disease. 2012 , 2012, 302847	27
1117	Focus on therapeutic strategies of nonalcoholic Fatty liver disease. 2012 , 2012, 464706	14
1116	Increased α Fetoprotein Predicts Steatosis among Patients with Chronic Hepatitis C Genotype 4. 2012 , 2012, 636392	6
1115	Non-alcoholic Fatty liver disease: the bile Acid-activated farnesoid x receptor as an emerging treatment target. 2012 , 2012, 934396	80
1114	Diagnosis and evaluation of nonalcoholic fatty liver disease. 2012 , 2012, 145754	145
1113	Fibroscan as a noninvasive tool in the assessment of the degree of hepatic steatosis in patients with nonalcoholic fatty liver disease. 2012 , 2, 83-87	2
1112	Non-invasive determination of hepatic steatosis by acoustic structure quantification from ultrasound echo amplitude. 2012 , 18, 3889-95	49
1111	Altered arsenic disposition in experimental nonalcoholic fatty liver disease. 2012 , 40, 1817-24	19
1110	Hydrogen-1 MR spectroscopy for measurement and diagnosis of hepatic steatosis. 2012 , 199, 2-7	42
1109	Surgical results after downstaging of initially marginal or non-resectable liver metastases. 2012 , 30 Suppl 2, 143-9	4
1108	Liver fibrosis in patients with non-alcoholic fatty liver disease: diagnostic options in clinical practice. 2012 , 6, 381-94	8
1107	Correlation of vitamin E, uric acid, and diet composition with histologic features of pediatric NAFLD. 2012 , 54, 90-6	80
1106	Validation of interventional fiber optic spectroscopy with MR spectroscopy, MAS-NMR spectroscopy, high-performance thin-layer chromatography, and histopathology for accurate hepatic fat quantification. 2012 , 47, 209-16	11
1105	Relation of epicardial adipose tissue and carotid intima-media thickness in patients with nonalcoholic fatty liver disease. 2012 , 24, 613-8	36

1104	The association between adipocytokines and biomarkers for nonalcoholic fatty liver disease-induced liver injury: a study in the general population. 2012 , 24, 262-9	25
1103	How adiponectin, leptin, and ghrelin orchestrate together and correlate with the severity of nonalcoholic fatty liver disease. 2012 , 24, 1166-72	63
1102	Hepatic fat quantification: a prospective comparison of magnetic resonance spectroscopy and analysis methods for chemical-shift gradient echo magnetic resonance imaging with histologic assessment as the reference standard. 2012 , 47, 368-75	92
1101	Quantification of hepatic steatosis with dual-energy computed tomography: comparison with tissue reference standards and quantitative magnetic resonance imaging in the ob/ob mouse. 2012 , 47, 603-10	56
1100	LPIN1 rs13412852 polymorphism in pediatric nonalcoholic fatty liver disease. 2012 , 54, 588-93	46
1099	Diagnosis of nonalcoholic fatty liver disease in children and adolescents: position paper of the ESPGHAN Hepatology Committee. 2012 , 54, 700-13	311
1098	Intrahepatic cholangiocarcinoma with predominant "ductal plate malformation" pattern: a new subtype. 2012 , 36, 1629-35	44
1097	Volumetric analysis of remnant liver regeneration after major hepatectomy in bevacizumab-treated patients: a case-matched study in 82 patients. 2012 , 256, 755-61; discussion 761-2	27
1096	Reticulin loss in benign fatty liver: an important diagnostic pitfall when considering a diagnosis of hepatocellular carcinoma. 2012 , 36, 710-5	48
1095	Serum concentrations of human insulin-like growth factor-1 and levels of insulin-like growth factor-binding protein-5 in patients with nonalcoholic fatty liver disease: association with liver histology. 2012 , 24, 255-61	28
1094	Gastrointestinal Physiology in Obesity. 2012 , 21-27	
1093	Magnetic resonance for quantitative assessment of liver steatosis: a new potential tool to monitor antiretroviral-drug-related toxicities. 2012 , 17, 965-71	10
1092	Science of Nonalcoholic Fatty Liver Disease in Anti-Aging Medicine 2011. 2012 , 9, 24-33	1
1091	Silymarin suppresses hepatic stellate cell activation in a dietary rat model of non-alcoholic steatohepatitis: analysis of isolated hepatic stellate cells. 2012 , 30, 473-9	46
1090	Markers of activated inflammatory cells correlate with severity of liver damage in children with nonalcoholic fatty liver disease. 2012 , 30, 49-56	46
1089	Effect of insulin versus triple oral therapy on the progression of hepatic steatosis in type 2 diabetes. 2012 , 60, 1059-63	9
1088	Resectable liver metastases from colorectal cancer: where we are now and where do we go from here?. 2012 , 1, 397-411	
1087	Bias in macrophage activation pattern influences non-alcoholic steatohepatitis (NASH) in mice. 2012 , 122, 545-53	53

1086	Adenosine A(2a) receptor stimulation prevents hepatocyte lipotoxicity and non-alcoholic steatohepatitis (NASH) in rats. 2012 , 123, 323-32		32
1085	Prospective evaluation of accuracy of liver biopsy findings in the identification of chemotherapy-associated liver injuries. 2012 , 147, 1085-91		12
1084	Pediatric nonalcoholic fatty liver disease: a multidisciplinary approach. 2012 , 9, 152-61		79
1083	Novel histologic scoring system for long-term allograft fibrosis after liver transplantation in children. 2012 , 12, 2986-96		68
1082	Analysis of adipokine concentrations in paediatric non-alcoholic fatty liver disease. 2012 , 7, 471-9		35
1081	Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice. 2012 , 143, 765-776.e3		400
1080	Dorothy Hodgkin Lecture 2012: non-alcoholic fatty liver disease, insulin resistance and ectopic fat: a new problem in diabetes management. 2012 , 29, 1098-107		69
1079	The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. 2012 , 142, 1592-609		1208
1078	Quercetin treatment ameliorates inflammation and fibrosis in mice with nonalcoholic steatohepatitis. 2012 , 142, 1821-8		116
1077	Physiology and Anatomy of the Liver. 2012 , 3-20		5
1076	Surgical treatment of hepatocellular carcinoma associated with the metabolic syndrome. 2013 , 100, 113-21		68
1075	Hepatic progenitor cells activation, fibrosis, and adipokines production in pediatric nonalcoholic fatty liver disease. <i>Hepatology</i> , 2012 , 56, 2142-53	11.2	108
1074	Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. <i>Hepatology</i> , 2012 , 56, 1751-9	11.2	438
1073	Hepatic progenitor cells: Another piece in the nonalcoholic fatty liver disease puzzle. <i>Hepatology</i> , 2012 , 56, 2013-5	11.2	7
1072	Liver vitamin D receptor, CYP2R1, and CYP27A1 expression: relationship with liver histology and vitamin D3 levels in patients with nonalcoholic steatohepatitis or hepatitis C virus. <i>Hepatology</i> , 2012 , 56, 2180-7	11.2	153
1071	Underlying steatohepatitis, but not simple hepatic steatosis, increases morbidity after liver resection: a case-control study. <i>Hepatology</i> , 2012 , 56, 2221-30	11.2	68
1070	Evolution of nonalcoholic fatty liver disease recurrence after liver transplantation. 2012 , 18, 1147-53		60
1069	Progressive graft fibrosis and donor-specific human leukocyte antigen antibodies in pediatric late liver allografts. 2012 , 18, 1333-42		132

1068	Macroscopic heterogeneity of liver fat: an MR-based study in type-2 diabetic patients. 2012 , 22, 2161-8	16
1067	A comparison of MR elastography and 31P MR spectroscopy with histological staging of liver fibrosis. 2012 , 22, 2790-7	41
1066	Unconjugated hyperbilirubinemia in patients with non-alcoholic fatty liver disease: a favorable endogenous response. 2012 , 45, 272-4	26
1065	Unconjugated hyperbilirubinemia and liver histology in patients with non-alcoholic fatty liver disease. 2012 , 45, 515	
1064	Preliminary evidence of a reduced serum level of fibroblast growth factor 19 in patients with biopsy-proven nonalcoholic fatty liver disease. 2012 , 45, 655-8	35
1063	Serum levels of pigment epithelium-derived factor (PEDF) are independently associated with procollagen III N-terminal peptide levels in patients with nonalcoholic fatty liver disease. 2012 , 45, 1554-7	3
1062	Sida rhomboidea.Roxb extract alleviates pathophysiological changes in experimental in vivo and in vitro models of high fat diet/fatty acid induced non-alcoholic steatohepatitis. 2012 , 64, 217-24	16
1061	Nonalcoholic fatty liver in children and adolescents: an overview. 2012 , 51, 305-12	33
1060	Patterns of surgical weight loss and resolution of metabolic abnormalities in superobese bariatric adolescents. 2012 , 47, 1633-9	15
1059	Liver elasticity in NASH patients evaluated with real-time elastography (RTE). 2012 , 38, 537-44	38
1058	Noninvasive assessment of nonalcoholic fatty liver disease in obese or overweight patients. 2012 , 10, 1162-8; quiz e87	52
1057	Restorative effect of (5E, 13E)B,13Docosadienoic acid on carbon tetrachloride induced oxidative stress in rats. 2012 , 2, S1592-S1599	1
1056	A myriad of pathways to NASH. 2012 , 16, 525-48	33
1055	Is nonalcoholic fatty liver disease in children the same disease as in adults?. 2012 , 16, 587-98	10
1054	Association between puberty and features of nonalcoholic fatty liver disease. 2012 , 10, 786-94	44
1053	Prevalence and indicators of portal hypertension in patients with nonalcoholic fatty liver disease. 2012 , 10, 1028-33.e2	52
1052	Reply to: ■ regulatory cell number and function: The autoimmune traits in liver diseases■ 2012 , 57, 1399-1400	2
1051	Lipidic last breath of life in patients with alcoholic liver disease. 2012 , 99, 51-6	25

1050	Association of serum lipoprotein-associated phospholipase A2 level with nonalcoholic fatty liver disease. 2012 , 10, 103-9	9
1049	Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor?. 2012 , 33, 1190-200	312
1048	Medical therapy for nonalcoholic fatty liver disease in children and adolescents. 2012 , 6, 1-3	6
1047	Cardiometabolic aspects of the polycystic ovary syndrome. 2012 , 33, 812-41	188
1046	Development and validation of a new histological score for pediatric non-alcoholic fatty liver disease. 2012 , 57, 1312-8	60
1045	The herbal composition GGEx18 from <i>Laminaria japonica</i> , <i>Rheum palmatum</i> , and <i>Ephedra sinica</i> inhibits high-fat diet-induced hepatic steatosis via hepatic PPAR α activation. 2012 , 50, 1261-8	14
1044	Toll-like receptor-4 mediates obesity-induced non-alcoholic steatohepatitis through activation of X-box binding protein-1 in mice. 2012 , 61, 1058-67	146
1043	Guidelines for liver transplantation for patients with non-alcoholic steatohepatitis. 2012 , 61, 484-500	52
1042	Pharmacologic ER stress induces non-alcoholic steatohepatitis in an animal model. 2012 , 211, 29-38	103
1041	Fatty liver disease. 2012 , 293-359	9
1040	Evaluation of transient elastography for fibrosis assessment compared with large biopsies in chronic hepatitis B and C. 2012 , 32, 622-8	58
1039	The outcomes of glucose abnormalities in pre-diabetic chronic hepatitis C patients receiving peginterferon plus ribavirin therapy. 2012 , 32, 962-9	18
1038	Beneficial effects of candesartan, an angiotensin-blocking agent, on compensated alcoholic liver fibrosis - a randomized open-label controlled study. 2012 , 32, 977-87	53
1037	Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography. 2012 , 32, 902-10	222
1036	Ultrasonographic fatty liver indicator, a novel score which rules out NASH and is correlated with metabolic parameters in NAFLD. 2012 , 32, 1242-52	124
1035	The housekeeping gene YWHAZ remains stable in a model of developmentally primed non-alcoholic fatty liver disease. 2012 , 32, 1315-21	19
1034	The serum hepcidin:ferritin ratio is a potential biomarker for cirrhosis. 2012 , 32, 1391-9	36
1033	Protective effects of lycorine against carbon tetrachloride induced hepatotoxicity in Swiss albino mice. 2012 , 26, 393-401	15

1032	Populus balsamifera L. (Salicaceae) mitigates the development of obesity and improves insulin sensitivity in a diet-induced obese mouse model. 2012 , 141, 1012-20	18
1031	Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort. 2012 , 56, 234-40	213
1030	Endogenous formation of Nε(carboxymethyl)lysine is increased in fatty livers and induces inflammatory markers in an in vitro model of hepatic steatosis. 2012 , 56, 647-55	76
1029	Serum interleukin 1 receptor antagonist as an independent marker of non-alcoholic steatohepatitis in humans. 2012 , 56, 663-70	69
1028	The value of pre-operative magnetic resonance spectroscopy in the assessment of steatohepatitis in patients with colorectal liver metastasis. 2012 , 56, 640-6	18
1027	Discordance in fibrosis staging between liver biopsy and transient elastography using the FibroScan XL probe. 2012 , 56, 564-70	112
1026	Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: comparison between M and XL probe of FibroScan®. 2012 , 56, 833-9	184
1025	Accumulation of endoplasmic reticulum stress and lipogenesis in the liver through generational effects of high fat diets. 2012 , 56, 900-7	118
1024	Structural and inflammatory heterogeneity in subcutaneous adipose tissue: relation with liver histopathology in morbid obesity. 2012 , 56, 1152-1158	61
1023	Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers. 2012 , 56, 1363-70	162
1022	Visceral adiposity index is not a predictor of liver histology in patients with non-alcoholic fatty liver disease. 2012 , 57, 392-8	38
1021	Critical role of cytochrome P450 2E1 (CYP2E1) in the development of high fat-induced non-alcoholic steatohepatitis. 2012 , 57, 860-6	170
1020	Translocator protein (18 kDa), a potential molecular imaging biomarker for non-invasively distinguishing non-alcoholic fatty liver disease. 2012 , 57, 1076-82	41
1019	Regular coffee but not espresso drinking is protective against fibrosis in a cohort mainly composed of morbidly obese European women with NAFLD undergoing bariatric surgery. 2012 , 57, 1090-6	106
1018	The modulation of hepatic adenosine triphosphate and inflammation by eicosapentaenoic acid during severe fibrotic progression in the SHRSP5/Dmcr rat model. 2012 , 90, 934-43	18
1017	[Nonalcoholic fatty liver disease]. 2012 , 41, 169-89	4
1016	Costaining for keratins 8/18 plus ubiquitin improves detection of hepatocyte injury in nonalcoholic fatty liver disease. 2012 , 43, 790-800	55
1015	Embolisation portale avant h̃patectomie majeure pour m̃tastases h̃patiques d̃origine colorectale : rationnel, indications, techniques, complications et r̃sultats. 2012 , 149, 94-106	

1014	Theaflavin attenuates ischemia-reperfusion injury in a mouse fatty liver model. 2012 , 417, 287-93	31
1013	A new computational method for hepatic fat microvesicles counting in histological study in rats. 2012 , 418, 284-9	4
1012	Ezetimibe reduces fatty acid quantity in liver and decreased inflammatory cell infiltration and improved NASH in medaka model. 2012 , 422, 22-7	11
1011	Apoptosis associated inhibition of DEN-induced hepatocellular carcinogenesis by ellagic acid in experimental rats. 2012 , 2, 1-8	10
1010	Which metabolic syndrome criteria best predict the presence of non-alcoholic fatty liver disease?. 2012 , 95, 19-24	8
1009	Elevated asymmetric dimethylarginine in plasma: an early marker for endothelial dysfunction in non-alcoholic fatty liver disease?. 2012 , 96, 47-52	26
1008	Fatty acid mobilization in voles--model species for rapid fasting response and fatty liver. 2012 , 163, 152-60	16
1007	Effectiveness of liver metastasectomies in patients with metastatic colorectal cancer treated with FIr-B/FOx triplet chemotherapy plus bevacizumab. 2012 , 11, 119-26	27
1006	SFRS10--a splicing factor gene reduced in human obesity?. 2012 , 15, 265-6; author reply 267-9	9
1005	Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. 2012 , 15, 665-74	395
1004	Accurate fat fraction quantification by multiecho gradient-recalled-echo magnetic resonance at 1.5T in rats with nonalcoholic fatty liver disease. 2012 , 81, 1122-7	7
1003	Acoustic radiation force impulse-imaging and transient elastography for non-invasive assessment of liver fibrosis and steatosis in NAFLD. 2012 , 81, e325-31	144
1002	Association of adiponectin gene functional polymorphisms (-11377C/G and +45T/G) with nonalcoholic fatty liver disease. 2012 , 496, 63-7	34
1001	Histological assessment of nonalcoholic fatty liver disease in adults and children. 2012 , 1, 108-111	18
1000	Management of nonalcoholic fatty liver disease: Role of bariatric surgery. 2012 , 1, 119-121	
999	Nonalcoholic fatty liver disease: Definitions, risk factors, and workup. 2012 , 1, 99-103	53
998	Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: new evidence on the potential therapeutic mechanism. <i>Hepatology</i> , 2012 , 56, 1291-9	11.2 112
997	Hepatic steatosis and steatohepatitis in human immunodeficiency virus/hepatitis C virus-coinfected patients. <i>Hepatology</i> , 2012 , 56, 1261-70	11.2 30

996	Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study. <i>Hepatology</i> , 2012 , 56, 1311-8	11.2	75
995	Lower serum hepcidin and greater parenchymal iron in nonalcoholic fatty liver disease patients with C282Y HFE mutations. <i>Hepatology</i> , 2012 , 56, 1730-40	11.2	35
994	Clinical relevance of antibodies to cardiolipin in patients with chronic hepatitis C. 2012 , 26, 342-8		7
993	The I148M PNPLA3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls. 2012 , 12, 111		50
992	Black rice (<i>Oryza sativa</i> L.) extract attenuates hepatic steatosis in C57BL/6 J mice fed a high-fat diet via fatty acid oxidation. 2012 , 9, 27		67
991	Non-alcoholic fatty liver disease. 2012 , 4, 266-80		38
990	Thiazolidinediones improve hepatic fibrosis in rats with non-alcoholic steatohepatitis by activating the adenosine monophosphate-activated protein kinase signalling pathway. 2012 , 39, 1026-33		25
989	Assessment of non-alcoholic fatty liver disease using serum total cell death and apoptosis markers. 2012 , 36, 1057-66		49
988	Combining semiquantitative measures of fibrosis and qualitative features of parenchymal remodelling to identify fibrosis regression in hepatitis C: a multiple biopsy study. 2012 , 61, 473-87		4
987	Therapeutic administration of the direct thrombin inhibitor argatroban reduces hepatic inflammation in mice with established fatty liver disease. 2012 , 181, 1287-95		31
986	Suboptimal performance of simple noninvasive tests for advanced fibrosis in Chinese patients with nonalcoholic fatty liver disease. 2012 , 13, 588-95		24
985	Macrophages, TGF- β expression and iron deposition in development of NASH. 2012 , 7, 599-603		1
984	Nonalcoholic fatty liver disease. 2012 , 16, 397-419		55
983	Serum vitamin B12 and folate levels in patients with non-alcoholic fatty liver disease. 2012 , 63, 659-66		15
982	Modulating fibroblast growth factor 21 in hyperphagic OLETF rats with daily exercise and caloric restriction. 2012 , 37, 1054-62		28
981	The relevance of liver histology to predicting clinically meaningful outcomes in nonalcoholic steatohepatitis. 2012 , 16, 487-504		37
980	Can NASH be diagnosed, graded, and staged noninvasively?. 2012 , 16, 567-85		53
979	Hepatic expression and serum levels of syndecan 1 (CD138) in patients with nonalcoholic fatty liver disease. 2012 , 47, 1488-93		11

978	Fibromodulin, an oxidative stress-sensitive proteoglycan, regulates the fibrogenic response to liver injury in mice. 2012 , 142, 612-621.e5	44
977	Intrahepatic diacylglycerol content is associated with hepatic insulin resistance in obese subjects. 2012 , 142, 1444-6.e2	130
976	Circulating microparticles as disease-specific biomarkers of severity of inflammation in patients with hepatitis C or nonalcoholic steatohepatitis. 2012 , 143, 448-58	137
975	Exercise training attenuates hepatic inflammation, fibrosis and macrophage infiltration during diet induced-obesity in mice. 2012 , 26, 931-41	77
974	Ursodeoxycholic acid with vitamin E in patients with nonalcoholic steatohepatitis: long-term results. 2012 , 36, 146-55	43
973	Non-alcoholic fatty liver disease in children. 2012 , 36, 297-300	13
972	Hyperresponsivity to low-dose endotoxin during progression to nonalcoholic steatohepatitis is regulated by leptin-mediated signaling. 2012 , 16, 44-54	232
971	Liver stiffness correlates with methotrexate cumulative dose in patients with rheumatoid arthritis. 2012 , 44, 149-53	26
970	N-glycan based biomarker distinguishing non-alcoholic steatohepatitis from steatosis independently of fibrosis. 2012 , 44, 315-22	29
969	Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor- β -lowering property. 2012 , 44, 492-6	45
968	Spirulina improves non-alcoholic steatohepatitis, visceral fat macrophage aggregation, and serum leptin in a mouse model of metabolic syndrome. 2012 , 44, 767-74	32
967	Increased insulinogenic index is an independent determinant of nonalcoholic fatty liver disease activity score in patients with normal glucose tolerance. 2012 , 44, 935-9	3
966	Effects of bile duct ligation and cholic acid treatment on fatty liver in two rat models of non-alcoholic fatty liver disease. 2012 , 44, 1018-26	14
965	Ultrasonography as a non-invasive tool for detection of nonalcoholic fatty liver disease in overweight/obese Egyptian children. 2012 , 81, 3120-3	22
964	Intragastric balloon significantly improves nonalcoholic fatty liver disease activity score in obese patients with nonalcoholic steatohepatitis: a pilot study. 2012 , 76, 756-60	78
963	Hepatic tumor necrosis factor- β -leptin and adiponectin expression in morbid obese patients: Clinicopathological correlations. 2012 , 6, e1-e90	1
962	Metabolic effects of lactoferrin during energy restriction and weight regain in diet-induced obese mice. 2012 , 4, 66-78	26
961	Non-alcoholic fatty liver disease: an emerging liver disease in Taiwan. 2012 , 111, 527-35	24

960	Portal vein occlusion before major hepatectomy in patients with colorectal liver metastases: rationale, indications, technical aspects, complications and outcome. 2012 , 149, e86-96	17
959	Features, diagnosis, and treatment of nonalcoholic fatty liver disease. 2012 , 10, 837-58	182
958	Nonalcoholic fatty liver disease: what the pathologist can tell the clinician. 2012 , 30 Suppl 1, 61-8	29
957	Chemotherapy-associated liver injury in patients with colorectal liver metastases: a systematic review and meta-analysis. 2012 , 19, 4287-99	143
956	Measuring altered disposition of xenobiotics in experimental models of liver disease. 2012 , Chapter 23, Unit 23.1.	2
955	Metabolic Syndrome and Related Liver Diseases. 2012 , 137-157	
954	Hepcidin expression in iron overload diseases is variably modulated by circulating factors. 2012 , 7, e36425	19
953	Diabetes and the Liver. 2012 , 67-82	
952	Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. 2012 , 482, 179-85	1651
951	Influence of hepatic parenchymal histology on outcome following right hepatic trisectionectomy. 2012 , 16, 2064-73	11
950	Metabolic disorders, non-alcoholic fatty liver disease and major liver resection: an underestimated perioperative risk. 2012 , 16, 2247-55	23
949	Serologic predictors of nonalcoholic steatohepatitis in a population undergoing bariatric surgery. 2012 , 8, 416-22	10
948	T regulatory cell number and function: the autoimmune traits in liver diseases. 2012 , 57, 1398-9; author reply 1399-400	
947	Non-alcoholic fatty liver disease and cardiovascular disease: epidemiological, clinical and pathophysiological evidences. 2012 , 7 Suppl 3, S291-6	24
946	Ultrasonography (US) and non-invasive diagnostic methods for non-alcoholic fatty liver disease (NAFLD) and early vascular damage. Possible application in a population study on the metabolic syndrome (MS). 2012 , 7 Suppl 3, S283-90	5
945	Protection from non-alcoholic steatohepatitis and liver tumorigenesis in high fat-fed insulin receptor substrate-1-knockout mice despite insulin resistance. 2012 , 55, 3382-91	34
944	Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial. 2012 , 33, 1142-9	152
943	The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. 2012 , 107, 811-26	279

942	Fuzheng Huayu recipe prevents nutritional fibrosing steatohepatitis in mice. 2012 , 11, 45	20
941	Management strategy after diagnosis of Abernethy malformation: a case report. 2012 , 6, 167	10
940	Liver and muscle in morbid obesity: the interplay of fatty liver and insulin resistance. 2012 , 7, e31738	34
939	Quantification of hepatic iron concentration in chronic viral hepatitis: usefulness of T2-weighted single-shot spin-echo echo-planar MR imaging. 2012 , 7, e33868	6
938	Cannabinoid receptor type 2 functional variant influences liver damage in children with non-alcoholic fatty liver disease. 2012 , 7, e42259	34
937	The A736V TMPRSS6 polymorphism influences hepatic iron overload in nonalcoholic fatty liver disease. 2012 , 7, e48804	37
936	Label-free evaluation of hepatic microvesicular steatosis with multimodal coherent anti-Stokes Raman scattering microscopy. 2012 , 7, e51092	34
935	Serum γ -glutamyl transferase levels, insulin resistance and liver fibrosis in patients with chronic liver diseases. 2012 , 7, e51165	24
934	Cholesterol and Inflammation at the Crossroads of Non-Alcoholic Fatty Liver Disease (NAFLD) and Atherogenesis. 2012 ,	1
933	Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. 2012 , 18, 2300-8	369
932	Overview and developments in noninvasive diagnosis of nonalcoholic fatty liver disease. 2012 , 18, 3945-54	55
931	Current treatment options for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. 2012 , 26, 353-7	35
930	Concentrations of Connective Tissue Growth Factor in Patients with Nonalcoholic Fatty Liver Disease: Association with Liver Fibrosis. 2012 , 33, 77-83	9
929	Perinatal exposure to environmental tobacco smoke (ETS) enhances susceptibility to viral and secondary bacterial infections. 2012 , 9, 3954-64	11
928	NASH is an Inflammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications. 2012 , 6, 149-71	278
927	Correlation of adipose tissue with liver histology in Asian Indian patients with nonalcoholic fatty liver disease (NAFLD). 2012 , 11, 478-486	31
926	Room-temperature susceptometry predicts biopsy-determined hepatic iron in patients with elevated serum ferritin. 2012 , 11, 77-84	9
925	Serum homocysteine levels in patients with nonalcoholic fatty liver disease. 2012 , 11, 68-76	37

924	Steatotic livers. Can we use them in OLTX? Outcome data from a prospective baseline liver biopsy study. 2012 , 11, 891-898		44
923	Nonalcoholic Fatty Liver Disease: A Pathological View. 2012 ,		5
922	Regional differences in hepatic fat fractions in over-weight children and adolescents observed by 3T 1H-MR spectroscopy. 2012 , 3,		
921	Nonalcoholic Fatty Liver Disease. 2012 , 941-968		3
920	The efficacy of pharmacological treatment in pediatric nonalcoholic Fatty liver disease. 2012 , 15, 256-65		8
919	Serum vaspin may be a good indicator of fibrosis in chronic hepatitis C and is not altered by antiviral therapy. 2012 , 63, 213-20		12
918	Deficiency in galectin-3 promotes hepatic injury in CDAA diet-induced nonalcoholic fatty liver disease. 2012 , 2012, 959824		21
917	The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans. 2012 , 122, 2176-94		254
916	Female mice are more susceptible to nonalcoholic fatty liver disease: sex-specific regulation of the hepatic AMP-activated protein kinase-plasminogen activator inhibitor 1 cascade, but not the hepatic endotoxin response. 2012 , 18, 1346-55		60
915	Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population. 2012 , 12, 2		210
914	The effect of cocoa, soy, oats and fish oil on metabolic syndrome in rats. 2012 , 92, 2349-57		8
913	Effect of bevacizumab added preoperatively to oxaliplatin on liver injury and complications after resection of colorectal liver metastases. 2012 , 106, 892-7		29
912	Fumonisin FB1 treatment acts synergistically with methyl donor deficiency during rat pregnancy to produce alterations of H3- and H4-histone methylation patterns in fetuses. 2012 , 56, 976-85		23
911	ISMRM workshop on fat-water separation: insights, applications and progress in MRI. 2012 , 68, 378-88		117
910	Vitamin D deficiency in obese rats exacerbates nonalcoholic fatty liver disease and increases hepatic resistin and Toll-like receptor activation. <i>Hepatology</i> , 2012 , 55, 1103-11	11.2	181
909	Hepatic ratio of phosphatidylcholine to phosphatidylethanolamine predicts survival after partial hepatectomy in mice. <i>Hepatology</i> , 2012 , 55, 1094-102	11.2	54
908	Endoplasmic reticulum-tethered transcription factor cAMP responsive element-binding protein, hepatocyte specific, regulates hepatic lipogenesis, fatty acid oxidation, and lipolysis upon metabolic stress in mice. <i>Hepatology</i> , 2012 , 55, 1070-82	11.2	135
907	Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease. <i>Hepatology</i> , 2012 , 55, 1809-19	11.2	147

906	Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2012 , 55, 1389-97	11.2	262
905	Hedgehog pathway activation parallels histologic severity of injury and fibrosis in human nonalcoholic fatty liver disease. <i>Hepatology</i> , 2012 , 55, 1711-21	11.2	143
904	Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial. <i>Hepatology</i> , 2012 , 56, 922-32	11.2	181
903	Nonalcoholic steatohepatitis versus steatosis: adipose tissue insulin resistance and dysfunctional response to fat ingestion predict liver injury and altered glucose and lipoprotein metabolism. <i>Hepatology</i> , 2012 , 56, 933-42	11.2	91
902	Real-time tissue elastography for evaluation of hepatic fibrosis and portal hypertension in nonalcoholic fatty liver diseases. <i>Hepatology</i> , 2012 , 56, 1271-8	11.2	83
901	The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. <i>Hepatology</i> , 2012 , 55, 2005-23	11.2	2285
900	Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. <i>Hepatology</i> , 2012 , 56, 943-51	11.2	302
899	Hydrogen-rich water prevents progression of nonalcoholic steatohepatitis and accompanying hepatocarcinogenesis in mice. <i>Hepatology</i> , 2012 , 56, 912-21	11.2	79
898	Obesity-dependent metabolic signatures associated with nonalcoholic fatty liver disease progression. 2012 , 11, 2521-32		137
897	Plasma free choline is a novel non-invasive biomarker for early-stage non-alcoholic steatohepatitis: A multi-center validation study. 2012 , 42, 757-66		23
896	Hepatic steatosis, steatohepatitis, and chemotherapy-related liver injury. 2012 , 999-1005.e1		
895	Cirrhosis and portal hypertension. 2012 , 1079-1091.e2		
894	Eugenia jambolana seed extract supplementation attenuates cardiac and hepatic oxidative stress and pathophysiological changes in hypercholesterolemic rats. 2012 , 12, 99-106		3
893	Genetic variation in the peroxisome proliferator activated receptor-gamma gene is associated with histologically advanced NAFLD. 2012 , 57, 952-7		35
892	Nutrition, intestinal permeability, and blood ethanol levels are altered in patients with nonalcoholic fatty liver disease (NAFLD). 2012 , 57, 1932-41		187
891	The role of innate cells is coupled to a Th1-polarized immune response in pediatric nonalcoholic steatohepatitis. 2012 , 32, 611-21		39
890	Effects of different sources of fructans on body weight, blood metabolites and fecal bacteria in normal and obese non-diabetic and diabetic rats. 2012 , 67, 64-70		40
889	Intraoperative detection of disappearing colorectal liver metastases as a predictor of residual disease. 2012 , 16, 806-14		47

888	Improvement of nonalcoholic fatty liver disease after bariatric surgery in morbidly obese Chinese patients. 2012 , 22, 1016-21	66
887	Association of ghrelin receptor promoter polymorphisms with weight loss following Roux-en-Y gastric bypass surgery. 2012 , 22, 783-90	29
886	Thyroid autoantibodies and dysfunction do not impact the treatment efficacy of peginterferon and ribavirin combination therapy in chronic hepatitis C. 2012 , 6, 613-9	4
885	Development of novel rat model for high-fat and high-cholesterol diet-induced steatohepatitis and severe fibrosis progression in SHRSP5/Dmcr. 2012 , 17, 173-82	38
884	Prolonged portal triad clamping increases postoperative sepsis after major hepatectomy in patients with sinusoidal obstruction syndrome and/or steatohepatitis. 2012 , 36, 1848-57	17
883	Specificity of unenhanced CT for non-invasive diagnosis of hepatic steatosis: implications for the investigation of the natural history of incidental steatosis. 2012 , 22, 1075-82	110
882	A multi-ethnic study of a PNPLA3 gene variant and its association with disease severity in non-alcoholic fatty liver disease. 2012 , 131, 1145-52	74
881	Thrombocytopenia is more severe in patients with chronic hepatitis C than in patients with nonalcoholic fatty liver disease. 2012 , 47, 606-7; author reply 608	9
880	Impaired renal function in morbid obese patients with nonalcoholic fatty liver disease. 2012 , 32, 241-8	55
879	Neutrophil to lymphocyte ratio: a new marker for predicting steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease. 2012 , 32, 297-302	161
878	Transitional features of histologic type of non-alcoholic fatty liver disease in Korean young men. 2012 , 27, 142-8	1
877	Peroxisome proliferator-activated receptor- β agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis. 2012 , 27, 341-50	65
876	Histological features of non-alcoholic fatty liver disease: what is important?. 2012 , 27, 5-7	15
875	Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. 2012 , 35, 66-75	213
874	The epidemiology, pathogenesis and histopathology of fatty liver disease. 2012 , 61, 141-52	125
873	Quantifying hepatic steatosis - more than meets the eye. 2012 , 60, 971-81	54
872	Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial. 2012 , 52, 1658-65	163
871	Sex-dependent programming of glucose and fatty acid metabolism in mouse offspring by maternal protein restriction. 2012 , 9, 166-179.e13	13

870	Folate exacerbates the effects of ethanol on peripubertal mouse mammary gland development. 2012 , 46, 285-92	6
869	Distinctive histopathological features that support a diagnosis of cholesterol ester storage disease in liver biopsy specimens. 2012 , 60, 1107-13	59
868	Usefulness of Technetium-99 m-2-methoxy-isobutyl-isonitrile liver scintigraphy for evaluating disease activity of non-alcoholic fatty liver disease. 2012 , 42, 273-9	9
867	Influence of chronic stress on the compositions of hepatic cholesterol and triglyceride in male Wistar rats fed a high fat diet. 2012 , 42, 686-95	6
866	Lipid profiling of pre-treatment liver biopsy tissue predicts sustained virological response in patients with chronic hepatitis C. 2012 , 42, 714-20	2
865	Clinical and pathological progression of non-alcoholic steatohepatitis to hepatocellular carcinoma. 2012 , 42, 767-73	45
864	Efficacy of rosuvastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label, pilot study. 2012 , 42, 1065-72	33
863	Dietary protein restriction induces steatohepatitis and alters leptin/signal transducers and activators of transcription 3 signaling in lactating rats. 2012 , 23, 791-9	21
862	Hepatic lipid composition analysis using 3.0-T MR spectroscopy in a steatotic rat model. 2012 , 30, 112-21	16
861	Quantification of macrovesicular and microvesicular hepatic steatosis in rats using 3.0-T ¹ H-magnetic resonance spectroscopy. 2012 , 44, 955-8	1
860	Ethanol extract of <i>Crinum asiaticum</i> attenuates hyperglycemia-mediated oxidative stress and protects hepatocytes in alloxan induced experimental diabetic rats. 2012 , 24, 171-177	17
859	Unconjugated hyperbilirubinemia is inversely associated with non-alcoholic steatohepatitis (NASH). 2012 , 35, 1416-23	31
858	Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease - MRI accurately quantifies hepatic steatosis in NAFLD. 2012 , 36, 22-9	234
857	Characterization of nonalcoholic fatty liver disease unrelated to the metabolic syndrome. 2012 , 42, 411-8	31
856	CD14 expression and Kupffer cell dysfunction in non-alcoholic steatohepatitis: superparamagnetic iron oxide-magnetic resonance image and pathologic correlation. 2012 , 27, 789-96	20
855	Should we stop "MaS"ing about with steatotic liver grafts and "MiS" out on potential donor livers?. 2012 , 27, 422-4	0
854	Assessment of inflammation and fibrosis in non-alcoholic fatty liver disease by imaging-based techniques. 2012 , 27, 1281-92	27
853	Energy expenditure and insulin sensitivity evaluation in obese children affected by hepatosteatosis. 2012 , 7, e14-7	9

852	Serum protein N-glycosylation in paediatric non-alcoholic fatty liver disease. 2012 , 7, 165-73		12
851	Amelioration of diet-induced nonalcoholic steatohepatitis in rats by Mn-salen complexes via reduction of oxidative stress. 2012 , 19, 26		31
850	Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. <i>Hepatology</i> , 2012 , 55, 199-208	11.2	335
849	IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. <i>Hepatology</i> , 2012 , 55, 384-94	11.2	124
848	"Normal" liver stiffness measure (LSM) values are higher in both lean and obese individuals: a population-based study from a developing country. <i>Hepatology</i> , 2012 , 55, 584-93	11.2	62
847	Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2012 , 55, 77-85	11.2	300
846	Hepatitis B virus mutants associated with hepatitis B surface antigen loss: chicken or egg?. <i>Hepatology</i> , 2012 , 55, 656-7	11.2	
845	Ethnicity and nonalcoholic fatty liver disease. <i>Hepatology</i> , 2012 , 55, 769-80	11.2	145
844	Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis. <i>Hepatology</i> , 2012 , 55, 455-64	11.2	126
843	Rifaximin reduces endotoxemia and improves liver function and disease severity in patients with decompensated cirrhosis. <i>Hepatology</i> , 2012 , 55, 655-6	11.2	47
842	Histological discrimination between autoimmune hepatitis and drug-induced liver injury. <i>Hepatology</i> , 2012 , 55, 657	11.2	5
841	Reply:. <i>Hepatology</i> , 2012 , 55, 652-652	11.2	
840	Re: indeterminate 1-2 cm nodules found on hepatocellular carcinoma surveillance: biopsy for all, some, or none?. <i>Hepatology</i> , 2012 , 55, 651; author reply 652	11.2	
839	Diagnostic algorithms for liver fibrosis in hepatitis C: are they ready to avoid liver biopsy?. <i>Hepatology</i> , 2012 , 55, 652-3; author reply 653	11.2	
838	Is M65 really better than M30 as a biomarker of hepatic fibrosis?. <i>Hepatology</i> , 2012 , 55, 654; author reply 654-5	11.2	2
837	Reply:. <i>Hepatology</i> , 2012 , 55, 654-655	11.2	
836	Reply:. <i>Hepatology</i> , 2012 , 55, 653-653	11.2	
835	Hepatic steatosis, fibrosis, and cancer in elderly cadavers. 2012 , 295, 40-50		18

834	Clinical significance of serum autoantibodies in patients with NAFLD: results from the nonalcoholic steatohepatitis clinical research network. 2012 , 6, 379-85	81
833	Prevalence of liver steatosis and fibrosis and the diagnostic accuracy of ultrasound in bariatric surgery patients. 2012 , 22, 240-7	21
832	Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. 2012 , 57, 545-53	290
831	Prevalence of hypothyroidism in nonalcoholic fatty liver disease. 2012 , 57, 528-34	119
830	Contribution of hyperammonemia and inflammatory factors to cognitive impairment in minimal hepatic encephalopathy. 2012 , 27, 51-8	114
829	Effect of preoperative chemotherapy on postoperative liver regeneration following hepatic resection as estimated by liver volume. 2013 , 11, 65	15
828	The effects of chronic AMPK activation on hepatic triglyceride accumulation and glycerol 3-phosphate acyltransferase activity with high fat feeding. 2013 , 5, 29	38
827	Dietary modification dampens liver inflammation and fibrosis in obesity-related fatty liver disease. 2013 , 21, 1189-99	22
826	Cell-to-cell heterogeneity in lipid droplets suggests a mechanism to reduce lipotoxicity. 2013 , 23, 1489-96	114
825	A gene variant of PNPLA3, but not of APOC3, is associated with histological parameters of NAFLD in an obese population. 2013 , 21, 2138-45	47
824	Betaine protects against high-fat-diet-induced liver injury by inhibition of high-mobility group box 1 and Toll-like receptor 4 expression in rats. 2013 , 58, 3198-206	66
823	Inhibition of pancreatic lipase, αglucosidase, αmylase, and hypolipidemic effects of the total flavonoids from Nelumbo nucifera leaves. 2013 , 149, 263-9	92
822	Other Diffuse Liver Diseases: Steatosis, Hemochromatosis, etc.. 2013 , 1027-1044	2
821	Hair selenium levels in hepatic steatosis patients. 2013 , 152, 305-9	10
820	The influence of pioglitazone on the plasma amino acid profile in patients with nonalcoholic steatohepatitis (NASH). 2013 , 7, 577-85	13
819	Metabolic disruption in male mice due to fetal exposure to low but not high doses of bisphenol A (BPA): evidence for effects on body weight, food intake, adipocytes, leptin, adiponectin, insulin and glucose regulation. 2013 , 42, 256-68	197
818	Impaired mitochondrial βoxidation in patients with chronic hepatitis C: relation with viral load and insulin resistance. 2013 , 13, 112	9
817	Pediatric non alcoholic fatty liver disease: old and new concepts on development, progression, metabolic insight and potential treatment targets. 2013 , 13, 40	107

816	Multiparametric and semiquantitative scoring systems for the evaluation of mouse model histopathology--a systematic review. 2013 , 9, 123		128
815	Desmosterol in human nonalcoholic steatohepatitis. <i>Hepatology</i> , 2013 , 58, 976-82	11.2	34
814	Plasma visfatin levels and gene expression in morbidly obese women with associated fatty liver disease. 2013 , 46, 202-8		49
813	Prevalence of nonalcoholic steatohepatitis among patients with resectable intrahepatic cholangiocarcinoma. 2013 , 17, 748-55		30
812	Noninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLD. 2013 , 1, 7		60
811	Autoimmune features in metabolic liver disease: a single-center experience and review of the literature. 2013 , 45, 143-8		29
810	Current histological classification of NAFLD: strength and limitations. 2013 , 7 Suppl 2, 765-70		33
809	B cell-activating factor is associated with the histological severity of nonalcoholic fatty liver disease. 2013 , 7, 539-47		27
808	Impact of combined therapy with alpha-lipoic and ursodeoxycolic acid on nonalcoholic fatty liver disease: double-blind, randomized clinical trial of efficacy and safety. 2013 , 7, 570-6		17
807	The Fatty Liver Index has limited utility for the detection and quantification of hepatic steatosis in obese patients. 2013 , 7, 592-9		15
806	Hepatic angiogenesis and fibrosis are common features in morbidly obese patients. 2013 , 7, 233-40		21
805	In the non-cirrhotic stage of nonalcoholic steatohepatitis, angioarchitecture of portal veins and lobular architecture are maintained. 2013 , 462, 533-40		5
804	Genome-wide scan revealed that polymorphisms in the PNPLA3, SAMM50, and PARVB genes are associated with development and progression of nonalcoholic fatty liver disease in Japan. 2013 , 132, 783-92		138
803	Resistin expression correlates with steatohepatitis in morbidly obese patients. 2013 , 27, 1310-4		13
802	Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. <i>Hepatology</i> , 2013 , 58, 1941-52	11.2	279
801	Noninvasive scoring systems in patients with nonalcoholic fatty liver disease with normal alanine aminotransferase levels. 2013 , 48, 1051-60		29
800	Non-alcoholic fatty liver disease and insulin resistance: from bench to bedside. 2013 , 39, 16-26		76
799	DNA methylation analysis in nonalcoholic fatty liver disease suggests distinct disease-specific and remodeling signatures after bariatric surgery. 2013 , 18, 296-302		298

798	Diagnosis and management of non-alcoholic fatty liver disease and related metabolic disorders: consensus statement from the Study Group of Liver and Metabolism, Chinese Society of Endocrinology. 2013 , 5, 406-15		71
797	Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis. 2013 , 38, 134-43		125
796	Evaluation of liver fat in the presence of iron with MRI using T2* correction: a clinical approach. 2013 , 23, 1643-9		17
795	Effects of Eucopherol supplementation on liver of rats chronically exposed to ethanol. 2013 , 6, 125-36		2
794	Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. <i>Hepatology</i> , 2013 , 58, 1930-40	11.2	315
793	Association between novel MRI-estimated pancreatic fat and liver histology-determined steatosis and fibrosis in non-alcoholic fatty liver disease. 2013 , 37, 630-9		88
792	Hepatic notch signaling correlates with insulin resistance and nonalcoholic fatty liver disease. 2013 , 62, 4052-62		65
791	Tumor necrosis factor receptor 1 gain-of-function mutation aggravates nonalcoholic fatty liver disease but does not cause insulin resistance in a murine model. <i>Hepatology</i> , 2013 , 57, 566-76	11.2	35
790	Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals. 2013 , 1281, 106-22		183
789	Novel anti-diabetic agents in non-alcoholic fatty liver disease: a mini-review. 2013 , 12, 584-8		17
788	Non-alcoholic steatohepatitis: a non-invasive diagnosis by analysis of exhaled breath. 2013 , 58, 543-8		40
787	Fenofibrate, a peroxisome proliferator-activated receptor ligand, prevents abnormal liver function induced by a fasting-refeeding process. 2013 , 442, 22-7		12
786	Post-transcriptional activation of PPAR alpha by KLF6 in hepatic steatosis. 2013 , 58, 1000-6		41
785	Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. 2013 ,		
784	Serum Mac-2 binding protein levels as a novel diagnostic biomarker for prediction of disease severity and nonalcoholic steatohepatitis. 2013 , 7, 648-56		40
783	Serum cytokeratin-18 fragment levels are useful biomarkers for nonalcoholic steatohepatitis in children. 2013 , 108, 1526-31		83
782	Manganese superoxide dismutase is reduced in the liver of male but not female humans and rodents with non-alcoholic fatty liver disease. 2013 , 95, 330-5		25
781	Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. 2013 , 145, 782-9.e4		335

780	Pathologie h�patique Cirrhose et carcinome h�patocellulaire : indications et r�les de la biopsie h�patique. 2013 , 2013, 39-48		
779	Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients. <i>Hepatology</i> , 2013 , 58, 1644-54	11.2	109
778	[Alcoholic and non-alcoholic steatohepatitis: who is affected and what can we do for them?]. 2013 , 36, 587-96		2
777	Prognostic implication of liver histology in patients with nonalcoholic fatty liver disease in diabetes. 2013 , 27, 293-300		39
776	Adipose tissue and liver expression of SIRT1, 3, and 6 increase after extensive weight loss in morbid obesity. 2013 , 59, 1315-22		78
775	Genetic signatures in choline and 1-carbon metabolism are associated with the severity of hepatic steatosis. 2013 , 27, 1674-89		32
774	Value of acoustic radiation force impulse imaging elastography for non-invasive evaluation of patients with nonalcoholic fatty liver disease. 2013 , 39, 1942-50		69
773	Quercetin decreases liver damage in mice with non-alcoholic steatohepatitis. 2013 , 112, 385-91		39
772	A new approach to facilitate diagnosis of nonalcoholic fatty liver disease through a galactose single point method in rats with fatty liver. 2013 , 45, 134-41		3
771	Blockade of B-cell-activating factor signaling enhances hepatic steatosis induced by a high-fat diet and improves insulin sensitivity. 2013 , 93, 311-21		21
770	Severity of non-alcoholic steatohepatitis is associated with substitution of adipose tissue in skeletal muscle. 2013 , 28, 1507-14		75
769	Excess iron modulates endoplasmic reticulum stress-associated pathways in a mouse model of alcohol and high-fat diet-induced liver injury. 2013 , 93, 1295-312		69
768	Osteopontin delays resolution of liver fibrosis. 2013 , 93, 1082-9		36
767	Reversal of hypertriglyceridemia, fatty liver disease, and insulin resistance by a liver-targeted mitochondrial uncoupler. 2013 , 18, 740-8		155
766	Transcriptomic and epigenetic changes in early liver steatosis associated to obesity: effect of dietary methyl donor supplementation. 2013 , 110, 388-95		86
765	A 360-degree overview of paediatric NAFLD: recent insights. 2013 , 58, 1218-29		120
764	Hibiscus sabdariffa L. aqueous extract attenuates hepatic steatosis through down-regulation of PPAR-� and SREBP-1c in diet-induced obese mice. 2013 , 4, 618-26		35
763	Hedgehog pathway and pediatric nonalcoholic fatty liver disease. <i>Hepatology</i> , 2013 , 57, 1814-25	11.2	46

762	Die nichtalkoholische Steatohepatitis als viszerale Manifestation des metabolischen Syndroms. 2013 , 8, 517-524		
761	Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab. 2013 , 108, 2549-56		45
760	Persistent fibrosis in the liver of choline-deficient and iron-supplemented L-amino acid-defined diet-induced nonalcoholic steatohepatitis rat due to continuing oxidative stress after choline supplementation. 2013 , 268, 264-77		30
759	Intraoperative liver ultrasound still affects surgical strategy for patients with colorectal metastases in the modern era. 2013 , 37, 2655-63		27
758	Utility of controlled attenuation parameter measurement for assessing liver steatosis in Japanese patients with chronic liver diseases. 2013 , 43, 1182-9		41
757	Nonalcoholic fatty liver disease and the metabolic syndrome: clinical implications and treatment. 2013 , 28, 40-51		46
756	Enhanced tumor growth after portal vein embolization in a rabbit tumor model. 2013 , 180, 89-96		28
755	Kinetic growth rate after portal vein embolization predicts posthepatectomy outcomes: toward zero liver-related mortality in patients with colorectal liver metastases and small future liver remnant. 2013 , 216, 201-9		190
754	Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. <i>Hepatology</i> , 2013 , 57, 601-9	11.2	904
753	PREP1 deficiency downregulates hepatic lipogenesis and attenuates steatohepatitis in mice. 2013 , 56, 2713-22		21
752	[Non-alcoholic fatty liver disease in obese children and adolescents]. 2013 , 56, 517-27		4
751	<i>Clostridium butyricum</i> MIYAIRI 588 improves high-fat diet-induced non-alcoholic fatty liver disease in rats. 2013 , 58, 3534-44		42
750	Sunitinib treatment enabling resection of massive liver metastasis: a case report. 2013 , 7, 234		0
749	Maternal hypoxia increases the susceptibility of adult rat male offspring to high-fat diet-induced nonalcoholic fatty liver disease. 2013 , 154, 4377-87		10
748	Markers in nonalcoholic steatohepatitis. 2013 , 61, 67-125		12
747	Fisetin, a tetra hydroxy flavone recuperates antioxidant status and protects hepatocellular ultrastructure from hyperglycemia mediated oxidative stress in streptozotocin induced experimental diabetes in rats. 2013 , 59, 249-55		47
746	Endogenous fructose production and metabolism in the liver contributes to the development of metabolic syndrome. 2013 , 4, 2434		132
745	Molecular mechanisms and the role of saturated fatty acids in the progression of non-alcoholic fatty liver disease. 2013 , 52, 165-74		264

744	Chemotherapy induced hepatotoxicity in metastatic colorectal cancer: a review of mechanisms and outcomes. 2013 , 88, 404-15		36
743	Association between liver-specific gene polymorphisms and their expression levels with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2013 , 57, 590-600	11.2	61
742	The role of Kupffer cells in the morphogenesis of nonalcoholic steatohepatitis - ultrastructural findings. The first report in pediatric patients. 2013 , 48, 352-7		22
741	The effects of caloric restriction on fetuin-A and cardiovascular risk factors in rats and humans: a randomized controlled trial. 2013 , 79, 356-63		43
740	Heterogeneity of fibrosis patterns in non-alcoholic fatty liver disease supports the presence of multiple fibrogenic pathways. 2013 , 33, 624-32		40
739	Inhibition of Glutamyl Cyclases alleviates CCL2-mediated inflammation of non-alcoholic fatty liver disease in mice. 2013 , 94, 217-25		21
738	Human and experimental evidence supporting a role for osteopontin in alcoholic hepatitis. <i>Hepatology</i> , 2013 , 58, 1742-56	11.2	73
737	Controlled attenuation parameter for non-invasive assessment of hepatic steatosis: does etiology affect performance?. 2013 , 28, 1194-201		75
736	Garlic-derived S-allylmercaptocysteine is a hepato-protective agent in non-alcoholic fatty liver disease in vivo animal model. 2013 , 52, 179-91		78
735	A novel noninvasive index for nonalcoholic steatohepatitis: a pilot study. 2013 , 18, 607-13		14
734	Liver, but not adipose tissue PEDF gene expression is associated with insulin resistance. 2013 , 37, 1230-7		21
733	Liver stiffness measurements in patients with different stages of nonalcoholic fatty liver disease: diagnostic performance and clinicopathological correlation. 2013 , 58, 265-74		64
732	Probucol ameliorates the development of nonalcoholic steatohepatitis in rats fed high-fat diets. 2013 , 58, 163-71		10
731	GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice. 2013 , 154, 127-39		234
730	Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: a single institution experience. 2013 , 216, 41-9		64
729	Sestrins activate Nrf2 by promoting p62-dependent autophagic degradation of Keap1 and prevent oxidative liver damage. 2013 , 17, 73-84		334
728	Transcriptome analysis identifies TNF superfamily receptors as potential therapeutic targets in alcoholic hepatitis. 2013 , 62, 452-60		119
727	Magnetic resonance imaging flowmetry demonstrates portal vein dilatation subsequent to oxaliplatin therapy in patients with colorectal liver metastasis. 2013 , 15, 265-72		1

726	Adiponectin negatively correlates with alcoholic and non-alcoholic liver dysfunction: Health check-up study of Japanese men. 2013 , 43, 238-48		9
725	Pitavastatin ameliorated the progression of steatohepatitis in ovariectomized mice fed a high fat and high cholesterol diet. 2013 , 43, 401-12		9
724	Increased insulin receptor substrate 2 expression is associated with steatohepatitis and altered lipid metabolism in obese subjects. 2013 , 37, 986-92		33
723	Epigenetic modification of liver mitochondrial DNA is associated with histological severity of nonalcoholic fatty liver disease. 2013 , 62, 1356-63		235
722	Separation of advanced from mild hepatic fibrosis by quantification of the hepatobiliary uptake of Gd-EOB-DTPA. 2013 , 23, 174-81		57
721	Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis. <i>Hepatology</i> , 2013 , 57, 81-92	11.2	169
720	Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2013 , 57, 103-11	11.2	81
719	Treatment of non-alcoholic steatohepatitis with <i>Phyllanthus urinaria</i> : a randomized trial. 2013 , 28, 57-62		19
718	Liver protective effects of aqueous extract of <i>Syzygium cumini</i> in Swiss albino mice on alloxan induced diabetes mellitus. 2013 , 6, 853-858		8
717	Accuracy of international guidelines for identifying significant fibrosis in hepatitis B e antigen-negative patients with chronic hepatitis. 2013 , 11, 1493-1499.e2		17
716	Elastography and Contrast-enhanced Ultrasonography in the Early Detection of Hepatocellular Carcinoma in an Experimental Model of Nonalcoholic Steatohepatitis. 2013 , 3, 96-101		6
715	<i>Antrodia camphorata</i> ameliorates high-fat-diet induced hepatic steatosis via improving lipid metabolism and antioxidative status. 2013 , 5, 1317-1325		15
714	Pharmacological inhibition of adipocyte fatty acid binding protein alleviates both acute liver injury and non-alcoholic steatohepatitis in mice. 2013 , 58, 358-64		46
713	Stage of change and motivation to healthier lifestyle in non-alcoholic fatty liver disease. 2013 , 58, 771-7		52
712	The role of hepassocin in the development of non-alcoholic fatty liver disease. 2013 , 59, 1065-72		43
711	Nonalcoholic Steatohepatitis: Diagnostic Challenges. 2013 , 6, 227-57		2
710	Metabolic effects of sleeve gastrectomy in female rat model of diet-induced obesity. 2013 , 9, 108-12		9
709	Presence and extent of estrogen receptor-alpha expression in patients with simple steatosis and NASH. 2013 , 209, 429-32		13

708	Diet-induced mouse model of fatty liver disease and nonalcoholic steatohepatitis reflecting clinical disease progression and methods of assessment. 2013 , 305, G483-95	153
707	Plasma fetuin-A is associated with endothelial dysfunction and subclinical atherosclerosis in subjects with nonalcoholic fatty liver disease. 2013 , 78, 712-7	59
706	The liver diseases of lipodystrophy: the long-term effect of leptin treatment. 2013 , 59, 131-7	118
705	A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. 2013 , 59, 550-6	326
704	Decreased hepatotoxic bile acid composition and altered synthesis in progressive human nonalcoholic fatty liver disease. 2013 , 268, 132-40	110
703	Bibliometrics of the top 100 clinical articles in digestive disease. 2013 , 144, 673-676.e5	22
702	Non-alcoholic fatty liver disease. 2013 , 23, 529-534	3
701	Vitamin D Status Presents Different Relationships with Severity in Metabolic-Associated Fatty Liver Disease Patients with or without Hepatitis B Infection. 2022 , 14, 2114	0
700	Hepatic steatosis leads to overestimation of liver stiffness measurement in both chronic hepatitis B and metabolic-associated fatty liver disease patients. 2022 , 101957	0
699	Liver PP2A-C β protects from parenteral nutrition-associated hepatic steatosis. 2022 ,	0
698	Kinin B1 receptor deficiency protects mice fed by cafeteria diet from abnormal glucose homeostasis. 2022 , 17, e0267845	
697	Incidental hepatic tissue detected at cholecystectomy is potentially clinically significant. 2022 , 28, 300651	
696	Corydalis saxicola Bunting Total Alkaloids ameliorate diet-induced non-alcoholic steatohepatitis by regulating hepatic PI3K/Akt and TLR4/NF- κ B pathways in mice. 2022 , 151, 113132	0
695	Exposure to glyphosate-based herbicide during early stages of development increases insulin sensitivity and causes liver inflammation in adult mice offspring. 2022 , 20,	
694	The improvement of nonalcoholic steatohepatitis by Poria cocos polysaccharides associated with gut microbiota and NF- κ B/CCL3/CCR1 axis. 2022 , 154208	0
693	Comparison of point-shear wave elastography (ElastPQ) and FibroScan for liver fibrosis staging in patients with NAFLD.	1
692	Danhe granule ameliorates nonalcoholic steatohepatitis and fibrosis in rats by inhibiting ceramide de novo synthesis related to CerS6 and CerK. 2022 , 115427	0
691	Vitamin E for people with non-alcoholic fatty liver disease. 2022 , 2022,	

- 690 A new preclinical model of western diet-induced progression of non-alcoholic steatohepatitis to hepatocellular carcinoma. **2022**, 36, 0
- 689 Interaction effect between NAFLD severity and high carbohydrate diet on gut microbiome alteration and hepatic de novo lipogenesis. **2022**, 14, 2
- 688 Triglyceride and Glucose Index as a Screening Tool for Nonalcoholic Liver Disease in Patients with Metabolic Syndrome. **2022**, 11, 3043 0
- 687 Applications of Quantitative Systems Pharmacology (QSP) in Drug Development for NAFLD and NASH and Its Regulatory Application. 0
- 686 The Role of Thiazolidinediones in the Amelioration of Nonalcoholic Fatty Liver Disease: A Systematic Review. **2022**,
- 685 Inulin may prevent steatosis by suppressing Cannabinoid receptor-1 and Patatin-like phospholipase-3 expression in liver. **2022**, 111742
- 684 Nonalcoholic Steatohepatitis (NASH) and Atherosclerosis: Explaining Their Pathophysiology, Association and the Role of Incretin-Based Drugs. **2022**, 11, 1060
- 683 Metabolic Stress Index Including Mitochondrial Biomarker for Noninvasive Diagnosis of Hepatic Steatosis. **2022**, 13,
- 682 Influence of NAFLD and bariatric surgery on hepatic and adipose tissue mitochondrial biogenesis and respiration. **2022**, 13, 0
- 681 Mega-Dose Vitamin C Ameliorates Nonalcoholic Fatty Liver Disease in a Mouse Fast-Food Diet Model. **2022**, 14, 2195 0
- 680 Differential Effects of Dietary versus Exercise Intervention on Intrahepatic MAIT Cells and Histological Features of NAFLD. **2022**, 14, 2198 0
- 679 A diet-induced murine model for non-alcoholic fatty liver disease with obesity and insulin resistance that rapidly develops steatohepatitis and fibrosis. 0
- 678 Noninvasive Diagnostic Methods for the Assessment of Hepatic Fibrosis in Liver Transplant Recipients. **2022**,
- 677 Non-invasive diagnosis and staging of non-alcoholic fatty liver disease. 0
- 676 Noninvasive proteomic biomarkers for alcohol-related liver disease. 5
- 675 Plant sterol ester of Linolenic acid improved non-alcoholic fatty liver disease by attenuating endoplasmic reticulum stress-triggered apoptosis via activation of the AMPK. **2022**, 109072 1
- 674 Vildagliptin alleviates liver fibrosis in NASH diabetic rats via modulation of insulin resistance, oxidative stress, and inflammatory cascades. **2022**, 120695 1
- 673 Longitudinal 16S rRNA Sequencing Reveals Relationships among Alterations of Gut Microbiota and Nonalcoholic Fatty Liver Disease Progression in Mice. 1

- 672 Human Mesenchymal Stromal Cells Resolve Lipid Load in High Fat Diet-Induced Non-Alcoholic Steatohepatitis in Mice by Mitochondria Donation. **2022**, 11, 1829
- 671 GW9662, a peroxisome proliferator-activated receptor gamma antagonist, attenuates the development of non-alcoholic fatty liver disease. **2022**, 133, 155233 1
- 670 Granulomas and Granulomatous Disease. **2022**, 113-147
- 669 Ultrasound diagnosis of fatty liver disease. **2022**,
- 668 Histopathological Evaluation of Steatohepatitis in Animal Experiments. **2022**, 53-72
- 667 Fatty Liver Disease. **2022**, 265-298
- 666 The Effects of High Fat Diet on the Liver of the White Rat Model Obesity. **2022**, 10, 709-714
- 665 Lower serum copper concentrations are associated with higher prevalence of nonalcoholic steatohepatitis: a matched case-control study. Publish Ahead of Print, 0
- 664 Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease. **2022**, 14, 2
- 663 Dectin-1 plays a deleterious role in high fat diet-induced NAFLD of mice through enhancing macrophage activation. 0
- 662 Histologic Severity of Nonalcoholic Fatty Liver Disease Associates with Reduced Bone Mineral Density in Children.
- 661 Circulating TREM2 as a non-invasive diagnostic biomarker for NASH in patients with elevated liver stiffness. *Hepatology*, 11.2 1
- 660 Dynamic changes in hepatic DNA methylation during the development of nonalcoholic fatty liver disease induced by a high-sugar diet.
- 659 The presence of interferon affects the progression of non-alcoholic fatty liver disease. 0
- 658 Incidence of Type 2 Diabetes in Children with Nonalcoholic Fatty Liver Disease. **2022**, 0
- 657 Hepatocyte PPAR α contributes to the progression of non-alcoholic steatohepatitis in male and female obese mice.
- 656 Label-free metabolic imaging of non-alcoholic-fatty-liver-disease (NAFLD) liver by volumetric dynamic optical coherence tomography. 1
- 655 Expression of IGF-1 receptor and GH receptor in hepatic tissue of patients with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. **2022**, 101482 2

- 654 Assessment of Noninvasive Markers of Steatosis and Liver Fibrosis in HIV-monoinfected Patients on Stable Antiretroviral Regimens. 1
- 653 Characterization of Buriti (*Mauritia flexuosa*) Pulp Oil and the Effect of Its Supplementation in an In Vivo Experimental Model. **2022**, 14, 2547
- 652 17 β -estradiol, a lifespan-extending compound, attenuates liver fibrosis by modulating collagen turnover rates in male mice. 0
- 651 Chronic intermittent hypoxia contributes to non-alcoholic steatohepatitis progression in patients with obesity. 0
- 650 Multi-Omics Integration Analysis Identifies Lipid Disorder of a Non-Alcoholic Fatty Liver Disease (NAFLD) Mouse Model Improved by ZexieBaizhu Decoction. 13, 0
- 649 Two-dimensional Shear-Wave Elastography and US Attenuation Imaging for Nonalcoholic Steatohepatitis Diagnosis: A Cross-sectional, Multicenter Study. 0
- 648 Beneficial effects of monounsaturated fatty acid-rich blended oils with an appropriate polyunsaturated/saturated fatty acid ratio and a low n-6/n-3 fatty acid ratio on the health of rats. 0
- 647 Accurate and generalizable quantitative scoring of liver steatosis from ultrasound images via scalable deep learning. **2022**, 28, 2494-2508 2
- 646 Higher Levels of Plasma Hyaluronic Acid and N-terminal Propeptide of Type III Procollagen Are Associated With Lower Kidney Function in Children With Non-alcoholic Fatty Liver Disease. 10, 0
- 645 Celecoxib attenuates hepatosteatosis by impairing de novo lipogenesis via Akt-dependent lipogenic pathway. 0
- 644 Combinational elastography for assessment of liver fibrosis in patients with liver injury. **2022**, 50, 030006052211001
- 643 Ferroptosis resistance cooperates with cellular senescence in the overt stage of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. **2022**, 66, 1
- 642 Prevalence and predictors of non-alcoholic steatohepatitis in subjects with morbid obesity and with or without type 2 diabetes. **2022**, 101363 1
- 641 Artificial intelligence improves pathologist agreement for fibrosis scores in non-alcoholic steatohepatitis patients. **2022**, 0
- 640 Lowering n-6/n-3 Ratio as an Important Dietary Intervention to Prevent LPS-Inducible Dyslipidemia and Hepatic Abnormalities in ob/ob Mice. **2022**, 23, 6384 2
- 639 Dysregulation of Lipid and Glucose Homeostasis in Hepatocyte-Specific SLC25A34 Knockout Mice. **2022**, 0
- 638 Evaluation of nonalcoholic fatty liver disease (NAFLD) in severe obesity using noninvasive tests and imaging techniques. 0
- 637 Multi-Omics Reveals Inhibitory Effect of Baicalein on Non-Alcoholic Fatty Liver Disease in Mice. 13, 0

636	Obesidad, hábitos de vida y valoración FLI en la población laboral española durante la pandemia. 93-98	
635	Prevalence estimation of significant fibrosis because of NASH in Spain combining transient elastography and histology.	0
634	Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis. 2022 , 23, 6696	1
633	Crohn's Disease Is Associated with Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease.	0
632	The Benefit of Bariatric Surgery on Histological Features of Metabolic Associated Fatty Liver Disease Assessed Through Noninvasive Methods.	0
631	Ptpn1 deletion protects oval cells against lipoapoptosis by favoring lipid droplet formation and dynamics.	0
630	Current therapies and new developments in NASH. gutjnl-2021-326874	6
629	Follow-up evaluation of patients with liver test abnormalities detected during SARS-CoV2 infection.	0
628	The Effects of Whole-Body Vibration Exercise Combined With an Isocaloric High-Fructose Diet on Osteoporosis and Immunomodulation in Ovariectomized Mice. 9,	
627	Arterial Calcifications in Patients with Liver Cirrhosis Are Linked to Hepatic Deficiency of Pyrophosphate Production Restored by Liver Transplantation. 2022 , 10, 1496	
626	Non-Alcoholic Fatty Liver Disease and Extrahepatic Cancers: A Wolf in Sheep's Clothing?. 2022 , 29, 4478-4510	0
625	NAFLD: Mechanisms, Treatments, and Biomarkers. 2022 , 12, 824	3
624	Compensated Advanced Chronic Liver Disease in Nonalcoholic Fatty Liver Disease: Two-Step Strategy is Better than Baveno Criteria.	0
623	Inhibition of ATP-citrate lyase improves NASH, liver fibrosis, and dyslipidemia. 2022 , 34, 919-936.e8	2
622	Alisol B Alleviates Hepatocyte Lipid Accumulation and Lipotoxicity via Regulating RAR α /PPAR γ /CD36 Cascade and Attenuates Non-Alcoholic Steatohepatitis in Mice. 2022 , 14, 2411	1
621	Whey protein hydrolysate alleviated atherosclerosis and hepatic steatosis by regulating lipid metabolism in apoE $^{-/-}$ mice fed a Western diet. 2022 , 157, 111419	1
620	Deep Learning-Based Automated Assessment of Hepatic Fibrosis on Magnetic Resonance Images and Non-Image Data.	
619	Histopathological findings of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. 2022 ,	

- 618 Detecting Early-Stage Liver Fibrosis Using Macromolecular Proton Fraction Mapping Based on Spin-Lock MRI : Preliminary Observations. 0
- 617 Assessing liver fibrosis distribution through liver elasticity estimates obtained using a biomechanical model of respiratory motion with magnetic resonance elastography. 1
- 616 The practical utility of non-invasive indices in metabolic hepatic steatosis. **2022**, 69, 418-425
- 615 Hepatoprotective effects of Aureobasidium pullulans derived β -1,3-1,6 glucans in a murine model of non-alcoholic steatohepatitis. **2022**, 1
- 614 Genetic Factors Associated with Response to Vitamin E Treatment in NAFLD. **2022**, 11, 1284 1
- 613 OBSTRUCTIVE SLEEP APNEA SYNDROME RISK IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE IS ASSOCIATED WITH OBESITY AND PRESENCE OF NASH. **2022**, 59, 251-256
- 612 Roux-en-Y gastric bypass with a long compared to a short biliopancreatic limb improves weight loss and glycemic control in obese mice. **2022**,
- 611 The liver-gut peripheral neural axis and nonalcoholic fatty liver disease pathologies via hepatic serotonin receptor 2A. 0
- 610 Loxin Reduced the Inflammatory Response in the Liver and the Aortic Fatty Streak Formation in Mice Fed with a High-Fat Diet. **2022**, 23, 7329
- 609 Transforming growth factor-beta 1: A new factor reducing hepatic SHBG production in liver fibrosis.
- 608 Histological Analysis of Hepatic Steatosis, Inflammation, and Fibrosis in Ascorbic Acid-Treated Ovariectomized Mice. **2022**, 28, 101-108 0
- 607 A case report of multinodular hepatic steatosis mimicking pseudotumors of the liver. **2022**, 26,
- 606 Developing a New qFIBS Model Assessing Histological Features in Pediatric Patients With Non-alcoholic Steatohepatitis. 9,
- 605 Replication stress triggered by nucleotide pool imbalance drives DNA damage and cGAS-STING pathway activation in NAFLD. **2022**, 1
- 604 Digital pathology with artificial intelligence analyses provides greater insights into treatment-induced fibrosis regression in NASH. **2022**, 2
- 603 β -Carotene from the Alga Dunaliella bardawil Decreases Gene Expression of Adipose Tissue Macrophage Recruitment Markers and Plasma Lipid Concentrations in Mice Fed a High-Fat Diet. **2022**, 20, 433 0
- 602 Enterohepatic Takeda G-Protein Coupled Receptor 5 Agonism in Metabolic Dysfunction-Associated Fatty Liver Disease and Related Glucose Dysmetabolism. **2022**, 14, 2707 2
- 601 RNA adenosine deaminase (ADAR1) alleviates high-fat diet-induced nonalcoholic fatty liver disease by inhibiting NLRP3 inflammasome. 0

600	Autoimmune Antibodies in Children and Adolescents with Nonalcoholic Fatty Liver Disease. Publish Ahead of Print,	0
599	Amelioration of Non-Alcoholic Steatohepatitis by Atractylodes macrocephala Polysaccharide, Chlorogenic Acid, and Geniposide Combination Is Associated With Reducing Endotoxin Gut Leakage. 12,	0
598	Diagnosing Pediatric NAFLD. 2022 , 1, 13-20	
597	Targeting Acid Ceramidase Ameliorates Fibrosis in Mouse Models of Nonalcoholic Steatohepatitis.	
596	Spirulina compounds show hypoglycemic activity and intestinal flora regulation in type 2 diabetes mellitus mice. 2022 , 66, 102791	0
595	Suppression of nitric oxide synthase aggravates non-alcoholic steatohepatitis and atherosclerosis in SHRSP5/Dmcr rat via acceleration of abnormal lipid metabolism.	0
594	The effect of aerobic exercise on metabolic parameters of patients with non-alcoholic fatty liver disease: systematic review and meta-analysis.	0
593	Plasma Metabolomics and Machine Learning-Driven Novel Diagnostic Signature for Non-Alcoholic Steatohepatitis. 2022 , 10, 1669	2
592	Interobserver Variability in Ultrasound-Based Liver Fat Quantification.	0
591	Early life stress exposure increases susceptibility to high fat/high sucrose diet in female mice.	
590	Current treatment of non-alcoholic fatty liver disease.	0
589	The Pathogenesis of HCC Driven by NASH and the Preventive and Therapeutic Effects of Natural Products. 13,	1
588	Differential Expression Profiles of mRNA and Noncoding RNA and Analysis of Competitive Endogenous RNA Regulatory Networks in Nonalcoholic Steatohepatitis. 2022 , 2022, 1-13	0
587	Impact of donor age on recipient morbidity and mortality after living donor liver transplantation.	
586	The GH/IGF-1 axis is associated with intrahepatic lipid content and hepatocellular damage in overweight/obesity.	3
585	AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review. 2022 ,	6
584	Low skeletal muscle mass is associated with more severe histological features of non-alcoholic fatty liver disease in male.	2
583	HSPA8 Single-Nucleotide Polymorphism Is Associated with Serum HSC70 Concentration and Carotid Artery Atherosclerosis in Nonalcoholic Fatty Liver Disease. 2022 , 13, 1265	0

- 582 Laparoscopic Sleeve Gastrectomy in Patients with Severe Obesity Restores Adaptive Responses Leading to Nonalcoholic Steatohepatitis. **2022**, 23, 7830 ○
- 581 Validation of the new 2021 EASL algorithm for the non-invasive diagnosis of advanced fibrosis in NAFLD. *Hepatology*, 11.2 1
- 580 Krüppel-like factor 10 (KLF10) as a critical signaling mediator: Versatile functions in physiological and pathophysiological processes. **2022**,
- 579 Lipocalin-2 Deficiency Reduces Hepatic and Hippocampal Triggering Receptor Expressed on Myeloid Cells-2 Expressions in High-Fat Diet/Streptozotocin-Induced Diabetic Mice. **2022**, 12, 878 ○
- 578 Berberrubine, a Main Metabolite of Berberine, Alleviates Non-Alcoholic Fatty Liver Disease via Modulating Glucose and Lipid Metabolism and Restoring Gut Microbiota. 13, ○
- 577 Identification of novel targets in adipose tissue involved in non-alcoholic fatty liver disease progression. **2022**, 36, ○
- 576 AGILE 3+ Score for the diagnosis of advanced fibrosis and for predicting liver-related events in NAFLD. **2022**, 1 ○
- 575 Glucosylated nanoparticles for the oral delivery of antibiotics to the proximal small intestine protect mice from gut dysbiosis. **2022**, 6, 867-881 1
- 574 RPA1 controls chromatin architecture and maintains lipid metabolic homeostasis. **2022**, 40, 111071
- 573 Microbial and Transcriptomic Profiling Reveals Diet-Related Alterations of Metabolism in Metabolic Disordered Mice. 9,
- 572 Machine Learning Models Are Superior to Non-Invasive Tests in Identifying Clinically Significant Stages of NAFLD and NAFLD-Related Cirrhosis. *Hepatology*, 11.2 ○
- 571 Hepatic patatin-like phospholipase domain-containing 3 levels are increased in I148M risk allele carriers and correlate with NAFLD in humans. ○
- 570 The impact of body mass index on clinicopathological features of nonalcoholic fatty liver disease in Taiwan. ○
- 569 Effectiveness and Tolerability of a Two-Week Hypocaloric Protein-Rich Diet Prior to Obesity Surgery with Two Different Diet Interventions: a Prospective Randomized Trial. 1
- 568 IGF1 regulates the development of nonalcoholic fatty liver disease through the attenuation of hepatic steatosis in mice. **2022**, 12, 2
- 567 Accurate liquid biopsy for the diagnosis of non-alcoholic steatohepatitis and liver fibrosis. [gutjnl-2022-327498](https://doi.org/10.1093/gutjnl/2022-327498) ○
- 566 Banting Memorial lecture 2022: Type 2 diabetes and nonalcoholic fatty liver disease: partners in crime ○
- 565 Safety and efficacy of dyslipidemia treatment in NAFLD Patients: a Meta-analysis of randomized controlled trials. **2022**, 100738 1

564	Sensitivity to thyroid hormones is associated with advanced fibrosis in euthyroid patients with non-alcoholic fatty liver disease: A cross-sectional study. 2022,	0
563	Loss of immunity-related GTPase GM4951 leads to nonalcoholic fatty liver disease without obesity. 2022, 13,	0
562	Hydroxynonenal Causes Hepatocyte Death by Disrupting Lysosomal Integrity in Nonalcoholic Steatohepatitis. 2022,	1
561	Potential Effect of Enzymatic Porcine Placental Hydrolysate (EPPH) to Improve Alcoholic Liver Disease (ALD) by Promoting Lipolysis in the Liver. 2022, 11, 1012	
560	Serum amyloid P component and pro-platelet basic protein in extracellular vesicles or serum are novel markers of liver fibrosis in chronic hepatitis C patients. 2022, 17, e0271020	0
559	New Insights of OLFM2 and OLFM4 in Gut-Liver Axis and Their Potential Involvement in Nonalcoholic Fatty Liver Disease. 2022, 23, 7442	1
558	Consumption of Grapes Modulates Gene Expression, Reduces Non-Alcoholic Fatty Liver Disease, and Extends Longevity in Female C57BL/6J Mice Provided with a High-Fat Western-Pattern Diet. 2022, 11, 1984	1
557	Prebiotic-like cyclodextrin assisted silybin on NAFLD through restoring liver and gut homeostasis. 2022, 348, 825-840	0
556	Virtual liver needle biopsy from reconstructed three-dimensional histopathological images: Quantification of sampling error. 2022, 147, 105764	1
555	Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis. 2022, 51, 101547	2
554	Oyster protein hydrolysates alleviated chronic alcohol-induced liver injury in mice by regulating hepatic lipid metabolism and inflammation response. 2022, 160, 111647	1
553	Macrophage-specific MyD88 deletion and pharmacological inhibition prevents liver damage in non-alcoholic fatty liver disease via reducing inflammatory response. 2022, 1868, 166480	0
552	The role of gut microflora dysbiosis in clinical manifestation of patients with non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.. 2022, 10, 658-667	
551	Transcriptome changes in stages of non-alcoholic fatty liver disease. 2022, 14, 1382-1397	2
550	Germline Mutations in CIDEB and Protection against Liver Disease. 2022, 387, 332-344	1
549	Gynostemma pentaphyllum polysaccharides ameliorate non-alcoholic steatohepatitis in mice associated with gut microbiota and the TLR2/NLRP3 pathway. 13,	1
548	Unraveling the Transcriptional Dynamics of NASH Pathogenesis Affecting Atherosclerosis. 2022, 23, 8229	
547	Macronutrient and Micronutrient Intake in Adolescents with Non-Alcoholic Fatty Liver Disease: the Association with Disease Severity. Publish Ahead of Print,	

- 546 Are isothiocyanates and polyphenols from Brassicaceae vegetables emerging as preventive/therapeutic strategies for NAFLD? The landscape of recent preclinical findings. **2022**, 13, 8348-8362 1
- 545 Advances in ultrasound elastography for nonalcoholic fatty liver disease. **2022**,
- 544 Zingerone as a Substitute to Zinc Bacitracin: Effects on Oxidative Stress, Systemic Antioxidant Status, Liver Fat Content, Function and Histomorphometry of Cobb500 Broiler Chicken.
- 543 Effect of MTTP -493G/T, I128T, Q95H and Q244E polymorphisms on hepatic steatosis in patients with chronic hepatitis. **2022**, 77, 100094
- 542 Non-Invasive Detection of Fibrotic NASH in NAFLD Patients with Low or Intermediate FIB-4. **2022**, 11, 4394 0
- 541 A maternal high-fat diet induces fetal origins of NASH-HCC in mice. **2022**, 12,
- 540 Fatty Liver Diagnosis Using Deep Learning in Ultrasound Image. **2022**,
- 539 Comparison of Tofogliflozin and Glimepiride Effects on Nonalcoholic Fatty Liver Disease in Participants With Type 2 Diabetes: A Randomized, 48-Week, Open-Label, Active-Controlled Trial. 0
- 538 Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease. 1
- 537 Reduction in gut-derived MUFAs via intestinal stearoyl-CoA desaturase 1 deletion drives susceptibility to NAFLD and hepatocarcinoma. 0
- 536 Best Practices in Liver Biopsy Histologic Assessment for Nonalcoholic Steatohepatitis Clinical Trials: Expert Opinion. **2022**, 2022, 1-11
- 535 Secreted folate receptor-gamma drives fibrogenesis in nonalcoholic steatohepatitis by amplifying TGF β signaling in hepatic stellate cells.
- 534 Liver Cancer-Specific Isoform of Serine Protease Inhibitor Kazal for the Detection of Hepatocellular Carcinoma: Results from a Pilot Study in Patients with Dysmetabolic Liver Disease. **2022**, 29, 5457-5465
- 533 The genetic interactions between non-alcoholic fatty liver disease and cardiovascular diseases. 13, 2
- 532 Prevalence and Significance of Antinuclear Antibodies in Biopsy-Proven Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. **2022**, 2022, 1-12 0
- 531 MicroRNAs in non-alcoholic fatty liver disease: progress and perspectives. **2022**, 101581 0
- 530 HBV Reactivation After Bariatric Surgery for HBV-Infected Obese Patients.
- 529 Beneficial effects of UDCA and norUDCA in a rodent model of steatosis are linked to modulation of GPBAR1/FXR signaling. **2022**, 159218 0

- 528 Clinicopathologic features of de novo non-alcoholic steatohepatitis in the post-transplant setting. **2022**, 17, 0
- 527 Magnetic resonance imaging improves stratification of fibrosis and steatosis in patients with chronic liver disease. 0
- 526 Comparison of long-term prognosis between non-obese and obese patients with non-alcoholic fatty liver disease. 0
- 525 Association between serum ferritin level and the various stages of non-alcoholic fatty liver disease: A systematic review. 9, 0
- 524 US Shear-Wave Elastography Dispersion for Characterization of Chronic Liver Disease. 1
- 523 Statins Efficacy in non-alcoholic fatty liver disease: A systematic review and meta-analysis. **2022**, 0
- 522 Dietary omega-6/omega-3 ratio is not associated with gut microbiota composition and disease severity in patients with non-alcoholic fatty liver disease. **2022**, 1
- 521 Acetyl-CoA Deficiency Is Involved in the Regulation of Iron Overload on Lipid Metabolism in Apolipoprotein E Knockout Mice. **2022**, 27, 4966 0
- 520 Metabolic Injury of Hepatocytes Promotes Progression of NAFLD and AALD. **2022**, 42, 233-249 1
- 519 Gypenosides ameliorate high-fat diet-induced non-alcoholic steatohepatitis via farnesoid X receptor activation. 9, 1
- 518 Adipose tissue dysfunction and visceral fat are associated with hepatic insulin resistance and severity of NASH even in lean individuals. 0
- 517 Quantitative Prediction of Steatosis in Patients with Non-Alcoholic Fatty Liver by Means of Hepatic MicroRNAs Present in Serum and Correlating with Hepatic Fat. **2022**, 23, 9298 0
- 516 Head to head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD. **2022**, 1
- 515 A comparative study on roles of natural killer T cells in two diet-induced non-alcoholic steatohepatitis-related fibrosis in mice. **2022**, 54, 2233-2245 0
- 514 Mouse model of NASH that replicates key features of the human disease and progresses to fibrosis stage 3. 1
- 513 Dapagliflozin protects against nonalcoholic steatohepatitis in db/db mice. 13, 0
- 512 Enterohepatic shunt-driven cholemia predisposes to liver cancer. **2022**, 0
- 511 Corilagin prevents non-alcoholic fatty liver disease via improving lipid metabolism and glucose homeostasis in high fat diet-fed mice. 9, 0

510	The effect of different weight loss strategies to treat non-alcoholic fatty liver disease focusing on fibroblast growth factor 21. 9,	
509	Inhibition of polyploidization in Pten -deficient livers reduces steatosis.	0
508	Role of Ultrasound Methods for the Assessment of NAFLD. 2022 , 11, 4581	2
507	Beneficial Effects of Flaxseed and/or Mulberry Extracts Supplementation in Ovariectomized Wistar Rats. 2022 , 14, 3238	
506	Disease state transition probabilities across the spectrum of NAFLD: A systematic review and meta-analysis of paired biopsy or imaging studies. 2022 ,	0
505	Outcomes after Liver Transplantation with Steatotic Grafts: Redefining Acceptable Cutoffs for Steatotic Grafts. 2022 , 12, S5-S14	
504	Ultrasound and FibroScan® Controlled Attenuation Parameter in patients with MAFLD: head to head comparison in assessing liver steatosis.	0
503	An Energy-Restricted Diet Including Yogurt, Fruit, and Vegetables Alleviates High-Fat Diet-Induced Metabolic Syndrome in Mice By Modulating the Gut Microbiota.	0
502	Multiancestry exome sequencing reveals INHBE mutations associated with favorable fat distribution and protection from diabetes. 2022 , 13,	0
501	Perinatal exposure to environmental endocrine disruptor bisphenol A aggravates the onset of non-alcoholic fatty liver disease (NAFLD) in weanling F1 offspring of obese rats.	0
500	Characterization of Nutrient Intake in Biopsy-Confirmed NAFLD Patients. 2022 , 14, 3453	
499	Diagnosis of hepatic steatosis based on ultrasound attenuation imaging is not influenced by liver fibrosis.	
498	Effects of Resveratrol Against Induced Metabolic Syndrome in Rats: Role of Oxidative Stress, Inflammation, and Insulin Resistance. 2022 , 2022, 1-13	1
497	Dietary Cholic Acid Exacerbates Liver Fibrosis in NASH Model of SpragueDawley Rats Fed a High-Fat and High-Cholesterol Diet. 2022 , 23, 9268	
496	Benefits of Physical Exercise as Approach to Prevention and Reversion of Non-Alcoholic Fatty Liver Disease in Children and Adolescents with Obesity. 2022 , 9, 1174	1
495	Clinically Important Alterations in Pharmacogene Expression in Histologically Severe Nonalcoholic Fatty Liver Disease.	
494	Severe Combined Immunodeficiency: Improved survival leading to detection of underlying liver disease.	
493	Automated Whole Slide Image Analysis for a Translational Quantification of Liver Fibrosis.	

- 492 Hepatocellular and extrahepatic cancers in non-alcoholic fatty liver disease: A systematic review and meta-analysis. **2022**, 173, 250-262 2
- 491 Effects of garlic and its major bioactive components on non-alcoholic fatty liver disease: A systematic review and meta-analysis of animal studies. **2022**, 96, 105206
- 490 Quantitative modeling of human liver reveals dysregulation of glycosphingolipid pathways in nonalcoholic fatty liver disease. **2022**, 25, 104949 0
- 489 Etat des lieux sur la physiopathologie, le diagnostic et les traitements de la stâto-hpatite non alcoolique (NASH). **2022**, 0
- 488 Stratifying Non-alcoholic Steatohepatitis With the Non-invasive Ultrasound Markers Shear Wave Dispersion Slope and Shear Wave Velocity: An Animal Study. **2022**, 0
- 487 Systematic analysis of transcriptional and epigenetic effects of genetic variation in Kupffer cells enables discrimination of cell intrinsic and environment-dependent mechanisms. 0
- 486 Ancestral BPA exposure caused defects in the liver of medaka for four generations. **2022**, 159067 0
- 485 Self-supervised neural network improves tri-exponential intravoxel incoherent motion model fitting compared to least-squares fitting in non-alcoholic fatty liver disease. 13, 0
- 484 Profile analysis and functional modeling identify circular RNAs in nonalcoholic fatty liver disease as regulators of hepatic lipid metabolism. 13, 0
- 483 Non-alcoholic fatty liver disease (NAFLD) in lean individuals Single centre large cohort clinicopathologic and immunophenotypic study. **2022**, 238, 154112 0
- 482 Deficiency of peroxisomal NUDT7 stimulates de novo lipogenesis in hepatocytes. **2022**, 25, 105135 0
- 481 Ultrasound biomicroscopy for the assessment of early-stage nonalcoholic fatty liver disease induced in rats by a high-fat diet. **2022**, 41, 750-760 0
- 480 Gestational PCB52 exposure induces hepatotoxicity and intestinal injury by activating inflammation in dam and offspring mice: A maternal and progeny study. **2022**, 313, 120186 0
- 479 Hepatic mir-122-3p, mir-140-5p and mir-148b-5p expressions are correlated with cytokeratin-18 serum levels in MAFLD. **2022**, 27, 100756 1
- 478 Integrated analysis of effect of daisaikoto, a traditional Japanese medicine, on the metabolome and gut microbiome in a mouse model of nonalcoholic fatty liver disease. **2022**, 846, 146856 0
- 477 Die Psoriasis als entzâdliche Hauterkrankung zwischen personalisierter Medizin und Anthroposophischer Medizin. **2022**, 75, 219-225 0
- 476 Non-Alcoholic Fatty Liver Disease and Steatohepatitis. **2022**, 0
- 475 An Assessment of Atherosclerotic Cardiovascular Disease in Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus. 0

- 474 Most Cases of Cryptogenic Cirrhosis May be Nonobese Nonalcoholic Steatohepatitis-Risk Factors of Liver Steatosis After Liver Transplantation for Cryptogenic Cirrhosis: A Retrospective Study. **2022,** ○
- 473 Nonalcoholic steatohepatitis-induced hepatocellular carcinoma. **2022, 7, 1** ○
- 472 Long non-coding RNA in Non-alcoholic fatty liver disease. **2022, 1-35** ○
- 471 Oat β -glucan and l-arabinose synergistically ameliorate glucose uptake in insulin-resistant HepG2 cells and exert anti-diabetic activity via activation of the PI3K/AKT pathway in db/db mice. **2022, 13, 10158-10170** ○
- 470 Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: new trends and role of ultrasonography. **2022, 49, 385-396** ○
- 469 Diagnostik: Blutbasierte Marker. **2022, 149-155** ○
- 468 Recent advances in liver organoids and their use in in vitro modeling of non-alcoholic fatty liver disease. **2, e6** ○
- 467 Pathologie. **2022, 21-28** ○
- 466 Deep Learning Based Steatosis Quantification of Liver Histopathology Images Using Unsupervised Feature Extraction. **2022,** ○
- 465 MR Fingerprinting for Liver Tissue Characterization: A Histopathologic Correlation Study. **1** ○
- 464 ANGPTL8 accelerates liver fibrosis mediated by HFD-induced inflammatory activity via LILRB2/ERK signaling pathways. **2022,** **1** ○
- 463 Evaluation of Liver Stiffness Measurement Based Scores in Liver Transplant Recipients. ○
- 462 Increased Secreted Frizzled-Related Protein 5 mRNA Expression in the Adipose Tissue of Women with Nonalcoholic Fatty Liver Disease Associated with Obesity. **2022, 23, 9871** ○
- 461 Effectiveness of Lifestyle Interventions for Nonalcoholic Fatty Liver Disease Treatment. ○
- 460 Nonalcoholic Fatty Liver Disease and Its Complex Relation with Type 2 Diabetes Mellitus: From Prevalence to Diagnostic Approach and Treatment Strategies. **2022, 11, 5144** **1** ○
- 459 Genetic variants associated with steatohepatitis and liver fibrosis in HIV-infected patients with NAFLD. **13,** ○
- 458 Triglyceride Glucose-Waist Circumference (TyG-WC) Is a Reliable Marker to Predict Non-Alcoholic Fatty Liver Disease. **2022, 10, 2251** ○
- 457 Sex-specific effects of maternal metformin intervention during glucose-intolerant obese pregnancy on body composition and metabolic health in aged mouse offspring. ○

- 456 Brazilian green propolis improves gut microbiota dysbiosis and protects against sarcopenic obesity. ○
- 455 High-fat diet combined with dextran sulfate sodium failed to induce a more serious NASH phenotype than high-fat diet alone. 13, ○
- 454 Clinical Utility of Combined MRI-PDFF and ALT Response in Predicting Histologic Response in Nonalcoholic Fatty Liver Disease. **2022**, ○
- 453 Trajectory of NAFLD characteristics after Roux-en-Y gastric bypass: a five-year historical cohort study. ○
- 452 Treatment strategies and mechanisms associated with the prevention of NASH-associated HCC by a toll-like receptor 4 inhibitor. ○
- 451 Real-world evidence on non-invasive tests and associated cut-offs used to assess fibrosis in routine clinical practice. **2022**, 100596 1
- 450 Pulse-Echo Quantitative US Biomarkers for Liver Steatosis: Toward Technical Standardization. ○
- 449 Updated S2k Clinical Practice Guideline on Non-alcoholic Fatty Liver Disease (NAFLD) issued by the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) [April 2022] AWMF Registration No.: 021025. **2022**, 60, e733-e801 ○
- 448 Effects of maternal cigarette smoke exposure on the progression of nonalcoholic steatohepatitis in offspring mice. ○
- 447 Human Allogeneic Liver-Derived Progenitor Cells Significantly Improve NAFLD Activity Score and Fibrosis in Late-Stage NASH Animal Model. **2022**, 11, 2854 ○
- 446 Curcumin nanoemulsion counteracts hepatic and cardiac complications associated with high-fat/high-fructose diet in rats. ○
- 445 LILRB2/PirB mediates macrophage recruitment in fibrogenesis of nonalcoholic steatohepatitis. ○
- 444 Vitamin D Status and Steatohepatitis in Obese Diabetic and Non-Diabetic Patients. **2022**, 11, 5482 ○
- 443 MAFLD was more easily diagnosed than NAFLD in liver transplantation recipients with abnormal liver function. **2022**, ○
- 442 The association between visceral adipocyte hypertrophy and NAFLD in subjects with different degrees of adiposity. ○
- 441 Sequential therapy of portal vein embolization and systemic chemotherapy for locally advanced perihilar biliary tract cancer. **2022**, ○
- 440 Rosavin Ameliorates Hepatic Inflammation and Fibrosis in the NASH Rat Model via Targeting Hepatic Cell Death. **2022**, 23, 10148 1
- 439 Non-alcoholic fatty liver disease: Is surgery the best current option and can novel endoscopy play a role in the future?. 14, 1704-1717 ○

- 438 FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models. **2022**, 12, 2
- 437 Hepatic Fat Quantification With Novel Ultrasound Based Techniques: A Diagnostic Performance Study Using Magnetic Resonance Imaging Proton Density Fat Fraction as Reference Standard. 084653712211236
- 436 Aktualisierte S2k-Leitlinie nicht-alkoholische Fettlebererkrankung der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) [April 2022] AWMF-Registernummer: 021025. **2022**, 60, 1346-1421 0
- 435 Probiotics suppress nonalcoholic steatohepatitis and carcinogenesis progression in hepatocyte-specific PTEN knockout mice. **2022**, 12, 0
- 434 Sucralose consumption ameliorates high-fat diet-induced glucose intolerance and liver weight gain in mice. 9, 0
- 433 Esteatohepatitis no alcohólica. **2022**, 0
- 432 Spermidine-mediated hypusination of translation factor EIF5A improves mitochondrial fatty acid oxidation and prevents non-alcoholic steatohepatitis progression. **2022**, 13, 3
- 431 Accuracy of Ultrasound Elastography and Fibrosis-4 Index (FIB-4) in Ruling Out Cirrhosis in Obese Non-Alcoholic Fatty Liver Disease (NAFLD) Patients. **2022**, 0
- 430 Ultrasound Methods for the Assessment of Liver Steatosis: A Critical Appraisal. **2022**, 12, 2287 0
- 429 Surgical Resection Is Superior to TACE in the Treatment of HCC in a Well Selected Cohort of BCLC-B Elderly Patients: A Retrospective Observational Study. **2022**, 14, 4422 0
- 428 Human hepatocyte PNPLA3-148M exacerbates rapid non-alcoholic fatty liver disease development in chimeric mice. **2022**, 40, 111321 0
- 427 Factors associated with the development of extrahepatic malignancy in patients with nonalcoholic fatty liver disease: a single-center longitudinal study. **2022**, 34, 1172-1177 0
- 426 Profiling the Oxylipidome in Aged Mice after Chronic Ethanol Feeding: Identifying Lipid Metabolites as Drivers of Hepatocyte Stress. **2022**, 0
- 425 Effect of common genetic variants on the risk of cirrhosis in nonalcoholic fatty liver disease during 20 years of follow-up. 3
- 424 Differences in HDL-Bound Apolipoproteins in Patients with Advanced Liver Fibrosis due to Nonalcoholic Fatty Liver Disease. 0
- 423 Alterations of Central Liver Metabolism of Pediatric Patients with Non-Alcoholic Fatty Liver Disease. **2022**, 23, 11072 1
- 422 N-terminal propeptide of type 3 collagen-based sequential algorithm can identify high-risk steatohepatitis and fibrosis in MAFLD. 0
- 421 IS HOMEOSTASIS MODEL ASSESSMENT FOR INSULIN RESISTANCE >2.5 A DISTINGUISHED CRITERIA FOR METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE IDENTIFICATION?. **2022**, 59, 402-407 1

420	The Role of FXR and TGR5 in Reversing and Preventing Progression of Western Diet-induced Hepatic Steatosis, Inflammation, and Fibrosis in Mice. 2022 , 102530	0
419	Targeting acid ceramidase ameliorates fibrosis in mouse models of non-alcoholic steatohepatitis. 9 ,	1
418	NLRP3 activation in neutrophils induces lethal autoinflammation, liver inflammation, and fibrosis.	0
417	Age-dependent effects of diabetes and obesity on liver-related events in nonalcoholic fatty liver disease: Subanalysis of CLIONE in Asia.	0
416	Impact of the COVID-19 pandemic on the care and outcomes of people with NAFLD-related cirrhosis. 2022 , 4, 100574	0
415	DEST: Deep Enhanced Swin Transformer Toward Better Scoring for NAFLD. 2022 , 204-214	0
414	Sex Difference is a Determinant of Gut Microbes and Their Metabolites SCFAs/MCFAs in High Fat Diet Fed Rats. 2022 , 79,	1
413	Qushi Huayu decoction attenuated hepatic lipid accumulation via JAK2/STAT3/CPT-1A-related fatty acid oxidation in mice with non-alcoholic steatohepatitis. 2022 , 60, 2124-2133	0
412	Ginsenoside Rg3-enriched Korean red ginseng extract attenuates Non-Alcoholic Fatty Liver Disease by way of suppressed VCAM-1 expression in liver sinusoidal endothelium. 2022 ,	0
411	Attenuation by Time-Restricted Feeding of High-Fat and High-Fructose Diet-Induced NASH in Mice Is Related to Per2 and Ferroptosis. 2022 , 2022, 1-20	0
410	Multi-parametric magnetic resonance imaging of liver regeneration in a standardized partial hepatectomy rat model. 2022 , 22,	0
409	Role of liquid fructose/sucrose in regulating the hepatic transcriptome in a high-fat Western diet model of NAFLD. 2022 , 109174	0
408	Immune cell C/EBPβ deficiency is associated with hepatic mononuclear defects and spontaneous hepatitis but not steatohepatitis induced liver fibrosis. 2022 , 10,	0
407	Stellate cell expression of SPARC-related modular calcium-binding protein 2 is associated with human non-alcoholic fatty liver disease severity. 2022 , 100615	0
406	A Sequential Machine Learning Model for Identifying At-risk NASH by Combining Liver Stiffness Measurement and Protein Biomarkers.	0
405	Morphological features of hepatic lipid changes in bearded dragons (<i>Pogona vitticeps</i>), and a proposed grading system. 030098582211289	0
404	Offspring NAFLD Liver Phospholipid Profiles are Differentially Programmed by Maternal High-fat Diet and Maternal One Carbon Supplement. 2022 , 109187	0
403	Different Types of Dietary Fat and Fructose Interactions Result in Distinct Metabolic Phenotypes in Male Mice. 2022 , 109189	0

- 402 One Carbon Metabolism and S-Adenosylmethionine in Non-Alcoholic Fatty Liver Disease Pathogenesis and Subtypes. **2022**, 2, 243-257 ○
- 401 Noninvasive Staging of Hepatic Steatosis Using Calibrated 2D US with Liver Biopsy as the Reference Standard. 1
- 400 Hypothalamic orexin prevents non-alcoholic steatohepatitis and hepatocellular carcinoma in obesity. **2022**, 41, 111497 1
- 399 A 3-step approach to predict advanced fibrosis in nonalcoholic fatty liver disease: impact on diagnosis, patient burden, and medical costs. **2022**, 12, ○
- 398 A liver secretome gene signature-based approach for determining circulating biomarkers of NAFLD severity. **2022**, 17, e0275901 ○
- 397 Serum keratin-18 detects hepatic inflammation and predicts progression in compensated alcohol-associated liver disease. ○
- 396 Plasma Fatty Acid Composition Is Associated with Histological Findings of Nonalcoholic Steatohepatitis. **2022**, 10, 2540 ○
- 395 The aldolase inhibitor aldometanib mimics glucose starvation to activate lysosomal AMPK. **2022**, 4, 1369-1401 ○
- 394 Higher Risk of Tumor Recurrence in NASH-Related Hepatocellular Carcinoma Following Curative Resection. **2022**, 14, 2427 ○
- 393 Mild methylenetetrahydrofolate reductase deficiency accelerates liver triacylglycerol and uric acid accumulation in fructose-fed mice. **2022**, ○
- 392 Clinical Performance of Transient Elastography with Comparison to Quantitative Magnetic Resonance Imaging, Ultrasound, and Biopsy in Children and Adolescents with Known or Suspected Fatty Liver Disease. ○
- 391 Low levels of osteocalcin, but not CTX or P1NP, associated with nonalcoholic hepatic steatosis and steatohepatitis. **2022**, 101397 ○
- 390 Nonalcoholic Steatohepatitis: A 9-Year Follow Up Cohort Study. **2022**, 11, 5969 ○
- 389 Effects of the Seed Oil of *Carica papaya* Linn on Food Consumption, Adiposity, Metabolic and Inflammatory Profile of Mice Using Hyperlipidic Diet. **2022**, 27, 6705 1
- 388 Long-term changes in the diurnal temporal regulation and set points of metabolic parameters associated with chronic maternal overnutrition in rabbits. ○
- 387 Roles of Macrophages in Advanced Liver Fibrosis, Identified Using a Newly Established Mouse Model of Diet-Induced Non-Alcoholic Steatohepatitis. **2022**, 23, 13251 1
- 386 Profiling of cell-free DNA methylation and histone signatures in pediatric NAFLD: A pilot study. ○
- 385 Non-alcoholic steatohepatitis. **2022**, 159, 388-395 ○

384	Advancements in MAFLD Modeling with Human Cell and Organoid Models. 2022 , 23, 11850	1
383	Iron overload accelerated lipid metabolism disorder and liver injury in rats with non-alcoholic fatty liver disease. 2022 , 9,	0
382	The additive effect of genetic and metabolic factors in the pathogenesis of nonalcoholic fatty liver disease. 2022 , 12,	0
381	Incidence and Impact of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients with Adenocarcinoma of the Esophagus Treated with Curative Intent.	0
380	Regulation of Hepatocyte Nuclear Factor 4 α Attenuated Lipotoxicity but Increased Bile Acid Toxicity in Non-Alcoholic Fatty Liver Disease. 2022 , 12, 1682	0
379	Gut bacteria alleviate smoking-related NASH by degrading gut nicotine. 2022 , 610, 562-568	3
378	TLCD1 and TLC2 regulate cellular phosphatidylethanolamine composition and promote the progression of non-alcoholic steatohepatitis. 2022 , 13,	0
377	Expression of SARS-Cov-2 Entry Factors in Patients with Chronic Hepatitis. 2022 , 14, 2397	0
376	Influence of Fasting Time on Serum and Hepatic Lipid Profiles in a Sprague-Dawley Rat Model of Nonalcoholic Steatohepatitis. 2022 , 68, 409-419	0
375	Effect of Fiber Supplementation on Systemic Inflammation and Liver Steatosis in Mice Fed with High-Carbohydrate Diets.	0
374	Critical Overview of Hepatic Factors That Link Non-Alcoholic Fatty Liver Disease and Acute Kidney Injury: Physiology and Therapeutic Implications. 2022 , 23, 12464	1
373	Microbiome-derived ethanol in nonalcoholic fatty liver disease. 2022 , 28, 2100-2106	2
372	Protective Role of Hepassocin against Hepatic Endoplasmic Reticulum Stress in Mice. 2022 , 23, 13325	0
371	Alcoholic Liver Disease and Intestinal Microbiota in an Experimental Model: Biochemical, Inflammatory and Histological Parameters. 2022 , 111888	0
370	MGAT2 inhibitor decreases liver fibrosis and inflammation in murine NASH models and reduces body weight in human adults with obesity. 2022 , 34, 1732-1748.e5	0
369	Risk of advanced fibrosis in first-degree relatives of patients with nonalcoholic fatty liver disease. 2022 , 132,	1
368	Phosphorylation of 17 β hydroxysteroid dehydrogenase 13 at serine 33 attenuates nonalcoholic fatty liver disease in mice. 2022 , 13,	0
367	Dietary salmon milt deoxyribonucleic acid prevents hepatosteatosis in mice.	0

- 366 Rhamnan sulfate reduces atherosclerotic plaque formation and vascular inflammation. **2022**, 291, 121865 1
- 365 Cutoff Values for Diagnosing Hepatic Steatosis Using Contemporary MRI-Proton Density Fat Fraction Measuring Methods. 23, 0
- 364 Plasma Metabolomic and Lipidomic Profiling of Metabolic Dysfunction-Associated Fatty Liver Disease in Humans Using an Untargeted Multiplatform Approach. **2022**, 12, 1081 1
- 363 Exercise training attenuates pulmonary inflammation and mitochondrial dysfunction in a mouse model of high-fat high-carbohydrate-induced NAFLD. **2022**, 20, 0
- 362 Endothelial Extracellular Signal-Regulated Kinase/Thromboxane A2/Prostanoid Receptor Pathway Aggravates Endothelial Dysfunction and Insulin Resistance in a Mouse Model of Metabolic Syndrome. 0
- 361 Identification of a Fatty Acid for Diagnosing Non-Alcoholic Steatohepatitis in Patients with Severe Obesity Undergoing Metabolic Surgery. **2022**, 10, 2920 0
- 360 Non-alcoholic fatty liver disease: the pathologist's perspective. 0
- 359 Role of Oxidative Stress and Lipid Peroxidation in the Pathophysiology of NAFLD. **2022**, 11, 2217 0
- 358 Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. **2022**, 1
- 357 Down regulation of NDUF51 is involved in the progression of parenteral-nutrition-associated liver disease by increasing Oxidative stress. **2022**, 109221 0
- 356 The protection conferred by HSD17B13 rs72613567 on hepatic fibrosis is likely mediated by lowering ballooning and portal inflammation. **2022**, 0
- 355 Mac-2 binding protein glycosylation isomer, the FIB-4 index, and a combination of the two as predictors of non-alcoholic steatohepatitis. **2022**, 17, e0277380 0
- 354 The HSF1-CPT1a Pathway Is Differentially Regulated in NAFLD Progression. **2022**, 11, 3504 0
- 353 Cerebrolysin Use in Patients with Liver Damage: A Translational Study. **2022**, 12, 1791 0
- 352 Therapeutic Effects of *Heterotrigona itama* (Stingless Bee) Bee Bread in Improving Hepatic Lipid Metabolism through the Activation of the Keap1/Nrf2 Signaling Pathway in an Obese Rat Model. **2022**, 11, 2190 0
- 351 In vivo grading of lipids in fatty liver by near-infrared autofluorescence and reflectance. 0
- 350 O-GlycNacylation Remission Retards the Progression of Non-Alcoholic Fatty Liver Disease. **2022**, 11, 3637 1
- 349 Automated whole slide image analysis for a translational quantification of liver fibrosis. **2022**, 12, 0

348	Exosomal microRNAs and Progression of Nonalcoholic Steatohepatitis (NASH). 2022 , 23, 13501	1
347	Fully connected neural network-based serum surface-enhanced Raman spectroscopy accurately identifies non-alcoholic steatohepatitis.	0
346	Review article: the role of HSD17B13 on global epidemiology, natural history, pathogenesis and treatment of NAFLD.	1
345	Pathologic features and differential diagnosis of chronic hepatitis. 2022 ,	0
344	Human umbilical cord mesenchymal stromal cell-derived exosomes protect against MCD-induced NASH in a mouse model. 2022 , 13,	0
343	Lactobacillus reuteri MJM60668 Prevent Progression of Non-Alcoholic Fatty Liver Disease through Anti-Adipogenesis and Anti-Inflammatory Pathway. 2022 , 10, 2203	0
342	iPLA2 ^{Null} Mice Show HCC Protection by an Induction of Cell-Cycle Arrest after Diethylnitrosamine Treatment. 2022 , 23, 13760	0
341	Identification of MAP3K4 as a novel regulation factor of hepatic lipid metabolism in non-alcoholic fatty liver disease. 2022 , 20,	1
340	Deep learning-based quantification of NAFLD/NASH progression in human liver biopsies. 2022 , 12,	0
339	Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores. 2022 ,	2
338	NAFLD as the metabolic hallmark of obesity.	0
337	Dietary squalene supplementation decreases triglyceride species and modifies phospholipid lipidomic profile in the liver of a porcine model of non-alcoholic steatohepatitis. 2022 , 109207	0
336	Ultrasound-based hepatic fat quantification: current status and future directions. 2022 ,	0
335	A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes. 2022 ,	1
334	Elafibranor modulates ileal macrophage polarization to restore intestinal integrity in NASH: Potential crosstalk between ileal IL-10/STAT3 and hepatic TLR4/NF- κ B axes. 2023 , 157, 114050	0
333	Dissecting the multifaceted impact of statin use on fatty liver disease: A multidimensional study. 2023 , 87, 104392	0
332	Manifestation of Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis in Different Dietary Mouse Models. 94-102	0
331	Radiomics Analysis of Magnetic Resonance Proton Density Fat Fraction for the Diagnosis of Hepatic Steatosis in Patients With Suspected Non-Alcoholic Fatty Liver Disease. 2022 , 37,	1

- 330 Metabolic dysfunctions promoted by AIN-93G standard diet compared with three obesity-inducing diets in C57BL/6J mice. **2022**, 5, 436-444 ○
- 329 Obesidad, hábitos de vida y valoración FLI en la población laboral española durante la pandemia. 93-98 ○
- 328 Non-alcoholic Steatohepatitis Diagnosis and Treatment Medical and Surgery, Based on Guideline Updates: A Mini Review. **2022**, 8, ○
- 327 Clinical Practice Guidelines of the Russian Scientific Liver Society, Russian Gastroenterological Association, Russian Association of Endocrinologists, Russian Association of Gerontologists and Geriatricians and National Society for Preventive Cardiology on Diagnosis and Treatment of Non-Alcoholic Liver Disease. **2022**, 32, 104-140 1
- 326 Feasibility of Attenuation Coefficient and Envelope Signal-to-Noise Ratio Estimation for Tissue Characterization of Liver Steatosis. **2022**, ○
- 325 Polyphenol-Rich Liupao Tea Extract Prevents High-Fat Diet-Induced MAFLD by Modulating the Gut Microbiota. **2022**, 14, 4930 1
- 324 Associations between subcutaneous adipocyte hypertrophy and nonalcoholic fatty liver disease. **2022**, 12, ○
- 323 Effect of aerobic exercise on GRP78 and ATF6 expressions in mice with non-alcoholic fatty liver disease. **2022**, ○
- 322 Obese mammary tumour-bearing mice are highly sensitive to doxorubicin-induced hepatotoxicity. **2022**, 22, ○
- 321 Association of serum albumin levels and long-term prognosis in patients with biopsy- confirmed nonalcoholic fatty liver disease. ○
- 320 Screening strategy for nonalcoholic fatty liver disease. ○
- 319 Moderate Treadmill Exercise Alleviates NAFLD by Regulating the Biogenesis and Autophagy of Lipid Droplet. **2022**, 14, 4910 1
- 318 Cytokine modulation by etanercept ameliorates metabolic syndrome and its related complications induced in rats administered a high-fat high-fructose diet. **2022**, 12, ○
- 317 Canary Seed (*Phalaris canariensis* L.) Peptides Prevent Obesity and Glucose Intolerance in Mice Fed a Western Diet. **2022**, 23, 14927 ○
- 316 CD47-SIRP α axis blockade in NASH promotes necroptotic hepatocyte clearance by liver macrophages and decreases hepatic fibrosis. **2022**, 14, ○
- 315 SENP1 prevents steatohepatitis by suppressing RIPK1-driven apoptosis and inflammation. **2022**, 13, ○
- 314 Molecular and cellular mechanisms underlying the hepatoprotective role of ghrelin against NAFLD progression. ○
- 313 Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future. ○

- 312 Hepatic transcriptome profiling reveals early signatures associated with disease transition from non-alcoholic steatosis to steatohepatitis. **2022,** ○
- 311 Spatial molecular and cellular determinants of STAT3 activation in liver fibrosis progression in non-alcoholic fatty liver disease. **2022,** 100628 1
- 310 Combining Dietary Intervention with Metformin Treatment Enhances Non-Alcoholic Steatohepatitis Remission in Mice Fed a High-Fat High-Sucrose Diet. **2022,** 12, 1787 ○
- 309 Adzuki Bean MY59 Extract Reduces Insulin Resistance and Hepatic Steatosis in High-Fat-Fed Mice via the Downregulation of Lipocalin-2. **2022,** 14, 5049 ○
- 308 Proteomic Analysis of Hepatic Fibrosis in HIV-Associated NAFLD Demonstrates Upregulation of Immune Response and Tissue Repair Pathways. ○
- 307 Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in nonalcoholic fatty liver disease. **2022,** ○
- 306 Lipid Droplet-Associated Proteins Perilipin 1 and 2: Molecular Markers of Steatosis and Microvesicular Steatotic Foci in Chronic Hepatitis C. **2022,** 23, 15456 ○
- 305 Are Non-alcoholic Fatty Liver Disease and Bone Mineral Density Associated? A cross-sectional study using liver biopsy and Dual energy X-ray absorptiometry. ○
- 304 *Levilactobacillus brevis* MG5311 Alleviates Ethanol-Induced Liver Injury by Suppressing Hepatic Oxidative Stress in C57BL/6 Mice. **2022,** 10, 2488 ○
- 303 Efficacy and safety of acetyl-CoA carboxylase (ACC) inhibitors in the treatment of nonalcoholic steatohepatitis (NASH): A protocol for systematic review. **2022,** 101, e32357 ○
- 302 Comparing magnetic resonance liver fat fraction measurements with histology in fibrosis: the difference between proton density fat fraction and tissue mass fat fraction. ○
- 301 Amelioration of Hepatic Steatosis by the Androgen Receptor Inhibitor EPI-001 in Mice and Human Hepatic Cells Is Associated with the Inhibition of CYP2E1. **2022,** 23, 16063 ○
- 300 *Terminalia bellirica* ethanol extract ameliorates nonalcoholic fatty liver disease in mice by amending the intestinal microbiota and faecal metabolites. **2022,** 116082 ○
- 299 Diagnostic comparison of vibration-controlled transient elastography and MRI techniques in overweight and obese patients with NAFLD. **2022,** 12, ○
- 298 Role of aerobic exercise in ameliorating NASH: Insights into the hepatic thyroid hormone signaling and circulating thyroid hormones. 13, ○
- 297 Age-dependent sex difference of non-alcoholic fatty liver disease in TSOD and db/db mice. **2022,** 17, e0278580 ○
- 296 Novel potential biomarkers for severe alcoholic liver disease. 13, ○
- 295 17 β -estradiol, a lifespan-extending compound, attenuates liver fibrosis by modulating collagen turnover rates in male mice. ○

- 294 Non-alcoholic fatty liver disease in type 1 diabetes: Prevalence and pathophysiology. 13, 1
- 293 Metabolomics and Lipidomics Screening Reveal Reprogrammed Signaling Pathways toward Cancer Development in Non-Alcoholic Steatohepatitis. **2023**, 24, 210 0
- 292 Serum metabolomics-based heterogeneities and screening strategy for metabolic dysfunction-associated fatty liver disease (MAFLD). **2022**, 1
- 291 Biomarkers reflecting pericellular fibrosis improve together with liver histology after bariatric surgery in early non-alcoholic fatty liver disease. **2022**, 0
- 290 A researcher's guide to preclinical mouse NASH models. **2022**, 4, 1632-1649 2
- 289 Effect of alternate day fasting combined with aerobic exercise on non-alcoholic fatty liver disease: A randomized controlled trial. **2022**, 2
- 288 Increased CHCHD2 expression promotes liver fibrosis in nonalcoholic steatohepatitis via Notch/osteopontin signaling. **2022**, 7, 0
- 287 Attenuation of streptozotocin induced high fat diet exacerbated dyslipidemia mediated hepatic and aortic injuries in male pigs by camel milk. **2023**, 10, 107-122 0
- 286 Validation of a Diet-Induced Macaca fascicularis Model of Nonalcoholic Steatohepatitis with Dietary and Pioglitazone Interventions. 0
- 285 Noninvasive imaging biomarkers for liver steatosis in NAFLD: present and future. 0
- 284 Diagnostic accuracy of enhanced liver fibrosis test for nonalcoholic steatohepatitis-related fibrosis: MULTICENTER STUDY. 0
- 283 MTARC1 and HSD17B13 Variants Have Protective Effects on Non-Alcoholic Fatty Liver Disease in Patients Undergoing Bariatric Surgery. **2022**, 23, 15825 0
- 282 Effects of homocysteine on nonalcoholic fatty liver related disease: A mendelian randomization study. 9, 0
- 281 Gallic acid impairs fructose-driven de novo lipogenesis and ameliorates hepatic steatosis via AMPK-dependent suppression of SREBP-1/ACC/FASN cascade. **2022**, 175457 1
- 280 Hypoglycemic Effects and Mechanisms of Buckwheat-Dal-Ba Composite Flour in Diabetic Rats. **2022**, 11, 3938 0
- 279 Quantification of DNA methylation for carcinogenic risk estimation in patients with non-alcoholic steatohepatitis. **2022**, 14, 0
- 278 Sea buckthorn pulp and seed oils ameliorate lipid metabolism disorders and modulate gut microbiota in C57BL/6J mice on high-fat diet. 9, 0
- 277 A monoclonal antibody targeting nonjunctional claudin-1 inhibits fibrosis in patient-derived models by modulating cell plasticity. **2022**, 14, 0

- 276 Experimental non-alcoholic fatty liver disease causes regional liver functional deficits as measured by the capacity for galactose metabolism while whole liver function is preserved. **2022**, 22, 0
- 275 Protective effect of Qingluotongbi formula against Tripterygium wilfordii induced liver injury in mice by improving fatty acid oxidation and mitochondrial biosynthesis. **2023**, 61, 80-88 0
- 274 Increased Number of Mucosal-Associated Invariant T Cells Is Associated with the Inhibition of Nonalcoholic Fatty Liver Disease in High Fat Diet Fed Mice. **2022**, 23, 15309 0
- 273 Effect of Calorie-Unrestricted Low-Carbohydrate, High-Fat Diet Versus High-Carbohydrate, Low-Fat Diet on Type 2 Diabetes and Nonalcoholic Fatty Liver Disease. 1
- 272 Microbiota-induced lipid peroxidation impairs obeticholic acid-mediated antifibrotic effect towards nonalcoholic steatohepatitis in mice. **2022**, 102582 0
- 271 Glycohemoglobin: A new warning strategy for non-alcoholic fatty liver disease: Study from the NHANES 2017- 2020. 13, 0
- 270 Low-Grade Hepatic Steatosis Is Associated with Long-term Remission of Type 2 Diabetes Independent of Type of Bariatric-Metabolic Surgery. 0
- 269 Metabolic crosstalk between skeletal muscle and liver through IRF4-FSTL1 in NASH. 0
- 268 Comparative Analysis of Global Hepatic Gene Expression in Adolescents and Adults with Non-alcoholic Fatty Liver Disease. 0
- 267 The capsaicinoid nonivamide suppresses the inflammatory response and attenuates the progression of steatosis in a NAFLD-rat model. 0
- 266 A new serotonin 2A receptor antagonist with potential benefits in non-alcoholic fatty liver disease. **2022**, 121315 0
- 265 Noninvasive biomarkers for liver inflammation in NAFLD: current and future. 1
- 264 Automated Segmentation and Morphological Characterization of Hepatic Steatosis and Correlation with Histopathology. **2022**, 0
- 263 Prolonged hypernutrition impairs TREM2-dependent efferocytosis to license chronic liver inflammation and NASH development. **2022**, 1
- 262 Quantitative MRI of diffuse liver diseases: techniques and tissue-mimicking phantoms. 0
- 261 Reliability of Non-invasive Liver Fibrosis Assessment Tools Versus Biopsy in Pre- and Post-bariatric Surgery Patients with Non-alcoholic Fatty Liver Disease. 0
- 260 Ferroptosis plays a novel role in nonalcoholic steatohepatitis pathogenesis. 13, 0
- 259 The surveillance of progression and assessment of treatment endpoint for nonalcoholic steatohepatitis. 0

- 258 Hypocholesterolemic effects of soy protein isolates from soybeans differing in 7S and 11S globulin subunits vary in rats fed a high cholesterol diet. **2022**, 99, 105347 ○
- 257 Gut microbiota and acylcarnitine connect the beneficial association between estrogen and lipid metabolism disorders in ovariectomized mice. ○
- 256 Association between iron metabolism and non-alcoholic fatty liver disease: results from the National Health and Nutrition Examination Survey (NHANES 2017-2018) and a controlled animal study. **2022**, 19, ○
- 255 Myocardial tissue characterization by cardiovascular magnetic resonance T1 mapping and pericardial fat quantification in adolescents with morbid obesity. Cardiac dimorphism by gender. ○
- 254 Periportal steatosis in mice affects distinct parameters of pericentral drug metabolism. **2022**, 12, ○
- 253 Nocellara Del Belice (*Olea europaea* L. Cultivar): Leaf Extract Concentrated in Phenolic Compounds and Its Anti-Inflammatory and Radical Scavenging Activity. **2023**, 12, 27 ○
- 252 Indian National Association for Study of the Liver (INASL) Guidance Paper on Nomenclature, Diagnosis and Treatment of Non-alcoholic Fatty Liver Disease (NAFLD). **2022**, 1 ○
- 251 Selective disruption of NRF2-KEAP1 interaction leads to NASH resolution and reduction of liver fibrosis in mice. **2022**, 100651 ○
- 250 Upper gut heat shock proteins HSP70 and GRP78 promote insulin resistance, hyperglycemia, and non-alcoholic steatohepatitis. **2022**, 13, ○
- 249 Hepatocyte Smoothed Activity Controls Susceptibility to Insulin Resistance and Nonalcoholic Fatty Liver Disease. **2022**, ○
- 248 Empagliflozin protects mice against diet-induced obesity, insulin resistance and hepatic steatosis. ○
- 247 Disease recurrence after liver transplantation for NAFLD cirrhosis is ineluctable. **2023**, 100668 ○
- 246 Phenobarbital, a hepatic metabolic enzyme inducer, inhibits preneoplastic hepatic lesions with expression of selective autophagy receptor p62 and ER-phagy receptor FAM134B in high-fat diet-fed rats through the inhibition of ER stress. **2023**, 113607 ○
- 245 Prognostic value of liver fibrosis assessed by the FIB-4 index in patients with acute coronary syndrome. **2023**, ○
- 244 Increased Hepatic ATG7 mRNA and ATG7 Protein Expression in Nonalcoholic Steatohepatitis Associated with Obesity. **2023**, 24, 1324 ○
- 243 Diagnostic accuracy of FibroScan-AST (FAST) score for the non-invasive identification of patients with fibrotic non-alcoholic steatohepatitis: a systematic review and meta-analysis. *gutjnl-2022-328689* ○
- 242 Moderate alcohol consumption is associated with significant fibrosis progression in NAFLD. **2023**, 7, e0003-e0003 ○
- 241 Cross-Sectional and Longitudinal Performance of Non-Invasive Tests of Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease. **2023**, 12, 650 1

- 240 Gene therapy targeting miR-212-3p exerts therapeutic effects on MAFLD similar to those of exercise. **2023**, 51, ○
- 239 Effects of Different Vegetable Oils on the Nonalcoholic Fatty Liver Disease in C57/BL Mice. **2023**, 2023, 1-10 ○
- 238 Protein restriction during lactation causes transgenerational metabolic dysfunction in adult rat offspring. 9, ○
- 237 Western diet contributes to the pathogenesis of non-alcoholic steatohepatitis in male mice via remodeling gut microbiota and increasing production of 2-oleoylglycerol. **2023**, 14, ○
- 236 Asperuloside alleviates lipid accumulation and inflammation in HFD-induced NAFLD via AMPK signaling pathway and NLRP3 inflammasome. **2023**, 175504 ○
- 235 Transmembrane protein 135 regulates lipid homeostasis through its role in peroxisomal DHA metabolism. **2023**, 6, ○
- 234 Hepatocyte PPAR α contributes to the progression of non-alcoholic steatohepatitis in male and female obese mice. **2023**, 80, 1
- 233 Meta-analysis: Enhanced liver fibrosis test to identify hepatic fibrosis in chronic liver diseases. 1
- 232 Phosphatidylethanolamines Are Associated with Nonalcoholic Fatty Liver Disease (NAFLD) in Obese Adults and Induce Liver Cell Metabolic Perturbations and Hepatic Stellate Cell Activation. **2023**, 24, 1034 ○
- 231 IL-1 β neutralization prevents diastolic dysfunction development, but lacks hepatoprotective effect in an aged mouse model of NASH. **2023**, 13, ○
- 230 The Predictive Role of Extracellular NAPRT for the Detection of Advanced Fibrosis in Biopsy-Proven Non-Alcoholic Fatty Liver Disease. **2023**, 24, 1172 ○
- 229 Imbalanced gut microbiota predicts and drives the progression of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in a fast-food diet mouse model. ○
- 228 Mass spectrometry-based proteomics imputation using self supervised deep learning. ○
- 227 Multicytokine-producing CD4+ T cells characterize the livers of patients with NASH. **2023**, 8, ○
- 226 Circulating microRNAs associated with non-alcoholic fatty liver disease. 1
- 225 Model to predict major complications following liver resection for HCC in patients with metabolic syndrome. Publish Ahead of Print, ○
- 224 Foreseeing Alcohol-Associated Liver Disease through Proteomic Biomarkers. ○
- 223 Protective Effect of *Annona muricata* Linn Fruit Pulp Lyophilized Powder against Paracetamol-Induced Redox Imbalance and Hepatotoxicity in Rats. **2023**, 11, 276 ○

- 222 Protective Effect of Vegan Microbiota on Liver Steatosis Is Conveyed by Dietary Fiber: Implications for Fecal Microbiota Transfer Therapy. **2023**, 15, 454 ○
- 221 Genetic deletion or pharmacologic inhibition of the Nlrp3 Inflammasome did not ameliorate experimental NASH. **2023**, 100330 ○
- 220 Benefits of Huang Lian mediated by gut microbiota on HFD/STZ-induced type 2 diabetes mellitus in mice. 14, ○
- 219 Saroglitazar suppresses the hepatocellular carcinoma induced by intraperitoneal injection of diethylnitrosamine in C57BL/6 mice fed on choline deficient, l-amino acid- defined, high-fat diet. **2023**, 23, ○
- 218 Impact of body mass index in elderly patients treated with laparoscopic liver resection for hepatocellular carcinoma. 15, 72-81 ○
- 217 Machine learning liver histology scores correlate with portal hypertension assessments in nonalcoholic steatohepatitis cirrhosis. ○
- 216 Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial. **2023**, 100661 ○
- 215 Gut microbiota and bile acids partially mediate the improvement of fibroblast growth factor 21 on methionine-choline-deficient diet-induced non-alcoholic fatty liver disease mice. **2023**, 195, 199-218 ○
- 214 5-Methoxyflavone ameliorates non-alcoholic fatty liver disease through targeting the cytochrome P450 1A1. **2023**, 195, 178-191 ○
- 213 Non-alcoholic Steatohepatitis: Global Impact and Clinical Consequences. 74-83 ○
- 212 Rho-Kinase Inhibition Ameliorates Non-Alcoholic Fatty Liver Disease in Type 2 Diabetic Rats. 615-630 ○
- 211 Alleviation Effects of Microbial Metabolites from Resveratrol on Non-Alcoholic Fatty Liver Disease. **2023**, 12, 94 1
- 210 Non-alcoholic fatty liver disease: Definition and subtypes. ○
- 209 Validation of the Hepamet fibrosis score in a multi-ethnic Asian population. **2022**, 100888 ○
- 208 The FIB-4 Index Predicts the Development of Liver-Related Events, Extrahepatic Cancers, and Coronary Vascular Disease in Patients with NAFLD. **2023**, 15, 66 ○
- 207 Loss of Slc12a2 specifically in pancreatic β cells drives metabolic syndrome in mice. **2022**, 17, e0279560 ○
- 206 PNPLA3(I148M) Inhibits Lipolysis by Perilipin-5-Dependent Competition with ATGL. **2023**, 12, 73 ○
- 205 Clinical value of thyroid related hormones combined with neutrophil to lymphocyte ratio in patients with nonalcoholic fatty liver disease. **2022**, 101, e31978 ○

- 204 Imaging Non-alcoholic Fatty Liver Disease Model Using H-1 and F-19 MRI. ○
- 203 Qingrequezhuo capsule alleviated methionine and choline deficient diet-induced nonalcoholic steatohepatitis in mice through regulating gut microbiota, enhancing gut tight junction and inhibiting the activation of TLR4/NF- κ B signaling pathway. 13, ○
- 202 Liver fibrosis: the good, the bad and the patchy - an update. **2023**, ○
- 201 The transcription factor ATF3 switches cell death from apoptosis to necroptosis in hepatic steatosis in male mice. **2023**, 14, ○
- 200 Effect of Metabolic Surgery on Non-Alcoholic Steatohepatitis. **2023**, 1005-1011 ○
- 199 Impact of a Novel Digital Therapeutics System on Nonalcoholic Steatohepatitis: The NASH App Clinical Trial. **2023**, Publish Ahead of Print, ○
- 198 Maternal Western diet is associated with distinct preclinical pediatric NAFLD phenotypes in juvenile nonhuman primate offspring. **2023**, 7, e0014-e0014 ○
- 197 Fatty acid-binding protein-4 (FABP4) and matrix metalloproteinase-9 (MMP9) as predictive values for nonalcoholic steatohepatitis (NASH). **2023**, 22, 1
- 196 A dual MTOR/NAD⁺ acting gerotherapy. ○
- 195 Orthosiphon aristatus (Blume) Miq Alleviates Non-Alcoholic Fatty Liver Disease via Antioxidant Activities in C57BL/6 Obese Mice and PalmiticOleic Acid-Induced Steatosis in HepG2 Cells. **2023**, 16, 109 ○
- 194 Low-Dose Colchicine Attenuates Sepsis-Induced Liver Injury: A Novel Method for Alleviating Systemic Inflammation. ○
- 193 Baicalein alleviates non-alcoholic fatty liver disease in mice by ameliorating intestinal barrier dysfunction. ○
- 192 Secondary bile acids improve risk prediction for non-invasive identification of mild liver fibrosis in nonalcoholic fatty liver disease. ○
- 191 Saroglitazar, A Dual PPAR α/γ Agonist, Improves Atherogenic Dyslipidemia in Patients with Non-Cirrhotic Nonalcoholic Fatty Liver Disease: A Pooled Analysis. **2023**, ○
- 190 Inhibition of VEGF-B signaling prevents non-alcoholic fatty liver disease development by targeting lipolysis in the white adipose tissue. **2023**, ○
- 189 Role of the Enzyme Heparanase in the Development of Fatty Liver. ○
- 188 Significant fibrosis assessed by liver biopsy among Chinese bariatric surgery patients: A prospective cross-sectional study. 14, ○
- 187 Role of B Cell-Activating Factor in Fibrosis Progression in a Murine Model of Non-Alcoholic Steatohepatitis. **2023**, 24, 2509 ○

186	Linguizhugan decoction improves non-alcoholic steatohepatitis partially by modulating gut microbiota and correlated metabolites. 2023 , 13,	0
185	The Nimble Stage 1 Study Validates Diagnostic Circulating Biomarkers for Nonalcoholic Steatohepatitis.	1
184	A multicenter, retrospective, cohort study shows platelet counts predict HCC development in patients with NAFLD.	0
183	Kidney-type glutaminase is a biomarker for the diagnosis and prognosis of hepatocellular carcinoma: a prospective study.	0
182	High fat/high sucrose diet worsens metabolic outcomes and widespread hypersensitivity following early life stress exposure in female mice.	0
181	Combinatorial therapy with BAR502 and UDCA resets FXR and GPBAR1 signaling and reverses liver histopathology in a model of NASH. 2023 , 13,	0
180	Impaired Function of Solute Carrier Family 19 Leads to Low Folate Levels and Lipid Droplet Accumulation in Hepatocytes. 2023 , 11, 337	0
179	Fructose Induced KHK-C Increases ER Stress and Modulates Hepatic Transcriptome to Drive Liver Disease in Diet-Induced and Genetic Models of NAFLD.	0
178	Impact of nonalcoholic fatty liver disease status change on antiviral efficacy of nucleos(t)ide analogues in HBeAg-positive chronic hepatitis B. 2023 , 95,	1
177	AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Publish Ahead of Print,	5
176	Unpaired virtual histological staining using prior-guided generative adversarial networks. 2023 , 105, 102185	0
175	The Link between NAFLD and Metabolic Syndrome. 2023 , 13, 614	0
174	Hepatic failure in a patient with rheumatoid arthritis treated with methotrexate: A case report. 2023 , 102, e32711	0
173	Pathological findings of liver steatosis that is difficult to evaluate with ultrasound. 2023 ,	0
172	Attenuation coefficient (ATT) measurement for liver fat quantification in chronic liver disease. 2023 ,	0
171	Diagnostic accuracy of ultrasound-guided attenuation parameter as a noninvasive test for steatosis in non-alcoholic fatty liver disease. 2023 ,	0
170	Artificial intelligence and deep learning: New tools for histopathological diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. 2023 , 21, 2495-2501	0
169	Sphingolipids Are Depleted in Alcohol-Related Liver Fibrosis. 2023 ,	0

- 168 A bibliometric analysis and visualization of nonalcoholic fatty liver disease from 2012 to 2021. ○
- 167 Liver saturated fat content associates with hepatic DNA methylation in obese individuals. **2023**, 15, ○
- 166 Gamma-Muricholic Acid Inhibits Nonalcoholic Steatohepatitis: Abolishment of Steatosis-Dependent Peroxidative Impairment by FXR/SHP/LXR/FASN Signaling. **2023**, 15, 1255 ○
- 165 Reconsidering low HDL-cholesterol levels as a predictive factor for the development of hepatocellular carcinoma. **2023**, 100752 ○
- 164 Pharmacological inhibition of CFTR attenuates nonalcoholic steatohepatitis (NASH) progression in mice. **2023**, 1869, 166662 ○
- 163 Screening for NAFLD: Current Knowledge and Challenges. **2023**, 13, 536 ○
- 162 Computed Tomography Imaging for Monitoring of Marburg Virus Disease: a Nonhuman Primate Proof-Of-Concept Study. ○
- 161 Rapid and Reliable Steatosis Rat Model Shrsp5-Dmcr for Cold Storage Experiment. **2023**, ○
- 160 Single-cell phenotypes of peripheral blood immune cells in early and late stages of non-alcoholic fatty liver disease. **2023**, 29, 417-432 ○
- 159 Lycium barbarum Oligosaccharides Alleviate Hepatic Steatosis by Modulating Gut Microbiota in C57BL/6J Mice Fed a High-Fat Diet. **2023**, 12, 1617 ○
- 158 The prophylactic treatment of Egyptian, *Trigonella foenum-graecum* L., Extract in comparison to pure diosgenin on experimentally induced non-alcoholic steatohepatitis: New targets via AMPK, RAR, and FXR pathways. **2023**, 3, 100421 ○
- 157 Hydrogen inhalation ameliorates hepatic inflammation and modulates gut microbiota in rats with high-fat diet-induced non-alcoholic fatty liver disease. **2023**, 947, 175698 ○
- 156 Monte Carlo modeling of hepatic steatosis based on stereology and spatial distribution of fat droplets. **2023**, 233, 107494 ○
- 155 Identification of potential feature genes in non-alcoholic fatty liver disease using bioinformatics analysis and machine learning strategies. **2023**, 157, 106724 ○
- 154 Noninvasive Tests Used in Risk Stratification of Patients with Nonalcoholic Fatty Liver Disease. **2023**, 27, 373-395 ○
- 153 Evaluation of PXL065 [Deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1). **2023**, 78, 914-925 ○
- 152 Hepatoprotective effects of the long-acting fibroblast growth factor 21 analog PF-05231023 in the GAN diet-induced obese and biopsy-confirmed mouse model of nonalcoholic steatohepatitis. **2023**, 324, G378-G388 ○
- 151 Histologic features of allograft livers in patients treated for rejection before biopsy. **2023**, 135, 11-21 ○

- 150 Special Population. **2023**, 27, 471-482 ○
- 149 Chlorogenic acid ameliorated non-alcoholic steatohepatitis via alleviating hepatic inflammation initiated by LPS/TLR4/MyD88 signaling pathway. **2023**, 376, 110461 ○
- 148 Role of Liver Biopsy in Clinical Trials and Clinical Management of Nonalcoholic Fatty Liver Disease. **2023**, 27, 353-362 ○
- 147 AMPK activation by AICAR reduces diet induced fatty liver in C57BL/6 mice. **2023**, 82, 102054 ○
- 146 Chemogenetic stimulation of the parasympathetic nervous system lowers hepatic lipid accumulation and inflammation in a nonalcoholic steatohepatitis mouse model. **2023**, 321, 121533 ○
- 145 Glycogenic hepatopathy is associated with type 1 diabetes mellitus in only a minority of cases in a contemporary adult population. **2023**, 64, 152130 ○
- 144 Clonal haematopoiesis and risk of chronic liver disease. ○
- 143 Betulin prevents high fat diet-induced non-alcoholic fatty liver disease by mitigating oxidative stress and upregulating Nrf2 and SIRT1 in rats. **2023**, 322, 121688 ○
- 142 A low-carbohydrate diet induces hepatic insulin resistance and metabolic associated fatty liver disease in mice. **2023**, 69, 101675 ○
- 141 Non-Neoplastic Disorders of the Liver. **2024**, 489-556 ○
- 140 Evaluating the effect of basic fibroblast growth factor on the progression of NASH disease by inhibiting ceramide synthesis and ER stress-related pathways. **2023**, 942, 175536 ○
- 139 Fructooligosaccharides attenuate non-alcoholic fatty liver disease by remodeling gut microbiota and association with lipid metabolism. **2023**, 159, 114300 ○
- 138 Patients with Nonalcoholic Steatohepatitis and Advanced Liver Disease Have the Lowest Cardiorespiratory Fitness. 1
- 137 An unsupervised transfer learning model based on convolutional auto encoder for non-alcoholic steatohepatitis activity scoring and fibrosis staging of liver histopathological images. ○
- 136 The nonalcoholic steatohepatitis extended hepatocyte ballooning score: histologic classification and clinical significance. **2023**, 7, e0033-e0033 ○
- 135 Patients With Autoimmune Hepatitis and Nonalcoholic Fatty Liver Disease. Publish Ahead of Print, ○
- 134 Brain N-Glycosylation and Lipidomic Profile Changes Induced by a High-Fat Diet in Dyslipidemic Hamsters. **2023**, 24, 2883 ○
- 133 Systemic Biomarkers and Liver Morphology in Rats during Chronic Low-Dose Toxicant Administration against the Background of Vitamin Deficiency. **2023**, 174, 365-369 ○

- 132 Empagliflozin versus sitagliptin for ameliorating intrahepatic lipid content and tissue-specific insulin sensitivity in patients with early-stage type 2 diabetes with non-alcoholic fatty liver disease: A prospective randomized study. ○
- 131 AICAR Ameliorates Non-Alcoholic Fatty Liver Disease via Modulation of the HGF/NF- κ B/SNARK Signaling Pathway and Restores Mitochondrial and Endoplasmic Reticular Impairments in High-Fat Diet-Fed Rats. **2023**, 24, 3367 ○
- 130 Technical acoustic measurements combined with clinical parameters for differential diagnosis of nonalcoholic steatohepatitis. ○
- 129 Splicing factor SRSF1 deficiency in the liver triggers NASH-like pathology and cell death. **2023**, 14, ○
- 128 A Spatial Atlas of Wnt Receptors in Adult Mouse Liver. **2023**, 193, 558-566 ○
- 127 Metabolic Profile Reflects Stages of Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease. **2023**, 24, 3563 ○
- 126 Tcf7l2 in hepatocytes regulates de novo lipogenesis in diet-induced non-alcoholic fatty liver disease in mice. **2023**, 66, 931-954 ○
- 125 Diagnostic efficiency on ultrasound shear wave elastography in evaluation of steatosis severity for non-alcoholic fatty liver disease: a rat model. **2023**, 28, ○
- 124 Collagen co-localised with macrovesicular steatosis for fibrosis progression in non-alcoholic fatty liver disease. ○
- 123 Strategies and Techniques for Liver Magnetic Resonance Imaging: New and Pending Applications for Routine Clinical Practice. **2023**, 24, 180 ○
- 122 Non-Alcoholic Fatty Liver Disease [Changing the Prevalence of Liver Cancer?]. 12-18 ○
- 121 Nonalcoholic Fatty Liver Disease Severity Is Related to Plasma Pro-Oxidative Biomarkers Rather Than Liver Tissue-Measured Nitrogen Metabolism Biomarkers in Population with Obesity and Metabolic Syndrome. **2023**, 21, 115-121 ○
- 120 CS27109, A Selective Thyroid Hormone Receptor- β Agonist Alleviates Metabolic-Associated Fatty Liver Disease in Murine Models. **2023**, 2023, 1-11 ○
- 119 Effect of Gestational Fish Oil Supplementation on Liver Metabolism and Mitochondria of Male and Female Rat Offspring Programmed by Maternal High-Fat Diet. **2023**, 67, ○
- 118 The genetic background shapes the susceptibility to mitochondrial dysfunction and NASH progression. **2023**, 220, 1
- 117 Improvement of obesity-induced fatty liver disease by intermittent hypoxia exposure in a murine model. 14, ○
- 116 Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial. **2023**, 29, 392-400 ○
- 115 Administration of Secretome Derived from Human Mesenchymal Stem Cells Induces Hepatoprotective Effects in Models of Idiosyncratic Drug-Induced Liver Injury Caused by Amiodarone or Tamoxifen. **2023**, 12, 636 ○

- 114 Berberine Ameliorates Metabolic-Associated Fatty Liver Disease Mediated Metabolism Disorder and Redox Homeostasis by Upregulating Clock Genes: Clock and Bmal1 Expressions. **2023**, 28, 1874 ○
- 113 Dendrobium mixture ameliorates type 2 diabetes mellitus with non-alcoholic fatty liver disease through PPAR gamma: An integrated study of bioinformatics analysis and experimental verification. 14, ○
- 112 Noninvasive tests predict liver-related events and mortality in patients with nonalcoholic fatty liver disease: sub-analysis of the CLIONE-Asia study. ○
- 111 Impact of Vancomycin Treatment and Gut Microbiota on Bile Acid Metabolism and the Development of Non-Alcoholic Steatohepatitis in Mice. **2023**, 24, 4050 ○
- 110 Comparison of strain elastography and shear wave elastography in diagnosis of fibrosis in nonalcoholic fatty liver disease. 1
- 109 Validation of the utility of Agile scores to identify advanced fibrosis and cirrhosis in Japanese patients with nonalcoholic fatty liver disease. ○
- 108 Raman imaging of rat nonalcoholic fatty liver tissues reveals distinct biomolecular states. ○
- 107 Vitamin A regulates tissue-specific organ remodeling in diet-induced obesity independent of mitochondrial function. 14, ○
- 106 MRI-AST (MAST) Score Accurately Predicts Major Adverse Liver Outcome, Hepatocellular Carcinoma, Liver Transplant, and Liver-Related Death. **2023**, ○
- 105 A novel approach to repositioning memantine for metabolic syndrome-induced steatohepatitis: Modulation of hepatic autophagy, inflammation, and fibrosis. **2023**, 319, 121509 ○
- 104 Involvement of eNAMPT / TLR4 inflammatory signaling in progression of non-alcoholic fatty liver disease, steatohepatitis, and fibrosis. **2023**, 37, ○
- 103 Filamin A is overexpressed in non-alcoholic steatohepatitis and contributes to the progression of inflammation and fibrosis. **2023**, 653, 93-101 ○
- 102 Oral Exposure to Polystyrene Microplastics of Mice on a Normal or High-Fat Diet and Intestinal and Metabolic Outcomes. **2023**, 131, ○
- 101 Patients with fibrosis from non-alcoholic steatohepatitis have heterogeneous intrahepatic macrophages and therapeutic targets. ○
- 100 p53 protects against alcoholic fatty liver disease via ALDH2 inhibition. **2023**, 42, 1
- 99 Baseline hepatocyte ballooning is a risk factor for adverse events in patients with chronic hepatitis B complicated with nonalcoholic fatty liver disease. 15, 237-254 ○
- 98 Molecular imaging of liver inflammation using an anti-VCAM-1 nanobody. **2023**, 14, 1
- 97 Hepatocyte apoptosis fragment product cytokeratin-18 M30 level and non-alcoholic steatohepatitis risk diagnosis: an international registry study. **2023**, 136, 341-350 ○

96	Fibroblast Growth Factors for Nonalcoholic Fatty Liver Disease: Opportunities and Challenges. 2023 , 24, 4583	1
95	Bifidobacterium-derived short-chain fatty acids and indole compounds attenuate nonalcoholic fatty liver disease by modulating gut-liver axis. 14,	0
94	Novel NF- κ B reporter mouse for the non-invasive monitoring of inflammatory diseases. 2023 , 13,	1
93	Human Neutrophil α -Defensins 1 β Are Upregulated in the Microenvironment of Fibrotic Liver. 2023 , 59, 496	0
92	The use of current knowledge and non-invasive testing modalities for predicting at-risk non-alcoholic steatohepatitis and assessing fibrosis.	0
91	Is it Possible to Avoid Liver Biopsy in Living Donors for Liver Transplantation by Using Two-Dimensional Shear Wave Elastography?. 2023 ,	0
90	PNPLA3 genotypes modify the adverse effect of the total energy intake on high-risk nonalcoholic steatohepatitis development. 2023 ,	0
89	Rifaximin- π For liver fibrosis in patients with alcohol-related liver disease (GALA-RIF): a randomised, double-blind, placebo-controlled, phase 2 trial. 2023 ,	0
88	Periodontitis salivary microbiota exacerbates nonalcoholic fatty liver disease in high-fat diet-induced obese mice. 2023 , 26, 106346	0
87	Evaluation of an Integrin α β Radiotracer, [18 F]F-FPP-RGD2, for Monitoring Pharmacological Effects of Integrin α siRNA in the NASH Liver.	0
86	The Role of Olfactomedin 2 in the Adipose Tissue-Liver Axis and Its Implication in Obesity-Associated Nonalcoholic Fatty Liver Disease. 2023 , 24, 5221	0
85	Administrative coding for non-alcoholic fatty liver disease is accurate in Swedish patients. 1-6	0
84	Therapeutic effects of CD133 + Exosomes on liver function after stroke in type 2 diabetic mice. 17,	0
83	Challenges and opportunities in NASH drug development. 2023 , 29, 562-573	0
82	Skeletal muscle atrophy is exacerbated by steatotic and fibrotic liver-derived TNF- α in senescence-accelerated mice.	0
81	Hepatic Lipid Droplet-Associated Proteome Changes Distinguish Dietary-Induced Fatty Liver from Insulin Resistance in Male Mice.	0
80	Impact of skeletal muscle mass evaluating methods on severity of metabolic associated fatty liver disease in non-elderly adults. 1-12	0
79	In Vitro Probiotic Properties of Bifidobacterium animalis subsp. lactis SF and Its Alleviating Effect on Non-Alcoholic Fatty Liver Disease. 2023 , 15, 1355	0

- 78 Azonal steatosis correlates with disease severity and poor outcome of nonalcoholic fatty liver disease. ○
- 77 Nobiletin Intake Attenuates Hepatic Lipid Profiling and Oxidative Stress in HFD-Induced Nonalcoholic-Fatty-Liver-Disease Mice. **2023**, 28, 2570 ○
- 76 Persistent steatosis retards fibrosis regression during anti-HBV treatment in patients with chronic HBV infection. ○
- 75 Polyunsaturated and Saturated Oxylin Plasma Levels Allow Monitoring the Non-Alcoholic Fatty Liver Disease Progression to Severe Stages. **2023**, 12, 711 ○
- 74 The Influence of Ultra-Low Tidal Volume Ventilation during Cardiopulmonary Resuscitation on Renal and Hepatic End-Organ Damage in a Porcine Model. **2023**, 11, 899 ○
- 73 Exploiting the biological effect exerted by lipid nanocapsules in non-alcoholic fatty liver disease. **2023**, 356, 542-553 ○
- 72 Novel urinary protein panels for the non-invasive diagnosis of non-alcoholic fatty liver disease and fibrosis stages. ○
- 71 Post-hepatectomy liver failure: A timeline centered review. **2023**, ○
- 70 Semaglutide 2.4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. **2023**, ○
- 69 Valor pronóstico de la fibrosis hepática valorada por el índice FIB4 en pacientes ingresados por síndrome coronario agudo. **2023**, ○
- 68 CT-based Hounsfield unit values reflect the degree of steatohepatitis in patients with low-grade fatty liver disease. **2023**, 23, ○
- 67 Honokiol acts as an AMPK complex agonist therapeutic in non-alcoholic fatty liver disease and metabolic syndrome. **2023**, 18, ○
- 66 Clinically important alterations in pharmacogene expression in histologically severe nonalcoholic fatty liver disease. **2023**, 14, ○
- 65 Mobile health lifestyle intervention program leads to clinically significant loss of body weight in patients with NASH. **2023**, 7, ○
- 64 Silencing of STE20-type kinase TAOK1 confers protection against hepatocellular lipotoxicity through metabolic rewiring. **2023**, 7, ○
- 63 Serum Fibroblast Growth Factor 21 Is Markedly Decreased following Exercise Training in Patients with Biopsy-Proven Nonalcoholic Steatohepatitis. **2023**, 15, 1481 ○
- 62 Bile Acid Alterations Characterize the Early Onset and Progression of Nonalcoholic Fatty Liver Disease in Young Mice Fed with High Fat and Fructose Diet. ○
- 61 Proteomic Analysis Reveals Changes in Tight Junctions in the Small Intestinal Epithelium of Mice Fed a High-Fat Diet. **2023**, 15, 1473 ○

- 60 Clinical-radiomic analysis for non-invasive prediction of liver steatosis on non-contrast CT: A pilot study. 14, ○
- 59 Extracellular volume fraction obtained by dual-energy CT depicting the etiological differences of liver fibrosis. ○
- 58 Characterization of hepatic fatty acids using magnetic resonance spectroscopy for the assessment of treatment response to metformin in an eNOS β mouse model of metabolic nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. ○
- 57 Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study. 2023, ○
- 56 Metabolic-Associated Fatty Liver Disease and Diabetes. 2023, ○
- 55 Fatty liver disease in children (MAFLD/PeFLD Type 2): unique classification considerations and challenges. 2023, 14, 204201882311603 ○
- 54 Comparative Accuracy of Clinical Fibrosis Markers, Hepascore and Fibroscan[®] to Detect Advanced Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. ○
- 53 Mouse strain-dependent variation in metabolic associated fatty liver disease (MAFLD): a comprehensive resource tool for pre-clinical studies. 2023, 13, ○
- 52 Microbially-derived indole-3-acetate alleviates diet induced steatosis and inflammation in mice. ○
- 51 Metabolic benefits of 17 β -estradiol in liver are partially mediated by ER α in male mice. ○
- 50 1,25-Dihydroxycholecalciferol down-regulates 3-mercaptopyruvate sulfur transferase and caspase-3 in rat model of non-alcoholic fatty liver disease. 2023, 54, 119-134 ○
- 49 The combination of the enhanced liver fibrosis and FIB-4 scores to determine significant fibrosis in patients with nonalcoholic fatty liver disease. ○
- 48 Second-Harmonic Generated Quantifiable Fibrosis Parameters Provide Signatures for Disease Progression and Regression in Nonalcoholic Fatty Liver Disease. 2023, 16, 2632010X2311623 ○
- 47 Integrated omics analysis for characterization of the contribution of high fructose corn syrup to non-alcoholic fatty liver disease in obesity. 2023, 155552 ○
- 46 Lean Indian patients with non-alcoholic fatty liver disease (NAFLD) have less metabolic risk factors but similar liver disease severity as non-lean patients with NAFLD. ○
- 45 Expression of STING in Women with Morbid Obesity and Nonalcoholic Fatty Liver Disease. 2023, 13, 496 ○
- 44 LIPOSOMAL TECHNOLOGIES FOR SILYBIN DELIVERY TO THE LIVER IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE. 2023, 50-62 ○
- 43 Western Diet Decreases Hepatic Drug Metabolism in Male LDLr^{-/-}ApoB100/100 Mice. 2023, 2023, 1-12 ○

- 42 Hypolipidemic and insulin sensitizing effects of salsalate beyond suppressing inflammation in a prediabetic rat model. 14, ○
- 41 Shorter leukocyte telomere length protects against NAFLD progression in children. **2023**, 13, ○
- 40 Hyperglycaemia, pregnancy outcomes and maternal metabolic disease risk during pregnancy and lactation in a lean gestational diabetes mouse model. ○
- 39 Application of Scores Assessing Histological Activity and Estimated Long-Term Risk Analysis of Hepatic Decompensation of Non-Alcoholic Fatty Liver Disease in Individuals Undergoing Bariatric Surgery. ○
- 38 Geniposide plus chlorogenic acid reverses non-alcoholic steatohepatitis via regulation of gut microbiota and bile acid signaling in a mouse model in vivo. 14, ○
- 37 The effect of hepatic steatosis on liver volume determined by proton density fat fraction and deep learning-measured liver volume. ○
- 36 Nichtalkoholische Fettleber | Diagnose und Therapie in 2022. **2023**, 4, 27-37 ○
- 35 Serum Cardiotrophin-1 Concentration Is Negatively Associated with Controlled Attenuation Parameters in Subjects with Non-Alcoholic Fatty Liver Disease. **2023**, 12, 2741 ○
- 34 Cellular and Molecular Techniques. **2024**, 96-121 ○
- 33 Expansion of macrophage and liver sinusoidal endothelial cell subpopulations during non-alcoholic steatohepatitis progression. **2023**, 26, 106572 ○
- 32 Introduction. **2024**, 1-6 ○
- 31 Noninvasive assessment of liver steatosis with ultrasound techniques. **2024**, 177-198 ○
- 30 Fatty Liver Disease. **2024**, 330-401 ○
- 29 Dietary cholesterol drives the development of non-alcoholic steatohepatitis by altering gut microbiota mediated bile acid metabolism in high-fat diet fed mice. **2023**, 109347 ○
- 28 The GCKR-P446L gene variant predisposes to raised blood cholesterol and lower blood glucose in the P446L mouse—a model for GCKR rs1260326. **2023**, 72, 101722 ○
- 27 A proteo-transcriptomic map of non-alcoholic fatty liver disease signatures. ○
- 26 DT-109 ameliorates nonalcoholic steatohepatitis in nonhuman primates. **2023**, ○
- 25 ROS-scavenging nanomedicine for multiple crosstalk modulation in non-alcoholic fatty liver disease. ○

- 24 Liver fibrosis quantified by image morphometry predicts clinical outcomes in patients with non-alcoholic fatty liver disease. ○
- 23 HILPDA promotes NASH-driven HCC development by restraining intracellular fatty acid flux in hypoxia. **2023**, ○
- 22 Recent Advances in Small Molecular Fluorescence Probes for Fatty Liver Diseases. **2023**, 11, 241 ○
- 21 CT Texture Analysis in Nonalcoholic Fatty Liver Disease (NAFLD). **2023**, ○
- 20 Increased let-7d-5p in non-alcoholic fatty liver promotes insulin resistance and is a potential blood biomarker for diagnosis. ○
- 19 Gsk3 β deficiency in macrophages alleviates the progression of nonalcoholic steatohepatitis by promoting PINK1-mediated mitophagic autophagy. ○
- 18 The human-derived novel gut commensal *Luoshenia tenuis* regulates body weight and food intake in mice. **2023**, 1-17 ○
- 17 Liver Anatomy and Cross-Sectional Imaging Techniques: A Practical Approach. ○
- 16 An end-to-end platform for digital pathology using hyperspectral autofluorescence microscopy and deep learning based virtual histology. ○
- 15 SteatoSITE: an Integrated Gene-to-Outcome Data Commons for Precision Medicine Research in NAFLD. ○
- 14 Integration of deep learning-based histopathology and transcriptomics reveals key genes associated with fibrogenesis in patients with advanced NASH. **2023**, 4, 101016 ○
- 13 Non-invasive diagnosis of alcohol-related steatohepatitis in patients ongoing alcohol withdrawal based on cytokeratin 18 and transient elastography. ○
- 12 Postprandial dysfunction in fatty liver disease. **2023**, 11, ○
- 11 Bariatric/metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial. **2023**, ○
- 10 Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease. **2023**, ○
- 9 Steatosis and Metabolic Disorders Associated with Synergistic Activation of the CAR/RXR Heterodimer by Pesticides. **2023**, 12, 1201 ○
- 8 *Limosilactobacillus fermentum* MG4294 and *Lactiplantibacillus plantarum* MG5289 Ameliorates Nonalcoholic Fatty Liver Disease in High-Fat Diet-Induced Mice. **2023**, 15, 2005 ○
- 7 Technical Acoustic Measurements Combined with Clinical Parameters for the Differential Diagnosis of Nonalcoholic Steatohepatitis. **2023**, 13, 1547 ○

- 6 Distinct features of two lipid droplets types in cell nuclei from patients with liver diseases. **2023**, 13,
- 5 The innate immune receptor RP105 promotes metabolic syndrome by altering gut microbiota composition and intestinal barrier function. **2023**, 664, 77-85
- 4 Exposure to a static magnetic field attenuates hepatic damage and function abnormality in obese and diabetic mice. **2023**, 1869, 166719
- 3 Atorvastatin Attenuates Diet-Induced Non-Alcoholic Steatohepatitis in APOE*3-Leiden Mice by Reducing Hepatic Inflammation. **2023**, 24, 7818
- 2 Triphenyltin (TPT) exposure causes SD rat liver injury via lipid metabolism disorder and ER stress revealed by transcriptome analysis. **2023**, 381, 60-71
- 1 Naringenin prevents NAFLD in the diet-induced C57BL/6J obesity model by regulating the intestinal barrier function and microbiota. **2023**, 105, 105578